The application of cardiac biomarkers as detectors for cardiac disease in horses by Van Der Vekens, Nicky
  
 
 
The application of 
cardiac biomarkers 
as detectors for cardiac 
disease in horses 
 
Nicky Van Der Vekens 
 
 
Dissertation submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy (PhD) in Veterinary Sciences 
 
 
2015 
 
 
Promotors: 
Prof. Dr. G. van Loon 
Dr. A. Decloedt 
Prof. Dr. P. Deprez 
 
 
 
Department of Large Animal Internal Medicine 
Faculty of Veterinary Medicine 
Ghent University 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research was funded by the Special Research Fund of Ghent University. 
Dit onderzoek werd gesubsidieerd door het Bijzonder Onderzoeksfonds 
(BOF) van Universiteit Gent.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Success is not final, 
Failure is not fatal, 
It’s the courage to continue that counts. 
- Winston Churchill -  
  
  
  
 
 
Table of contents 
List of abbreviations 
Chapter 1: General introduction .......................................................................................... 1 
1.1 The heart muscle in the equine athlete ............................................................. 3 
1.2 Cardiac biomarkers: definition, physiology and structure ................................. 3 
1.3 Use of cardiac biomarkers in human medicine................................................ 12 
1.4 Use of cardiac biomarkers in small animal veterinary medicine  .................... 21 
1.5 Use of cardiac biomarkers in horses  ............................................................... 26 
Chapter 2: Human and equine cardiovascular endocrinology: beware to compare  ....... 47 
 2.1 Introduction ..................................................................................................... 49 
 2.2 Comparison of cardiovascular physiology and pathophysiology  .................... 49 
2.3 Species differences in cardiac biomarkers ....................................................... 53 
2.4 Conclusion ........................................................................................................ 58 
Chapter 3: Scientific aims................................................................................................... 71 
Chapter 4: Cardiac troponin assays for detection of myocardial damage in horses  ........ 75 
4.1 Evaluation of assays for troponin I in healthy horses and horses with cardiac 
disease .................................................................................................................... 77 
4.2 Analytical characteristics of a high-sensitivity cardiac troponin T test in horses
 ................................................................................................................................ 97 
4.3 Cardiac troponin I as compared to cardiac troponin T for the detection of 
myocardial damage in horses  ............................................................................. 113 
 
  
Chapter 5: Atrial natriuretic peptides for detection of left atrial dilatation in horses  ... 131 
5.1 ANP versus NT-proANP for the detection of left atrial dilatation in horses  . 133 
5.2 Total plasma proANP increases with atrial dilatation in horses .................... 157 
Chapter 6: B-type natriuretic peptide: pilot studies of an unexplored cardiac biomarker 
in horses  .......................................................................................................................... 175 
6.1 Equine BNP measurement using a porcine BNP enzyme-linked immunoassay 
 .............................................................................................................................. 177 
6.2 Development of an equine NT-proBNP enzyme-linked immunoassay ......... 199 
Chapter 7: Best cardiac biomarker for detection of atrial dilatation  ............................. 223 
Chapter 8: General discussion ......................................................................................... 237 
8.1 Cardiac troponin I and T can detect myocardial damage .............................. 239 
8.2 Atrial natriuretic peptides can detect atrial dilatation .................................. 244 
8.3 The challenge of equine B-type natriuretic peptide determination .............. 253 
8.4 Future prospects  ........................................................................................... 256 
Summary .......................................................................................................................... 267 
Samenvatting ................................................................................................................... 275 
Curriculum vitae ............................................................................................................... 283 
Bibliography ..................................................................................................................... 287 
Dankwoord ....................................................................................................................... 293 
  
 
List of abbreviations 
2DST Two-dimensional speckle tracking 
ABTS 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid 
AF atrial fibrillation 
AM atypical myopathy 
AMI acute myocardial infarction 
ANP atrial or A-type natriuretic peptide 
ANP-20 ANP concentration stored at -20°C 
ANP-80 ANP concentration stored at -80°C 
APD atrial premature depolarization 
AR aortic regurgitation 
AUC area under the curve 
BCA bicinchoninic acid 
BNP brain or B-type natriuretic peptide 
BNP-20 BNP concentration stored at -20°C 
BNP-80 BNP concentration stored at -80°C 
Cb bias correction 
CI confidence interval 
CK-MB creatine kinase myocardial band enzymes 
CNP C-type natriuretic peptide 
CRP C-reactive protein 
cTnC cardiac troponin C 
cTnI cardiac troponin I 
cTnT cardiac troponin T 
CV coefficient of variation 
ECG electrocardiography 
EDC N-ethyl-N’-(3-diethylaminopropyl)carbodiimide 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
  
FC flow cell 
HCM hypertrophic cardiomyopathy 
HI hemolysis index 
hs-cTnT assay high-sensitive troponin T assay 
IQR interquartile range 
ir immunoreactive 
Ka association rate constant 
Kd dissociation rate constant 
kDa kilodalton 
Keq equilibrium constant 
KLH keyhole limpet hemocyanin 
LAA/AoA left atrial-to-aortic area ratio 
LAD short axis end-systolic diameter of the left atrium 
LAD/AoD left atrial-to-aortic diameter ratio 
LDH lactate dehydrogenase 
LOD limit of detection 
LVIDd left ventricular internal diameter during diastole 
MR mitral regurgitation 
MR-proANP mid-regional proANP 
MW molecular weight 
NHS N-hydroxisuccinimide 
NPR A, B or C natriuretic peptide receptor A, B or C 
NPs natriuretic peptides 
NPV negative predictive value 
NT-proANP N-terminal pro atrial natriuretic peptide 
NT-proANP-20 NT-proANP concentration stored at -20°C 
NT-proANP-80 NT-proANP concentration stored at -80°C 
NT-proBNP N-terminal pro B-type natriuretic peptide 
OD optical density 
  
 
PBS phosphate buffered saline 
PCO2 partial CO2 pressure 
PPV positive predictive value 
PR pulmonary regurgitation 
proANP-20 proANP concentration stored at-20°C 
proANP-80 proANP concentration stored at -80°C 
R2 regression coefficient 
RAAS renin-angiotensin-aldosterone system 
RC concordance coefficient 
RIA radioimmunoassay 
ROC curve receiver operator characteristic curve 
RU resonance units 
SD standard deviation 
SPR surface plasmon resonance 
T1/2 half-life 
Tb serum antibody titer after biotinylation 
Te serum antibody titer at euthanasia 
TDI Tissue Doppler imaging 
TMB 3,3’,5,5’ tetramethylbenzidin 
TNF-α tumor necrosis factor alpha 
TR tricuspid valve regurgitation 
VHD valvular heart disease 
VO2max maximal oxygen uptake 
VPD ventricular premature depolarization 
VSD ventricular septal defect 
  
 
 
 
  
 
  
Chapter 1 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from N. Van Der Vekens, A. Decloedt, D. De Clercq, T. Verheyen, G. van Loon 
(2012). The use of cardiac biomarkers in veterinary medicine: the equine perspective. 
Flemish Veterinary Journal 81, 319-327.   

 Chapter 1: General introduction 
 
3 
 
Chapter 1: General introduction 
1.1 The heart muscle in the equine athlete  
The horse is one of the most athletic species thanks to a superior cardiovascular system 
which is highly adapted to exercise [1]. In order to deliver the necessary oxygen during 
exercise, a high cardiac output is needed. Values up to 900 mL/kg/min have been found 
in horses and are the result of a high heart rate range (25-240 bpm) and a high stroke 
volume (1700 mL) [1-3]. In addition, the circulating blood volume is increased at the 
onset of exercise by splenic contraction [4]. The high cardiac output results in a 
spectacular maximal oxygen uptake, which can be over 200 ml/kg/min in racehorses and 
is directly related to the heart size of the horse [5]. A complicated hormonal regulating 
system controls this cardiac output. In response to the high cardiac pressure during 
exercise natriuretic peptides (NPs) are released into the circulation from granules within 
cardiac myocytes and regulate the fluid balance [6]. Similarly, these NPs are released in 
pathological cases of atrial or ventricular stretch [7]. The cardiac muscle contraction 
itself is formed by cross bridging between thick and thin filaments of the myocardial cells 
[8]. These thin filaments are built of cardiac troponins, structural components which are 
released into the circulation in case of myocardial cell damage [9].   
Currently, cardiovascular disease is usually diagnosed by echocardiographic or 
electrocardiographic examination, techniques which are not always available in first line 
clinical practice. Specific cardiac hormones (natriuretic peptides) or structural 
components (cardiac troponins) can be measured by blood biochemistry. These “cardiac 
biomarkers” provide information on cardiac function and the presence of cardiovascular 
disease and might be a useful diagnostic tool in first line clinical practice [10, 11].  
1.2 Cardiac biomarkers: definition, physiology and structure  
The term biomarker was defined in 2001 as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological, pathogenic processes or 
pharmacologic responses to a therapeutic intervention” [11]. An ideal biomarker has to 
be accurate, reproducible, easy to interpret and has a high sensitivity and specificity for 
the outcome which it has to identify [11]. Several hormones, enzymes and other 
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proteins (Table 1) have appeared during the last two decades as markers for cardiac 
disease [10] and can be used for the diagnosis, prognosis or monitoring of therapy in 
case of cardiovascular disease. Since cardiac troponins and NPs are mostly used in 
human clinical practice [12-15], these cardiac biomarkers were selected and will be 
discussed more into detail below.  
Table 1. Summary of the most important cardiac biomarkers in human medicine. 
Biomarkers in bold are discussed more in detail below (adapted from Braunwald, 
(2008)[10]).  
Markers of myocyte stress B-type Natriuretic Peptide (BNP) 
 N-terminal pro B-type Natriuretic Peptide (NT-proBNP) 
 Atrial Natriuretic Peptide (ANP) 
 N-terminal pro Atrial Natriuretic Peptide (NT-proANP) 
 Midregional proadrenomedullin 
 ST2 (member of the interleukine-1 receptor family) 
Markers of myocyte injury Cardiac troponin T 
 Cardiac troponin I 
Creatine kinase MB fraction 
Lactate dehydrogenase 
 Myosin light chain kinase I 
 Heart type fatty acid protein 
Neurohormones Aldosterone 
 Norepinephrine 
 Renin 
 Angiotensin II 
 Arginine vasopressin 
 (Big) endotheline 1 
Markers of remodeling Matrix metalloproteinases 
 Tissue inhibitors of matrix metalloproteinases 
 Collagen propeptides 
Markers of inflammation C-Reactive Protein (CRP) 
 Interleukins 1, 6 and 19 
 Tumor Necrosis Factor alpha (TNF-α) 
 Apoptosis-antigen-1 
Indirect markers of oxidative 
stress 
Oxidized low density lipoproteins 
Myeloperoxidase 
 Urinary biopyrrins 
 Urinary and plasma isoprostanes 
 Plasma malondialdehyde 
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1.2.1 Cardiac troponins 
Cardiac troponins are part of the contractile apparatus and are found in both skeletal 
and muscle tissue. Within the myofibrils, troponin I, T and C form the thin filaments 
together with actin and tropomyosin (Figure 1). They regulate the calcium-mediated 
interaction of the actin and myosin proteins and thus control muscle contraction [9, 16]. 
The different troponin parts all have a specific function: while troponin C can bind to 
calcium and troponin T to tropomyosin, the troponin I molecule can switch between 
binding to actin and troponin C-calcium (Figure 2). At rest, tropomyosin blocks the 
binding sites between actin and myosin. After release of calcium by the sarcoplasmic 
reticulum and binding of calcium to troponin C, troponin I interacts with the troponin C-
calcium complex and the troponin complex changes shape. This shape change causes a 
movement of the troponins, which releases the tropomyosin molecule and exposes the 
myosin-binding sites on actin [8, 17].  
 
Figure 1. Schematic representation of the thin filament of cardiac muscle. Adapted from 
Parmacek et Solaro (2004) [18]. 
 
For troponin C (18 kDa), a cardiac (cTnC) and a skeletal isoform exists [18, 19]. Homology 
between these two isoforms reduces the cardiac specificity of troponin C. Therefore, it 
cannot be used for detection of cardiac damage. Several troponin T (35 kDa) genes also 
exist, and can undergo alternative splicing [18, 20]. Therefore, multiple skeletal troponin 
T isoforms can be present in skeletal muscle. In the human heart, only four troponin T 
isoforms are present and three of these isoforms are expressed in fetal cardiac tissue. 
The last troponin T isoform is characteristic for the human heart and expression of this 
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cardiac troponin T (cTnT) has only been described in patients with regenerating skeletal 
muscles and skeletal myopathies [18, 21]. Therefore, in all other individuals, it can be 
used as diagnostic tool for cardiac damage [9, 20].  
For troponin I (23 kDa), three isoforms exist, of which two are present in the skeletal and 
one in the cardiac muscle [9, 18, 20]. The cardiac troponin I (cTnI) form has a specific 32 
amino acid N-terminal peptide and is not expressed after damage or regeneration of 
skeletal muscle. Therefore, both cTnI and cTnT can be used for diagnosis of myocardial 
damage in human patients. 
 
Figure 2. Crystal structure of the cardiac troponin complex demonstrating the calcium 
binding site. Adapted from Davis et Tikunova (2007) [22]. 
 
The cardiac troponins I and T are mainly bound to the myofibrils and only 6-8% of cTnT 
and 2.8-4.1% of cTnI can be found in the cytosol of the cardiac myocytes. Damaging 
these cardiac myocytes primarily causes release of the cytosolic pool, which results in an 
early rise of troponin levels. The structural bound troponins are released at a slower rate 
and sustain the troponin elevation [9, 21]. During coronary artery occlusion, the cardiac 
myocytes become hypoxic and necrotic and a prolonged troponin release follows [23]. 
The cTnI and cTnT concentrations begin to rise 2-8 hours after coronary artery occlusion 
[21, 24] and a peak is found after 12-24 hours [21]. Although the troponin half-life (T1/2) 
is very short (about 2 hours), the cTnI and cTnT levels remain raised for 10-14 days and 
7-10 days, respectively [23]. This can be explained by the continuous leakage of the 
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troponins from necrotic cells. However, some conditions (e.g. supraventricular 
tachycardia, extreme physical exertion or profound hypotension) only cause temporarily 
ischemia whereby troponin concentrations drop very quickly. In these cases, the cardiac 
myocytes do probably not become necrotic, but only form blebs. Blebs are bubbles in 
the plasma membrane, which can be re-absorbed or shed into the circulation when re-
oxygenation after an ischemic period occurs. When the blebs are released into the 
circulation, they cause a very short troponin increase, which is quickly cleared from the 
plasma [23].  
After release into the circulation, cTnI, cTnT and cTnC can form different complexes: Wu 
et al. [25] and Bates et al. [26] have reported the presence of a cTnI-cTnC complex and a 
cTnT-cTnI-cTnC complex in serum of human patients with acute myocardial infarction 
(AMI). In contrast to cTnT, no free cTnI was identified, which might be caused by binding 
of the free cTnI to other surfaces or proteins [27]. Besides the formation of these 
troponin complexes, cTnI or cTnT might also be altered under physiological or 
pathological conditions by degradation or post-translational modifications such as 
phosphorylation and proteolysis [28]. Therefore, the circulating cTnI and cTnT forms 
might differ from the cardiac troponins bound to the thin filament.  
The exact clearance system of cTnI and cTnT remains unknown. However, clearance 
through the reticulo-endothelial system has been proposed. Since free cTnT and bound 
troponin complexes are large molecules, clearance by the kidney seems less probable 
[27]. 
 1.2.2 Natriuretic peptides 
The natriuretic peptides are a family of structurally related peptides which regulate fluid 
homeostasis [29, 30]. All NP members have a similar molecular structure which consists 
of a peptide ring formed by a disulphide binding between two cysteine molecules 
(Figure 3) [31]. The peptide ring is genetically conserved, since it forms the binding site 
to the NP receptor, while the NH2- and COOH-terminus might vary between species [30, 
31]. In literature, the nomenclature of NPs is confusing and incoherent, which makes 
interpretation of different studies very difficult [32, 33]. Table 2 gives the nomenclature 
which will be used throughout the text and is related to the origin of the NPs as 
proposed by Goetze (2004) [33].   
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Figure 3. Peptides chains of atrial natriuretic peptide (ANP), B-type natriuretic peptide 
(BNP) and C-type natriuretic peptide (CNP) adapted from Clerico et al. (2006) [31]. 
  
De Bold et al. [29] discovered atrial natriuretic peptide (ANP) in 1981 in atrial tissue. 
They found that injection of atrial tissue in rats caused diuresis and natriuresis. 
Therefore, the endocrine function of the heart was demonstrated [31]. B-type NP was 
also called brain natriuretic peptide (BNP) since it was originally discovered by Sudoh et 
al. [34] in the porcine brain 7 years after the ANP discovery. Since it is not mainly 
secreted by the brain, but the ventricles [35], its name has been changed into B-type NP 
[29]. In contrast to ANP and BNP, C-type natriuretic peptide (CNP) is mainly produced in 
the endothelial cells and is found at lower concentrations in the human heart [7, 31]. 
Since CNP only caused mild diuresis and natriuresis, only ANP and BNP are used in 
clinical practice to detect cardiac disease.   
Table 2. Nomenclature of the natriuretic peptide family, based on their origin.  
Natriuretic 
peptides 
(NPs) 
Atrial NPs 
proANP 
Prohormone, stored in the granules, 
 amino acids 1-126 
ANP COOH-terminal peptide, amino acids 99-126 
NT-proANP NH2-terminal peptide, amino acids 1-98 
B-type NPs 
proBNP 
Prohormone, stored in the granules, 
 amino acids 1-108 
BNP COOH-terminal peptide, amino acids 77-108 
NT-proBNP NH2-terminal peptide, amino acids 1-76 
 
The NPs are stored as prohormones (proANP and proBNP) in the cardiomyocytes and 
can be enzymatically cleaved in response to cardiac stretch into a (supposedly) inactive 
NH2-terminal peptide (NT-proANP and NT-proBNP) and a biologically active COOH-
terminal peptide (ANP and BNP). Although degradation by enzymes, metabolism by 
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target tissues and excretion into urine has been described, the majority of NP clearance 
is probably mediated by receptor binding. NPs can bind with their peptide ring (Figure 3) 
to three different NP receptor (NPR A, NPR B and NPR C) [7]. The biological function of 
ANP and BNP is especially mediated by binding to NPR A (Figure 4) [36] and activation of 
gyanylyl cyclase. This NPR A is mostly present in blood vessels, kidneys and adrenal gland 
and stimulates natriuresis, vasorelaxation and decreases aldosterone synthesis (Figure 2, 
Chapter 2) [36]. NPR B has the highest affinity for CNP [29]. The final receptor, NPR C, is 
mostly involved in the clearance of ANP and BNP, although some authors [36] believe 
that NPR C can adapt the physiological effects of NPs to local needs.  
 
Figure 4. Crystal structures of the natriuretic peptide receptor A (ribbon model) and the 
bound ANP hormone (in green). Adapted from Ogawa et al. (2004) [37]. 
1.2.2.1 Atrial natriuretic peptides  
The atrial NPs are mostly stored as proANP1-126 in the atrial cardiomyocytes [38], but are 
also present in other organs such as the pituitary gland, lungs, hypothalamus, kidney and 
gastro-intestinal tract [39, 40]. In response to atrial stretch, the proANP1-126 molecule is 
cleaved into NT-proANP1-98 and ANP99-126 (Figure 5)[41]. After release, ANP has a short 
T1/2 of about 2-5 minutes in humans. The T1/2 of NT-proANP is longer (about 55-60 
minutes). Therefore, NT-proANP can be used to assess endogenous secretion of ANP 
[41-43].  
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Figure 5. Enzymatic cleavage of proANP1-126 by corin into NT-proANP1-98 and ANP99-126.  
 
1.2.2.2. B-type natriuretic peptides 
B-type natriuretic peptides can be found in the myocardium, brain and adrenal glands. 
Similarly to atrial NPs, myocyte stretching stimulates BNP expression and results in 
cleavage of proBNP1-108 by furin into NT-proBNP1-76 and BNP77-108. The biosynthesis of 
BNP and its post-translational phase has been more elaborately studied than of ANP [33, 
40]. Studies show that the maturation of proBNP is probably more complex; other 
proBNP-derived fragments might be developed during the post-translational phase [33]. 
A summary of the proBNP processing is given in Figure 6.   
Although BNP is often referred to as the ventricular hormone, BNP gene expression 
occurs mainly in the atria of healthy individuals and an up-regulation in the ventricles 
can only be found in people with heart failure [33]. Both BNP (12-20 min) and NT-
proBNP (120 min) have a longer T1/2 than ANP [44-47]. However, this is still under 
discussion, since the first NT-proBNP T1/2 studies were performed in sheep [45] and a 
lower NT-proBNP T1/2 (24.8 min) has recently been described using a single-
compartment model [47].  
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Figure 6. Processing and metabolism of the proBNP-derived peptides. ProBNP is 
enzymatically cleaved into the BNP and NT-proBNP peptide during secretion. High and 
low molecular weight (MW) immunoreactive (ir) molecules have been described, 
probably due to degradation or post-translational modification of proBNP-derived 
peptides. More research is necessary to expose the different circulating proBNP-derived 
peptides in more detail (adapted from Mair (2008) [40]).  
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1.3 Use of cardiac biomarkers in human medicine 
1.3.1 Cardiac troponins, markers for myocyte injury 
The primary role of cardiac troponin testing in humans is the diagnosis of AMI. In the last 
decade, the troponins have replaced the less sensitive lactate dehydrogenase and 
creatine kinase-myocardial band isoenzymes. Not only are the cardiac troponins more 
specific, their elevations remain longer, making them an excellent biomarker for 
detection of AMI [9, 21].  
1.3.1.1 Assay comparison for diagnosis of acute myocardial infarction 
The diagnosis of AMI is based on a troponin value which has to be greater than the 99th 
percentile of a reference population with an assay imprecision of ≤10% [48]. The first 
generation troponin assays did not achieve such precision, but the new generation high-
sensitive (hs) assays can indeed reach these high standards. Table 3 gives a summary of 
the most important troponin assays with their 99th percentile troponin values. As Table 3 
demonstrates, many different cTnI assays are available, while only one manufacturer 
produces cTnT assays [48-50]. Comparison between the different cTnI assays seems 
difficult [51-53], which can be explained by differences in the detection and capture 
antibodies, which recognize different epitopes on the troponin molecule [49, 53].   
Besides the laboratory troponin assays, point of care assays (e.g. i-STAT assaya) have also 
been developed in order to perform troponin measurement immediately at the patient’s 
bedside. A comparison with other laboratory troponin assays demonstrated that the 
point of care assays have a decreased sensitivity [54, 55]. However, some authors think 
that using a lower cut-off value might reduce this difference [55].  
1.3.1.2 Pre-analytical factors 
The guarantee of a reliable troponin result does not only depend on assay 
characteristics. Pre-analytical factors such as storage time, storage temperature, 
anticoagulants and endogenous substances could also influence sample results [56]. For 
cTnT, samples storage at room temperature for 24 hours, at 4°C for one week, at -20°C 
for one month and at -70°C for 12 months did not affect sample concentrations [57, 58]. 
For cTnI, storage for 3 days at -20°C gave a 5% lower concentration than fresh samples 
[59]. In addition, the troponin value seems to be mainly dependent upon the used 
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method and the stability of the measured molecule [56]. The presence of troponin 
degradation products can explain this assay variability [60]. Rapid proteolytic 
degradation of serum cTnI has been described and therefore, a mixture of proteolytic 
cTnI fragments with different stability can be present in serum samples [61]. The epitope 
recognition site can differ between assays, thus recognition of these troponin 
degradation fragments can also vary between the assays [49, 53]. Therefore, the 
manufacturer’s recommendations regarding maximum in vitro sample stability should 
be followed [56].   
Table 3. Comparison of four important cardiac troponin assays. Adapted from the 
manufacturer’s instructions, Casals et al. (2007) and Bock et al. (2008) [62, 63] (CV= 
coefficient of variation; cTnI = cardiac troponin I). 
Assay Manufacturer Test principle 
99
th
 
percentile 
Detection 
limit 
Lowest 
troponin 
value 
with a 
10% CV 
Access 
Accu cTnI 
Beckman 
Coulter 
Corporations, 
Fullerton, 
California 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal) 
0.04 
ng/mL 
0.01 
ng/mL 
0.06 
ng/mL 
ADVIA 
Centaur 
TnI-Ultra 
Siemens 
Healthcare, 
Beersel, 
Belgium 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal+polyclonal) 
0.044 
ng/mL 
0.006 
ng/mL 
0.042 
ng/mL 
Architect 
STAT 
troponin-
I assay 
Abbott 
Diagnostics, 
Wavre, 
Belgium 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal) 
0.028 
ng/mL 
0.01 
ng/mL 
0.032 
ng/mL 
High-
sensitive 
troponin 
T 
assay 
Roche 
Diagnostics 
Vilvoorde, 
Belgium 
sandwich 
electrochemiluminescence 
immunoassay 
(monoclonal) 
0.014 
ng/mL 
0.005 
ng/mL 
0.013 
ng/mL 
 
Information on the influence of anticoagulants should also be provided by the 
manufacturer. Serum can be used in all troponin assays, but has the disadvantage that 
extra time is needed to allow sample clotting [56]. Variation between serum, 
ethylenediaminetetraacetic acid (EDTA) plasma and heparin samples exists. A mean 
decrease of 15% has been described in heparin plasma compared to serum samples [64]. 
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This might be caused by binding of the negatively charged anions of the heparin to the 
positively charged troponins [64, 65]. Addition of heparinase cannot reverse this 
reaction, thus besides direct covering of epitopes, irreversible conformational changes 
of the cardiac troponin molecules could also be induced by heparin addition [65]. EDTA 
can break the calcium-dependent cTnI-cTnC and cTnT-cTnI-cTnC complexes up into 
individual fragments and thus can cause a release of free cTnI in samples. This might also 
cause decreased plasma concentrations for assays which use antibodies that 
preferentially bind to these complexes [25, 56]. Finally, sample hemolysis might have a 
negative effect on cardiac troponin results. Since hemolysis is one of the most common 
pre-analytical interferences, samples should always be handled appropriately [48].  
1.3.1.3 Cardiac troponin I vs cardiac troponin T 
As mentioned above, only Roche Diagnostics has marketed different cTnT assays [21, 49, 
50] and recently a high-sensitive cTnT (hs-cTnT) assayb was developed [66]. The 
existence of only one cTnT assay facilitates data interpretation and comparison between 
studies. However, the cardiac specificity of cTnT has been questioned. The antibodies of 
the first generation assay showed cross reactivity with troponin T from skeletal muscle 
[67, 68]. In comparison to cardiac muscle (10.0 mg/g myofibrillair protein), the cTnT 
expression was also present in skeletal muscle fibers of patients with polymyositis (0.7 
mg/g myofibrillair protein), patients with Duchenne muscular dystrophy (4.37 mg/g 
myofibrillair protein) and even in normal skeletal muscle (0.8 mg/g myofibrillair protein) 
[68]. Since cTnT is also strongly present in fetal cardiac and skeletal muscle tissue, cTnT 
is probably the predominant isoform in the early development phase of muscle fibers. 
Thus, the presence of cTnT in skeletal muscle is probably due to re-expression and thus 
regeneration of muscle fibers [21, 68]. A second generation cTnT ELISA was developed to 
counter this cross reactivity. The cTnT capture antibody was replaced by a more cardiac 
specific antibody and no cTnT increase was seen in serum from patients with severe 
skeletal muscle damage [69]. Recently, the cTnT specificity has been re-questioned [70] 
and cross reactivity was found between the three antibodies used in the fourth 
generation and hs-cTnT assay and diseased skeletal muscle biopsies. Therefore, cTnI 
might me more useful than cTnT in case of extreme skeletal muscle damage [70].    
In patients without skeletal muscle damage, cTnI and cTnT are comparable in diagnostic 
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and prognostic efficacy [21, 71, 72]. A good correlation between cTnTc and cTnId values 
has been found 6 hours after patient admission [72] and a similar clinical performance 
was demonstrated for diagnosis of AMI [71].    
1.3.1.4 Other causes of troponin elevation 
Cardiac troponins are mainly used in human medicine for diagnosis of AMI, but also 
other (non-)cardiac causes can lead to increase of both cTnI and cTnT. Elevated cardiac 
troponin concentrations have been demonstrated after open heart surgery, septic 
shock, acute pulmonary embolism, strenuous exercise, heart failure, pericarditis, 
myocarditis, cardiotoxic chemotherapy, cardiac infiltrative disorders and myocardial 
contusion [73]. This troponin increase can mostly be explained by the presence of mild 
myocardial damage and is almost always correlated with a bad prognosis. For example, a 
significant correlation has been found between cTnI and right ventricular dilatation in 
patients with pulmonary embolism [74]. Similarly, cTnI is associated with decreased left 
ventricular ejection fraction in case of decompensated heart failure [75].   
Other causes of cardiac troponin increase are less clear. Patients with end-stage renal 
disease frequently have increased cardiac troponin values, without any evidence of 
myocardial ischemia [73]. The exact mechanism is not fully revealed, but interestingly, 
cTnT is more elevated than cTnI [27]. The influence of hemodialysis on serum levels 
might explain this difference. Blood dialysis can cause increased cTnT levels by 
concentrations effects. In contrast, cTnI is a hydrophobic molecule, which can adsorb to 
the dialysis membrane and be cleared out of the blood. An alternative explanation is the 
modification of the cTnI molecule during dialysis, which can cause changes in epitope 
recognition and can therefore give false-negative results [76]. Some authors report that 
a re-expression of cTnT occurs in skeletal muscle due to uremic induced skeletal 
myopathy and that false-positive cTnT results are present in patients with renal disease 
[77]. However, the patient population in this study was small (n=5) and the antibody 
used in this study has been reported to cross react with human skeletal muscle troponin 
T isoforms [78]. In a consecutive study, no cTnT expression was found in skeletal muscle 
tissue from patients with end-stage renal disease and increased serum cTnT [78]. In this 
study, a correlation between the presence of cTnT and indicators of coronary heart 
disease was demonstrated. Therefore, the cTnT increase might be related to subclinical 
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myocardial cell injury. Since cardiovascular disease is one the most important causes of 
death in patients with renal failure, it is probable that underlying cardiac pathology is in 
the end still the cause of the troponin elevations.   
Finally, troponin values can also be elevated due to analytical causes such as micro 
particles, fibrin clot formation or the presence of rheumatoid factor [73]. False-positive 
troponin results can also be caused by the presence of heterophile antibodies [73, 79]. 
These are antibodies which can bind to foreign immunoglobin and can cause interaction 
between animal-derived antibodies. If these antibodies form a cross-link between the 
capture and detection antibody in a troponin sandwich enzyme-linked immunoassay 
(ELISA), a (false) positive result can be present in the absence of a high troponin 
concentration (Figure 7).    
 
Figure 7. Normal binding of analyte in a sandwich enzyme-linked immunoassay (right) 
and cross-linking of an heterophile antibody between the capture and the detection 
antibody of the same assay (left).  
1.3.2 Atrial and B-type natriuretic peptides, markers of myocyte stress 
1.3.2.1 Diagnosis of heart failure 
BNP and NT-proBNP levels are routinely determined in the emergency department to 
differentiate between cardiac and non-cardiac causes of dyspnea [80, 81]. Compared to 
ANP, BNP and NT-proBNP seem to be superior for clinical use: they have a longer T1/2, a 
more rapid production and are more stable. A comparison of ANP, NT-proANP and BNP 
demonstrated that BNP was the best indicator for heart failure [82]. Similarly, BNP and 
NT-proBNP seemed better than NT-proANP for diagnosis of reduced left ventricular 
ejection fraction [83]. As this may be caused by fragmentation of the NT-proANP 
molecule [84], measurement of the more stable mid-regional part of this molecule (MR-
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proANP) was suggested to be a better option [84]. This has been confirmed in a recent 
study, which showed that mid-regional proANP (MR-proANP) is comparable to BNP for 
diagnosis of heart failure in patients with acute dyspnea [85]. Recently, a new technique 
called “processing independent analysis” has been proposed for measurement of the 
total proANP product [86-88]. Specific antibodies against a stable proANP1-16 fragment 
(extended with cysteine and coupled to bovine serum albumin) were produced by 
immunization of rabbits and used in combination with a porcine iodinated proANP1-16 
tracer molecule in a radioimmunoassay. Before sample analysis, plasma samples were 
extracted and treated with trypsin. This trypsin treatment exposes the C-terminal region 
of a stable proANP fragment (Figure 8), an epitope which was selected because it is not 
modified during post-translational processing. In this way, the total proANP product 
could be measured irrespective of post-translational modifications such as glycosylation 
or phosphorylation. Since post-translational maturation can vary between species, this is 
an excellent technique for comparative studies [87]. In addition, total proANP 
measurement seems to be a good predictor of mortality in acutely hospitalized patients 
[88]. 
 
Figure 8. Human preproANP sequence. The C-terminal region of the proANP epitope is 
released after trypsin treatment. Adapted from Hunter et al. (2011) [87].  
Both BNP and NT-proBNP can also be used for prognosis assessment and therapy 
monitoring in patients with heart failure [89]. Multiple assays have become available 
(Table 4) [90], all with a total imprecision of <15%, as recommended [91]. Similar as for 
cardiac troponins, the automated assays seem to perform better than the point of care 
assays [92]. The different assays also use antibodies directed against different epitopes. 
Since post-translational processing (1.2.2.2) can alter the B-type NP molecules, results 
can vary according to the assay [91, 93].  
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Table 4. Comparison of the analytical characteristics of five B-type natriuretic peptide 
(BNP) assays and a N-terminal BNP (NT-proBNP) assay. Adapted from the 
manufacturer’s instructions, Silver et al. (2004) and Sanz et al. (2006) [89, 93] (CV= 
coefficient of variation; * = point of care assay). 
Biomarker Assay Manufacturer Test principle Range 
Imprecision 
(total CV%) 
Cut-
off 
NT-
proBNP 
Elecsys 
NT-
proBNP 
Roche 
Diagnostics, 
Vilvoorde, 
Belgium 
sandwich 
electrochemiluminescence 
immunoassay 
(polyclonal) 
5-
35000 
pg/mL 
 
2.2-5.8% 
<75 
years: 
125 
pg/mL 
>75 
years: 
450 
pg/mL 
BNP 
Access 
BNP 
assay 
Beckman 
Coulter 
Corporations, 
Fullerton, 
California 
sandwich 
chemiluminescent  
immunoassay 
(monoclonal) 
 
  
116 
pg/mL 
ADVIA 
Centaur 
BNP 
Bayer 
Healthcare, 
Diegem, 
Belgium 
sandwich 
chemiluminescent  
immunoassay 
(monoclonal) 
 
2.0-
5000 
pg/mL 
2.3%-4.7% 
100 
pg/mL 
Architect 
BNP 
Abbott 
Diagnostics, 
Wavre, 
Belgium 
chemiluminescent 
microparticle 
immunoassay  
(monoclonal) 
 
0-
5000 
pg/mL 
1.7-6.7% 
100 
pg/mL 
i-STAT 
BNP* 
Abbott 
Diagnostics, 
Wavre, 
Belgium 
sandwich  
electrochemiluminescence 
immunoassay 
(monoclonal) 
 
15-
5000 
pg/mL 
8.1-11.1% 
100 
pg/mL 
Triage 
BNP 
Test* 
Biosite BVBA, 
Afsnee, 
Belgium 
sandwich 
chemiluminescence  
immunoassay 
(monoclonal+polyclonal) 
5-
1300 
pg/mL 
10.1-16.2% 
100 
pg/mL 
1.3.2.2 Preanalytical factors 
ANP and BNP are unstable molecules, thus knowledge of the influence of preanalytical 
factors is essential for sample interpretation. Long-term storage of EDTA plasma samples 
at -20°C or even at -80°C did not prevent BNP degradation and was most pronounced for 
high BNP concentrations [94]. NT-proBNP seemed to be more stable than BNP when 
stored at -20°C [95]. In contrast, for ANP samples no evidence of degradation was found 
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when samples were stored at -80°C for one year [96]. However, another study 
demonstrated that only storage in liquid nitrogen could keep ANP stable for one month 
[97]. A small decrease (<10%) in BNP was found with the Triage BNP teste when samples 
were stored at 4°C or at room temperature for 24 hours. However, this decrease was 
larger for the Access BNPf assay and sample analysis within 8 hours of collection has 
been recommended [98]. Plastic tubes with EDTA have been suggested for 
measurement of BNP and serum can only be used on the Elecsys NT-proBNP assayg [92]. 
The addition of proteinase inhibitors such as aprotinin has been proposed to improve 
sample stability. However, no significant effect has been seen for BNP or NT-proANP 
samples measured with radioimmunoassays (RIAs). In contrast, aprotinin addition 
improved the ANP stability when samples were stored for 24 hours at room 
temperature [99].  
As mentioned above, the use of different antibodies in these assays can explain these 
differences in stability. Therefore, manufacturer’s recommendations for sample 
collection and storage should always be followed [91, 93]. For example, the Triage BNP 
assaye uses a detection antibody against the NH2-terminus of the BNP molecule, while 
the ADVIA Centaur BNP assayh has an antibody against the COOH-terminus. Since 
proteolytic cleavage of N-terminal amino acids has been described in the circulation and 
in blood samples, this region might be a less appropriate choice for antibody production.  
1.3.2.3 Other causes of increased natriuretic peptide levels 
Non-cardiac disease such as respiratory disease, endocrine disorders, liver cirrhosis, 
renal failure, shock, chronic inflammatory disease, paraneoplastic syndrome and 
diabetes mellitus can also cause increases of the atrial or B-type NP concentration [100]. 
Similar as for cardiac troponins, these extra-cardiac diseases might lead to an increased 
activity of the NP system by indirect influence on the heart and can predict 
cardiovascular complications. For example, renal failure can not only cause water 
retention and thus volume overload, NP are also cleared through the kidney. Therefore, 
a decreased glomerular filtration rate can lead to increased NP levels [100]. NP levels 
can also be influenced by non-pathological factors. Significantly higher BNP values have 
been demonstrated in women than in men [35]. An estrogen driven stimulation of the 
NP system might be “cardio-protective” and might explain the lower incidence of cardiac 
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disease in women [101]. A positive correlation between age and BNP has also been 
described [35, 102]. In contrast, healthy individuals with a higher body mass index, seem 
to have a lower BNP and NT-proBNP concentration [103]. In this study, a close 
association was found between the lean body mass and the NP concentration. Since 
androgens can promote the lean body mass and the influence of sex hormones has been 
demonstrated, androgens might have an inhibitory effect on NP synthesis [100]. The 
influence of these non-pathological factors should be kept in mind when interpreting NP 
levels in clinical practice. An adjustment of the cut-off values depending on the patient’s 
age has already been proposed for NT-proBNP (Table 4). In a recent study, a higher 
specificity for diagnosis of cardiac dyspnea was also found when a BNP cut-off value was 
used which was corrected for age, sex and body mass index [81].  
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1.4 Use of cardiac biomarkers in small animal veterinary medicine 
1.4.1 Cardiac troponins 
The cardiac troponin structure is much conserved across species, which suggests that 
human assays can be used in different species. In comparison to men, both feline and 
canine cTnI have one additional amino acid. Feline cTnI also lacks another single amino-
acid. Since the cTnI region which is mostly targeted as epitope for antibody production 
in cTnI assays is very homologous, human cTnI assays can be used in dogs and cats [104]. 
In dogs and cats, reference values have already been established with several human 
assays (Table 5) and demonstrated that, similarly as in human medicine, cTnI assays can 
give different results and reference ranges should be developed for each assay 
individually [105].   
In contrast to human medicine, AMI is very rare in dogs and cats [106]. However, since 
cardiac troponins can also increase in other cardiac diseases such as heart failure and 
myocarditis (1.3.1.4), several authors have studied the use of cardiac troponins in 
clinically relevant conditions in dogs and cats. A higher cTnI and cTnT value was also 
found in dogs with blunt chest trauma and in dogs with gastric dilatation-volvulus, which 
indicates the presence of myocardial damage in these cases [107]. CTnI measured with a 
point of care analyzera was also able to differentiate non-cardiac and cardiac causes of 
respiratory distress [108]. Similarly, an increased cTnI was found in cats with cardiac 
dyspnea [109]. A significantly higher cTnI concentration was demonstrated in cats with 
hyperthropic cardiomyopathy (HCM), which is characterized by a concentric 
hypertrophy of the left ventricle wall [110]. This high cTnI concentration might be 
explained by the presence of myocardial damage due to intramural coronary artery 
disease or limited coronary reserve, which can cause ischemia of the ventricular wall 
[110]. A correlation was found in this study between the presence of heart failure and 
the cTnI concentrations. Similarly, a cut-off value for detection of heart failure was 
established to identify dogs with heart failure [111] caused by a variety of heart 
conditions.   
The use of cTnI to assess the severity and prognosis of cardiac disease has also been 
studied in dogs [112]. This study demonstrated that a persistently high cTnI 
concentration or a cTnI concentration higher than 1.0 ng/mLi indicates a poor outcome. 
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A similar conclusion was found in a second, smaller study, in which a non-detectable 
cTnI concentration indicated a longer survival time in dogs with mitral valve disease 
[113].   
In small animal veterinary medicine, cTnI is mostly studied. Only a few articles have 
compared cTnI and cTnT measurements [107, 113-115] and demonstrated that cTnI 
seems to be more sensitive than cTnT for the detection of myocardial damage in small 
animals. One paper [113] suggested that this may be caused by the smaller size of the 
cTnI molecule, that facilitates its release from the thin filament of the myocardium. This 
has not been described in human medicine. In another study, cTnI and not cTnT 
increased in dogs with gastric dilatation-volvulus [107]. This troponin increase can be 
explained by myocardial damage caused by a decreased cardiac output due to 
compression of the abdominal vena cava [107]. In this study, dogs with gastric 
dilatation-volvulus were presented very quickly (1.5 hours) after the first signs and it has 
been described that cTnI increases earlier than cTnT in dogs. CTnT was indeed higher 
after 24 hours, which may explain the differences between both molecules [107]. 
Schober et al. (2002) [114] also demonstrated that cTnI was more sensitive than cTnT for 
detection of myocardial injury in dogs after gastric dilatation-volvulus operation. 
However, both cTnI and cTnT had similar sensitivity and specificity for prediction of the 
outcome.  
1.4.2 Atrial and B-type natriuretic peptides 
The primary sequence of ANP is well conserved between species and 100% homology 
exists between human, feline and canine ANP (Table 6) [30, 116]. Therefore, the use of 
human ANP assays for detection of ANP in small animals has been proposed [30]. ANP 
has been measured in dogs with a commercially available human RIAj [117]. Not only did 
dogs with severe cardiac disease have higher ANP values compared to dogs with mild 
cardiac disease, the plasma ANP concentration was also a good predictor of survival. In 
cats, ANP concentrationsk increased significantly after the infusion of fluids to induce 
volume overload of the heart [118]. Secondly, the ANP concentration was also higher in 
cats with cardiomyopathy such as HCM compared to normal cats [118]. Similar to 
human medicine, measurement of a more stable mid-regional proANP31-67 fragment has 
been proposed for diagnosis of heart failure in dogs [119]. A significantly higher 
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proANP31-67 concentration was found in dogs with heart failure compared to healthy 
dogs. However, no association was found with the severity of the disease. In contrast, 
ANP increased gradually in dogs with progressive heart failure caused by myxomatous 
mitral valve disease [120].  
In comparison with atrial NPs, the B-type NPs are genetically more variable between 
species (Table 6) [30]. Therefore, species specific BNP and NT-proBNP assays have been 
used. Measurement of NT-proBNP with the CardioPet proBNP assayl demonstrated that, 
similar as in human medicine, NT-proBNP can be used to distinguish acute respiratory 
problems caused by heart failure from non-cardiac causes in small animals [121-124]. In 
dogs, a cut-off value of 6.21 pg/mL has been demonstrated for the detection of dilated 
cardiomyopathy [125]. A cut-off value (95.0 pmol/L) with high sensitivity (88.1%) and 
specificity (100%) was found for the detection of asymptomatic cats with cardiac 
enlargement, caused by HCM, hyperthyroidism or systemic hypertension [126]. 
Similarly, a cut-off value of 100 pmol/L has been established with a feline NT-proBNP 
assaym for detection of even mild forms of HCM [127]. In another study, only severe 
forms of HCM could be detected by measurement of NT-proBNP with a CardioCare NT-
proBNP assayn [128].  
The influence of extra-cardiac factors on natriuretic peptides has also been examined in 
small animals. A significantly higher NT-proANP and NT-proBNP concentration has been 
demonstrated in cats with severe chronic kidney disease [129]. Similarly, a higher NT-
proBNP concentration was found in dogs with renal disease [130]. Only a limited 
correlation with creatinine levels was found, which might suggest that not only 
decreased renal NT-proBNP clearance, but also increased NT-proBNP production might 
cause these high NT-proBNP values in case of renal disease. This increased NT-proBNP 
production might be caused by left ventricular wall dilatation, due to the plasma 
overload secondary to chronic renal disease [130].  
The NT-proBNP concentrations in small animals might also be influenced by breed 
differences, age, sex or body weight. A significant influence of the breed on proANP31-67 
and NT-proBNP values has been described in dogs: Labrador retrievers and 
Newfounlanders had highest NT-proBNP concentrations, while German Shepherds and 
Cavalier King Charles Spaniels had highest proANP31-67 values [132]. Breed differences in 
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heart rate, blood pressure and other cardiovascular variables might explain these 
differences [132], but also genetic mutations in the molecules could possibly play a role. 
In a second study, no breed differences was found. Since only dogs of smaller size were 
included in this study, breed differences could be limited in this population [133]. This 
study also found a higher NT-proBNP in female compared to male dogs, while no 
influence of age or body weight could be demonstrated in another study [133].  
Table 5. References values for different cardiac troponin assays in dogs and cats. 
Adapted from Herndon et al. (2002), Adin et al. (2005), Burgener et al. (2006), Payne et 
al. (2011) [107, 108, 110, 131] (cTnI= cardiac troponin I, cTnT= cardiac troponin T, * = 
point of care assay). 
 
Biomarker Assay Manufacturer Test principle Species Median Range 
cTnI 
Axsym 
Abbott 
Diagnostics, 
Wavre, 
Belgium 
sandwich 
microparticle 
immunoassay 
(monoclonal+polyclonal) 
Dogs 
(n=56) 
0.1 
ng/mL 
0.1-0.7 
ng/mL 
(2.5-
97.5%) 
i-STAT* 
sandwich 
electro- 
chemiluminescence 
immunoassay 
(monoclonal+polyclonal) 
Dogs 
(n=26) 
0.03 
ng/mL 
0.0-0.11 
ng/mL 
(min-
max) 
Immulite 
Siemens 
Healthcare, 
Beersel, 
Belgium 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal+polyclonal) 
Dogs 
(n=26) 
0.05 
ng/mL 
0.05-0.24 
ng/mL 
(min-
max) 
Stratus 
CS 
analyzer 
sandwich 
radial partition 
immunoassay 
(monoclonal) 
Cats 
(n=33) 
0.03 
ng/mL 
0.03-0.16 
ng/mL 
(min-
max) 
Triage 
Meter* 
Biosite BVBA, 
Afsnee, 
Belgium 
immunochromatographic 
fluorescence 
immunoassay 
(monoclonal) 
Dogs 
(n= 55) 
0.05 
ng/mL 
0.05-0.12 
ng/mL 
(5%-95%) 
Cats 
(n=58) 
0.05 
ng/mL 
0.05-0.05 
ng/mL 
(5%-95%) 
cTnT 
Cardiac 
reader* 
Roche 
Diagnostics, 
Vilvoorde, 
Belgium 
sandwich  
lateral flow immunoassay 
(monoclonal) 
Dogs 
(n=56) 
0.05 
ng/mL 
0.05-0.05 
ng/mL 
(2.5-
97.5%) 
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1.5 Use of cardiac biomarkers in horses 
1.5.1 Cardiac troponins 
Cardiac troponins have been studied in horses for the last ten years. The human and 
equine cTnI sequence are also very similar. In comparison to other species, a unique 6-
amino-acid N-terminal deletion has been identified in horses [134]. This deletion also 
lies outside the epitope region of human commercial cTnI assays. Therefore, as in small 
animals, human assays can also be used in horses. Reference values have been 
established with different assays and recently, the equine cTnI T1/2 (0.47 h) [135] has 
even been determined. Table 7 demonstrates the reference values for different cTnI and 
cTnT assays in horses. In a recent study, a point of care analyzera was compared with a 
Beckman Access Immunoassayo, achieving plasma concentrations from 0.0-0.06 ng/mL 
for normal healthy horses of different breeds [136]. A good correlation (r=0.83) was 
found between both assays. However, only blood samples from six horses treated with 
monensin were compared. Only a few studies have determined cTnT in horses [137, 
138]. In one study, a human quantitative ELISAp and qualitative assayq were used. Similar 
to cTnI, all healthy horses had cTnT values under the limit of detection.   
In horses, primary myocardial damage can have different causes such as inflammatory 
processes or toxic agents [136, 137, 139-141]. Retrospective studies show positive 
associations between a cTnI increase and the degree of cardiac damage at necropsy 
[136, 142]. In some case reports, this increase is extremely high. In a study by 
Schwarzwald et al. [140], a cTnI concentration of 404 ng/mL was measuredr in a horse 
with multiform ventricular tachycardia. An even higher value (816.00 ng/mLd) has been 
reported in a horses with lasalocid intoxication [141]. High cTnI [143] and cTnT [137] 
values have also been reported in horses with atypical myopathy indicating cardiac 
involvement and in horses with structural heart disease such as valvular regurgitation or 
congenital cardiac lesions [139]. Similarly, horses with cardiac dilatation caused by 
valvular regurgitation had higher cTnT values [137].  
The influence of other factors on cardiac troponin values has also been examined in 
horses. A weak correlation between age and cTnI has been found [144] and increased 
cTnI concentrations have been seen in horses after racing [145], horses with septicemia 
[138], endotoxemia [146] and colic [147, 148]. Elevated cTnI values in horses with colic 
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are probably caused by the leakage of endotoxin from the damaged gastro-intestinal 
tract into the circulation and can be an indicator of prognosis [147, 148]. No influence of 
transportation [149], sex [144] or acute pulmonary obstruction [150] on cTnI values has 
been detected. Three studies have looked at troponin values after transvenous electrical 
cardioversion of atrial fibrillation: in the first study, only a small significant cTnI increase 
was seen [151], while no cTnI or cTnT elevation was seen in the two other studies [152, 
153].  
1.5.2 Atrial and B-type natriuretic peptides 
No specific equine BNP or NT-proBNP is yet available. Therefore, equine NP studies are 
limited to the measurement of atrial NPs with human assays (Table 6). The median ANP 
concentration in normal horses (n=6) with a human RIAs was 12.5 pg/mL (6.3-18.9 
pg/mL) [154]. A similar plasma ANP concentration (mean: 21±5.4 pg/mL) was found in 
second study with another human RIAt [155]. Although the exact same assay was used, 
much higher ANP concentrations (51.00±33.94 pg/mL) were demonstrated in a recent 
study [156]. Differences in sample processing [156] might partly explain these results, 
but the high inter-assay coefficient of variation of this test (21-60%) [157] is probably the 
most important factor to explain these large differences. A large inter-assay coefficient 
of variation was also found for two other human ANP assays [158]. In this study a poor 
agreement between different human ANP assays was also demonstrated [158], which 
could be caused by antibody differences, differences in sample protocols or targeted 
proteins.  
Even with the human ANP assays, a positive correlation between the ANP concentration 
and left atrial size has been demonstrated [155, 156]. A significantly higher plasma ANP 
concentration was also found in horses with moderate or severe valvular regurgitation 
compared to horses with mild or no valvular regurgitation and in horses with congestive 
heart failure [156]. Different ANP cut-off values for detection of mitral valve 
regurgitation have been proposed by Trachsel et al. (2013) [157] at rest (97 pg/mL), five 
minutes (455 pg/mL) or ten minutes after exercise (332 pg/mL). Therefore, even with 
the human ANP assays, the plasma ANP concentration in horses seems to be useful to 
detect severe valvular regurgitation in horses. However, the same authors suggested 
[158] that because of the high inter-assay coefficient of variation and thus the poor 
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analytical performance of the human tests there is a need for an optimized ANP assay. 
Since post-translational processing might differ between species and structural 
differences could exist even in case of 100% homology, an equine specific assay might 
be the best option. The influence of extra-cardiac factors has been poorly investigated in 
horses. Increased ANP and NT-proANP concentrations in horses have been reported 
post-exercise [159-161] as described in Chapter 2. 
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Table 7. Reference values for different cardiac troponin assays in healthy horses (cTnI = 
cardiac troponin I, cTnT= cardiac troponin T). 
Bio-
marker 
Assay Manufacturer Test principle Horses Median 
Reference 
values 
[study] 
cTnI 
Access 
Immuno-
assay 
Beckman 
Coulter Corp., 
Fullerton, 
California 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal) 
Foals (n=52) 
Different 
breeds 
0.14 
ng/mL 
0.01-0.51 
ng/mL 
[138] 
ADVIA 
Centaur 
Assay TnI-
Ultra 
Siemens 
Healthcare, 
Beersel, 
Belgium 
 
sandwich 
chemi- 
luminescence 
immunoassay 
(monoclonal 
+polyclonal) 
Thoroughbreds 
(n=18) 
<0.03 
ng/mL 
<0.03 
ng/mL 
[139] 
ADVIA 
Centaur 
cTnI assay 
sandwich 
chemi- 
luminescence 
immunoassay 
(monoclonal 
+polyclonal) 
Thoroughbreds 
(n=23) 
<0.15 
ng/mL 
<0.15 
ng/mL 
[162] 
Dimension 
Hetero-
geneous 
Immuno-
assay 
sandwich 
enzyme 
immunoassay 
(monoclonal) 
Thoroughbreds 
(n=20) 
<0.04 
ng/mL 
<0.04-
0.35 
ng/mL 
[163] 
Stratus CS 
immuno-
assay 
sandwich 
radial partition 
immunoassay 
(monoclonal) 
Warmbloods 
(n=10) 
<0.1 
ng/mL 
<0.1 
ng/mL 
[137] 
Standardbreds 
(n=586) 
0 
ng/mL 
0-0.15 
ng/mL 
[144] 
 
Architect 
CI8200 
Abbott 
Diagnostics, 
Wavre, 
Belgium 
sandwich 
chemiluminescence 
immunoassay 
(monoclonal) 
Standardbreds 
(n=67) 
Thoroughbreds 
(n=34) 
Warmbloods 
(n=35) 
<0.022 
ng/mL 
<0.022 
µg/L-
0.043 
ng/mL 
[145] 
cTnT 
Elecsys 
2010 
immuno-
assay 
Beckman 
Coulter Corp., 
Fullerton, 
California 
sandwich 
electro- 
chemiluminescence 
immunoassay 
(monoclonal) 
Foals (n=52) 
Different 
breeds 
0.009 
ng/mL 
0.009-
0.041 
ng/mL 
[138] 
ELISA 
troponin T 
test 
Boehringer 
Mannheim 
GmbH, now 
Roche 
Diagnostics, 
Vilvoorde, 
Belgium 
sandwich 
enzyme-linked 
immunoassay 
(monoclonal) 
Warmbloods 
(n=10) 
<0.04 
ng/mL 
<0.04 
ng/mL 
[137] 
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Footnotes
 
a i-STAT assay, Abbott Diagnostics, Wavre, Belgium 
b High Sensitive (hs) troponin T assay, Roche Diagnostics, Vilvoorde, Belgium 
c ELISA Troponin T, Boehringer Mannheim GmbH, now Roche Diagnostics, Vilvoorde, 
Belgium 
d Opus Magnum Device, Dade Behring, now Siemens Healthcare, Beersel, Belgium 
e Triage BNP test, Biosite BVBA, Afsnee, Belgium 
f Access BNP assay, Beckman Coulter Corporations, Fullerton, California 
g Elecsys NT-proBNP assay, Roche Diagnostics, Vilvoorde, Belgium 
h ADVIA Centaur BNP, Bayer Healthcare, Diegem, Belgium 
i Immunolite, Siemens Healthcare, Beersel, Belgium 
j ANF RIA kit, Peninsula Laboratories, Belmont, California 
k Shionoria-ANP, Shionogi Co, Osaka, Japan 
l Cardiopet proBNP assay, IDEXX Laboratories Inc, Hoofddorp, the Netherlands 
m Feline Cardioscreen NT-proBNP, Biomedica, Vienna, Austria 
n CardioCare NT-proBNP assay, Veterinary Diagnostics Institute, Irivine, California 
o Access Accu cTnI, Beckman Coulter Corporations, Fullerton, California 
p Quantitative ELISA, Boehringer Mannheim GmbH, now Roche Diagnostics, Vilvoorde, 
Belgium 
q Trop T sensitive rapid assay, Boehringer Mannheim GmbH, now Roche Diagnostics, 
Vilvoorde, Belgium 
r ADVIA Centaur TnI assay, Siemens Healthcare, Beersel, Belgium 
s RK-005-06 ANP-α, Phoenix Pharmaceuticals Inc, Mannheim, Germany 
t RIA S-2011, Peninsula Laboratories, San Carlos, California 
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Chapter 2: Human and equine cardiovascular endocrinology: 
beware to compare 
2.1 Introduction 
Over the last two decades, studies on biomarker stability [1-3], half-life (T1/2)[4-9], assay 
differences [10-13], and extra-cardiac influences [14, 15] have been carried out and 
specific guidelines on the use of biomarkers in human medicine have been published 
[16, 17]. These studies show that the interpretation of results in clinical practice is at 
times challenging [1, 14, 18, 19]. As Chapter 1 demonstrates, cardiac biomarker 
measurement is now emerging in veterinary medicine and the use of biomarkers in 
small animal and equine clinical practice is growing [20-33]. Although species specific 
studies have been carried out [5, 34, 35], it is still frequently assumed that human and 
veterinary cardiac biomarker behavior is comparable. Therefore, data such as T1/2 and 
stability have been extrapolated from human medicine to veterinary sciences, and 
animal models have been used to study human (patho)physiology [36-42]. However, 
before results can be exchanged between different species, a thorough species 
comparison is necessary. Therefore, this chapter compares the (patho)physiology 
related to the most important cardiac biomarkers in humans and horses.  
2.2 Comparison of cardiovascular physiology and pathophysiology 
2.2.1 The human versus the equine athlete 
Human and equine cardiac anatomy is similar, apart from small differences in the 
ventricular blood supply [43]. Anatomical differences also exist in the conduction 
system: whereas in humans, the Purkinje fibers are limited to the subendocardial 
myocardium, they extend throughout the myocardium in horses and other ungulates, 
making ventricular excitation more efficient and thus relatively short [44]. Recently, a 
difference between human and equine ventricular repolarization has also been 
described [45]. In contrast to the linear regression model in humans [46], a piecewise 
regression model between the QT-interval and the R-R interval has been found in horses 
[45]. Differences in the expression of kinetics of slow delayed rectifier potassium 
channels (KCNQ1) could explain these findings. However, more studies are definitely 
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needed.  
Comparison of human and equine physiology shows that the horse is better adapted to 
performance and has an extraordinary aerobic capacity (Figure 1). Normal human 
resting heart rate lies between 60 and 90 bpm and can increase up to 220 bpm during 
maximal exercise. The human heart weighs on average 4 g/kg body weight and a stroke 
volume of 1.5-2.2 mL/kg has been described. The stroke volume can reach values up to 
189 mL in human athletes [47, 48]. Stroke volume and heart rate determine cardiac 
output, which can increase up to 200-400 mL/kg/min at maximal exercise [48, 49]. 
 
Figure 1. Proportional anatomy of the human (left) and equine heart (right). Ao: aorta; 
LA: left atrium, LV: left ventricle, P: pulmonary artery, RA: right atrium, RV: right 
ventricle.  
The superiority of the equine cardiovascular system is because of the wide heart rate 
range and the large cardiac mass. Equine heart rate is determined in different breeds 
and can vary between 25 bpm at rest and 240 bpm during maximal exercise [50-53]. The 
heart can weigh more than 10 g/kg and a maximal size of 20 g/kg body weight has been 
described [50, 54]. This contributes toward a high stroke volume, up to 1700 mL or 3-4 
mL/kg [55]. As both stroke volume and heart rate are relatively higher in horses, cardiac 
output can achieve values twice as high as seen in humans, up to 450 L/min or 900 
mL/kg/min [50, 52]. In addition, horses can increase their blood volume at the onset of 
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exercise because of splenic contraction, releasing up to 12 L of splenic blood into the 
circulation [56-58]. This results in a significant increase in oxygen-carrying capacity [59, 
60]. A maximal oxygen uptake (VO2max) of 200 mL/kg has been described in 
Thoroughbred horses, whereas human champion endurance athletes have a VO2max of 
70-85 mL/kg [59, 61]. In comparison with other large animals of equal size, the equine 
O2 supply is strengthened by a lower peripheral tissue resistance, a two-fold larger 
diffusing capacity, and a higher mitochondrial skeletal muscle density [62-65]. A detailed 
comparison with human oxygen transport shows that the lung function of the horse is a 
limiting factor [57, 66]. The Bohr effect (or the decrease in O2-hemoglobine affinity with 
an increase in blood temperature, PCO2 (the partial pressure of CO2), and free hydrogens 
ions) is much more important in humans. This reflects in significant O2 desaturation and 
hypoxemia in sport horses, an event that is rarely seen in human athletes. In conclusion, 
the human and equine physiological response to exercise is similar. However, in contrast 
to humans, horses have a limiting pulmonary function, which is overcome by a 
compliant cardiovascular system.  
2.2.2 Species differences in cardiovascular disease  
Cardiovascular disease is responsible for about 40% of human deaths in most European 
countries. More than 50% of these human cardiac deaths are caused by coronary heart 
disease. Other important causes are hypertension and stroke. The risk of stroke is highly 
associated with atrial fibrillation, the most common cardiac arrhythmia [67]. The 
prevalence of atrial fibrillation in humans increases from 2% until 9% in patients 
between 60-69 and 80-89 years old [68]. In comparison, valvular heart disease (VHD) is 
less frequently diagnosed. Mitral regurgitation and aortic valve disease are the most 
important [69]. Tricuspid regurgitation is associated with training and can be identified 
frequently in human athletes [70].   
In horses, cardiovascular death is rare and most commonly caused by congestive heart 
failure or cardiac arrhythmia. Coronary heart disease and hypertension are rarely 
reported. Nevertheless, cardiac disease is the third most common cause (after 
musculoskeletal and respiratory disorders) of poor performance in horses requiring a 
thorough cardiovascular examination [71]. VHD, especially mitral regurgitation, is the 
most frequently diagnosed structural cardiac disease [72-74]. Both in humans and in 
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horses, tricuspid regurgitation probably results from right ventricular remodeling 
because of a high pulmonary arterial systolic pressure during exercise [75]. In 
comparison with humans, (aortic) stenosis is very rare and frequently congenital in 
nature. Aortic regurgitation is more common, especially in older horses [76]. Although 
the prevalence of atrial fibrillation in horses is comparable with humans [77], embolic 
stroke has never been reported in horses. In well-trained human athletes, second 
degree atrioventricular block can be physiological and is associated with a high vagal 
tone [78]. This arrhythmia is also very commonly observed in horses at rest with a 
prevalence of 23% [79]. The clinical significance of other arrhythmia such as atrial and 
ventricular premature depolarizations, is less clear in horses, especially during warm-up, 
exercise, and recovery [80-84]. In humans, a correlation between exercise-induced 
ventricular premature depolarizations and long-term cardiovascular death has been 
described [85, 86]. Both in men and in horses, systemic or myocardial disease is 
suspected when a high burden of ectopy is present. Electrolyte disturbances (potassium, 
magnesium, calcium, and sodium) significantly affect the electrophysiological properties 
of the heart and are mainly drug induced in humans [87, 88], or because of hypertonic 
sweat loss in horses [89]. 
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2.3 Species differences in cardiac biomarkers 
2.3.1 The troponins 
2.3.1.1 Difference in half-life 
The human troponin T1/2 is about 2 hours [90](1.2.1). Recently, an even shorter cTnI T1/2 
(0.47h) has been described in horses [5]. This indicates that optimal sampling time is not 
similar to humans; in theory the optimal sampling time should be 1-2 hours after the 
suspected maximal increase of cTnI.   
 
2.3.1.2 Influence of exercise  
Since the introduction of newer high-sensitive troponin assays, a mild increase in cTnT 
and cTnI has been measured after prolonged and strenuous exercise such as seen in 
marathon runners [91, 92]. No exact explanation has been determined for this ‘runners 
syndrome’. However, one hypothesis states that cardiac ischemia during exercise 
interferes with the normal function and integrity of the plasma membrane and that 
‘blebs’ (bubbles in the plasma membrane, cfr. 1.2.1) are formed [92].   
In horses, no [93, 94] or a very mild [95, 96] elevation in cTnI was found after racing and 
no post-exercise equine cTnT values have been studied yet. Comparison with human 
studies is very difficult: not only are less sensitive assays used, a 2-min equine race is not 
comparable with a human marathon. However, both in humans and in horses, it seems 
unlikely that these mild troponin increases reflect real myocardial damage [92, 96, 97]. 
More studies are needed to establish normal post-exercise reference values and to 
compare these levels with post-exercise troponin levels in humans or horses with 
cardiac disease.  
2.3.2 Natriuretic peptides 
As mentioned above, the primary sequence is well conserved between species and there 
is 100% homology between human and equine ANP, suggesting that humans assays can 
be used to measure ANP plasma concentrations in horses (Table 6, Chapter 1)[98]. 
Although its NH2-terminal counterpart (NT-proANP) is more species specific, with only 
80-90% homology, human assays still yield good results for NT-proANP determination in 
horses [99].  
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2.3.2.1 Regional expression 
In healthy individuals, both ANP and BNP gene expressions are mainly found in the atria 
[100]. In comparison, patients with left ventricular systolic dysfunction and heart failure 
show a marked up regulation of the BNP gene expression in the ventricles [101]. The 
number of animal studies on NP gene expression is limited; thus it is often assumed in 
equine clinical studies that gene expression is similar to humans. Differences in animal 
ANP storage have been reported by Mifune et al. [102, 103] using antiserum against 
human ANP. Similar to humans, all studied animals (pigs, cattle and horses) had granules 
with ANP reactivity in the atria and no ANP reaction was observed in the ventricular 
muscles. The ANP reaction was more prominent in the right atrium than in the left 
atrium. When comparing the right atrium with the right auricle, pigs and cattle showed 
more ANP reactivity in the right auricle [102]. This is in contrast to horses, in which no 
difference was observed [102, 103]. Furthermore, horses expressed fewer granules in 
the atria and these granules also had a smaller diameter [102]. In non-mammalian 
species, it has been described that fewer and smaller ANP granules are associated with a 
higher ANP synthesis [104]; this might indicate that, in comparison with other animals, 
horses have a higher secretory ability of ANP. These species differences probably reflect 
variations in physiological parameters such as body size, heart rate, blood pressure, and 
water intake and thus show real endocrine differences between these related species 
[102, 105]. Unfortunately, no similar study has been carried out for regional expression 
of BNP as no cross reactivity between human and equine antisera exists. One study 
reported BNP-like activity in the equine atria using porcine BNP antisera [103]. Porcine 
antisera were chosen as there is a greater molecular similarity between equine and 
porcine than between equine and human BNP (Table 6, Chapter 1). This could indicate 
that, similar to humans, the equine atria secrete both atrial and B-type NPs. As no 
ventricular tissue has been examined as yet, a full comparison with human data is still 
warranted. 
2.3.2.2 Basal levels and elimination 
As described in Chapter 1 (1.3.2.3), higher NP concentrations are consistently shown in 
eldery and in females [106]. These differences are probably because of physiological 
variations and show that age-specific and sex-specific reference limits should be used in 
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human clinical practice [107-109]. Sampling time should also be considered as a diurnal 
plasma concentration variation has been confirmed recently [110]. Diurnal differences 
have not been studied in horses. No correlation between age and plasma ANP 
correlation was seen in one study [111]. However, another study has described a 
significant sex influence: in 36 horses, six stallions had lower ANP and NT-proANP values 
[99]. As only a limited number of horses were included, more research should be carried 
out.   
A T1/2 of about 2-5 min and 55-60 min has been described for human ANP and NT-
proANP, respectively (Section 1.2.2.1) [4, 6]. No equine T1/2 has been reported as yet. 
However, post-exercise ANP and NT-proANP kinetics show similar results as in humans: 
NT-proANP reaches higher values and remains elevated longer, which might indicate 
that, similar to humans, the T1/2 of NT-proANP is longer [112].  
2.3.2.3 Influence of exercise 
The influence of exercise on atrial NP levels has been investigated thoroughly both in 
humans and in horses [112-117]. Comparison of these different studies is complicated as 
both the methodology and the physical fitness of the participants differ. In humans, a 
clear effect of the exercise-testing protocol on ANP plasma concentrations has been 
reported [115]. Short-term maximal exercise significantly increased ANP values, whereas 
intermittent exercise did not. In horses, Nyman et al. (1998) [113] found no difference in 
maximal ANP plasma concentrations between a submaximal and a near-maximal 
exercise test. However, the post-exercise return to baseline differed significantly : a 
faster decrease in ANP concentrations was observed after the less intensive test. ANP 
concentrations were, however, still significantly higher than the baseline values 30 
minutes after exercise for both exercise protocols. This decrease in ANP is considerably 
different from humans, where an actual ANP ‘drop’ occurs and baseline values are 
already reached 30 minutes after exercise [115]. The rapid decrease in ANP might 
possibly be explained by the short human ANP T1/2 and might indicate that horses have 
an attenuated ANP elimination [4, 113]. Another hypothesis is the effect of splenic 
contraction at the onset of exercise. As mentioned above, horses can significantly 
increase their blood volume in this way and the maintenance of a high venous return 
after exercise will affect right atrial pressure [99]. The influence of splenic contraction on 
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plasma ANP concentration has been reported by McKeever et al. [56] who found that 
splenectomized horses reached lower ANP concentrations during exercise compared 
with spleen-intact horses.  
2.3.3 The renin-angiotensin-aldosterone system 
In normal individuals, a complicated balance between NPs and the plasma aldosterone 
concentration maintains fluid and electrolyte homeostasis. Decompensated heart 
failure, however, triggers the renin-angiotensin-aldosterone system (RAAS) and 
counteracts with the NP action [118] (Figure 2). This leads to increased aldosterone 
release, which promotes sodium reabsorption and increases blood volume [119]. Since a 
close relationship with NPs exists, a comparison between the human and equine RAAS is 
necessary to understand the differences between human and equine cardiovascular 
endocrinology. Aldosterone is also a cardiac biomarker (Table 1, Chapter 1), although 
less used in clinical practice. In humans, high aldosterone levels have been associated 
with increased risk of mortality and aldosterone blockade of the RAAS (for example by 
angiotensin-converting enzyme inhibitors) remains an important strategy in heart failure 
treatment [120-123]. In horses, only one study has found a correlation between the 
aldosterone concentration and the severity of VHD [124]. 
2.3.3.1 Normal circadian rhythm 
When measuring plasma aldosterone in clinical practice, circadian variation should be 
considered. In humans, aldosterone levels begin to rise at 05:00 a.m., with the highest 
values achieved from 08.00 a.m. until 02:00 p.m. Thus, in humans, aldosterone reaches 
high values during daytime [125]. Interestingly, the opposite has been found in horses 
and the highest values were reached at nighttime [126]. However, feeding habits such as 
frequency and electrolyte intake clearly have an important effect on the RAAS and a 
postprandial plasma aldosterone increase has been described in horses [127, 128]. In 
humans, it has been shown that episodic food intake induces peak renin activity and a 
correlation between meal intake and higher metabolic rate of aldosterone has been 
described [129, 130]. However, feeding habits differ between horses and humans, which 
makes comparison very difficult. Similarly, body posture has been described to influence 
plasma renin activity and plasma aldosterone in healthy individuals [131]. Human 
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studies are often carried out on participants in the supine position. In contrast, blood 
samples are normally obtained from standing horses.  
 
 
Figure 2. Influence of aldosterone and atrial natriuretic peptide (ANP) interaction on the 
water and salt homeostasis (adapted from Bouley (2012) [132]).  
2.3.3.2 RAAS response to hypovolemia  
An immediate RAAS response in hypovolemic cases is necessary to maintain blood 
volume and thus prevent collapse because of severe hypotension. Human neonates are 
much more susceptible to dehydration in comparison with adults and the mean basal 
aldosterone levels are generally high in newborns [133]. This may indicate the presence 
of a less sensitive distal tube in the neonatal kidney. Similar findings have been reported 
in foals [134]. However, Hollis et al. (2008) [134] also found a significant difference 
between the RAAS of human and equine neonati. Normally, a decrease in blood volume 
causes an increase in renin, which is followed by a higher aldosterone level. Foals 
respond with an increase in plasma aldosterone and renin during dehydration. However, 
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despite the increase in renin activity, no such plasma aldosterone changes has been 
described in human newborns [135]. This could indicate that the human neonate RAAS 
acts differently or might be influenced by other factors. 
2.3.3.3 RAAS response to exercise 
During exercise, both ANP and aldosterone increase, despite their contradictory actions. 
The net results, however, seem to be dominated by aldosterone as the final outcome is 
a reduction in the glomerular filtration rate [18]. At a lower intensity, the effects of ANP 
seem to overrule aldosterone and human urine flow and sodium excretion increases 
[18]. A correlation between aldosterone concentration and exercise intensity has also 
been described in horses [136]. However, the human and equine RAAS response to 
exercise is considerably different: in Thoroughbreds, a small increase of 30% in plasma 
renin activity corresponds with a high increase in plasma aldosterone (of 500%). Basal 
plasma aldosterone is comparable with humans, but the renin response to exercise 
seems smaller. An exact reason for this specific renin activity is unknown, although some 
authors report that a small increase in plasma potassium during exercise may also have 
a direct effect on aldosterone levels [137-139].  
2.4 Conclusion  
Cardiac biomarker properties such as expression, metabolism, and stability are often 
assumed to be similar across species. Although there are similarities, a comparison 
between human and equine studies shows that large physiological and 
pathophysiological variations exists. Therefore, the extrapolation of data from humans 
to other species and vice versa should always be carried out with caution and further 
species specific studies are needed.  
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Chapter 3: Scientific aims 
Cardiac troponins and natriuretic peptides are successfully used in human medicine and 
small animal veterinary medicine for diagnosis, prognosis and monitoring of cardiac 
therapy. Although cardiac disease is the third most common cause (after 
musculoskeletal and respiratory disorders) of poor performance in horses, only a few 
studies have examined the clinical utility of cardiac biomarkers.   
The general aim of this thesis was to evaluate the use of cardiac biomarkers for 
detection of cardiac disease in horses. 
The specific scientific aims were: 
(1) To assess the use of cardiac troponin I and cardiac troponin T for detection of 
myocardial damage (Chapter 4.1-4.3) by: 
a. Determination of reference values 
b. Comparison of cardiac troponin I and T assays 
c. Determination of cardiac troponin I and T cut-off values  
 
(2) To assess the use of equine atrial natriuretic peptides (ANP, NT-proANP and the 
total proANP product) for detection of atrial dilatation (Chapter 5.1-5.2) by: 
a. Determination of reference values  
b. Studying the influence of the sample storage temperature  
c. Determination of cut-off values  
 
(3) To assess the applicability of B-type natriuretic peptide in horses (Chapter 6.1-
6.2) by: 
a. BNP measurement in normal and diseased horses 
b. Development of an equine NT-proBNP sandwich enzyme-linked 
immunosorbent assay  
 
(4) To investigate the relationship between atrial natriuretic peptides and cardiac 
troponins (Chapter 7).  
 
  
 
 
  
  
Chapter 4 
Cardiac troponin assays for 
detection of myocardial 
damage in horses 
 
 
 
  
  
 
  
  
4.1 Evaluation of assays for 
troponin I in healthy horses 
and horses with cardiac 
disease 
 
 
 
 
 
 
 
 
 
 
 
Adapted from N. Van Der Vekens, A. Decloedt, S. Sys, S. Ven, D. De Clercq, G. van Loon 
(2015). Evaluation of assays for troponin I in healthy horses and horses with cardiac 
disease. The Veterinary Journal, 203, 97-102. 
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Summary 
Cardiac troponin I (cTnI) has proven to be a valuable marker for detection of myocardial 
damage in horses. However, a wide variety of cTnI assays exists and human studies show 
that clinical performance of assays differs. In horses, troponin assay differences have 
hardly been investigated. The aim of this study was to compare two different cTnI 
assays. Serum samples were taken from 23 healthy horses (group 1) and 72 horses with 
cardiac disease (group 2). CTnI was determined with the Access Accu assay in lab A (limit 
of detection (LOD): 0.03 ng/mL) and STAT-I assay in lab B and C (LOD: 0.01 ng/mL). In 
group 1, a median cTnI of <0.03 (<0.03-0.04) ng/mL and <0.01 (<0.01-0.15) ng/mL was 
found with the Access Accu and STAT-I assay, respectively. A higher value was 
demonstrated in group 2 for both assays (0.11, 0.03-58.27 ng/mL Access Accu, P<0.001; 
0.02, 0.01-22.87 ng/mL STAT-I, P=0.044). Although a significant correlation between 
assays existed, large mean differences that could be important for clinical interpretation 
of test results were found. A small mean difference was found between laboratory B and 
C. A significant, optimal (P<0.001) cut-off value for detection of cardiac disease could 
only be determined for the Access Accu assay (0.035 ng/mL, sensitivity: 70%, specificity: 
91%). Therefore, the Access Accu assay seemed to perform better to detect cardiac 
disease in horses. 
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Introduction 
Troponin I, T and C form a regulatory complex and are part of the contractile apparatus 
of skeletal and cardiac muscle tissue [1]. Specific cardiac isoforms exist for troponin I and 
T. As a result, cardiac troponin I (cTnI) and T (cTnT) are used for detection of acute 
myocardial injury in human beings and have replaced the less specific lactate 
dehydrogenase and creatine kinase myocardial band isoenzymes [2]. Both cTnI and cTnT 
are part of the sarcomere component and bound to myofibrils; 6-8% of cTnI and 2.8-4% 
of cTnT form a cytoplasmic component [2]. Damage to cardiac myocytes causes 
primarily leakage of the cytosolic troponin pool. With prolonged cellular stress, the 
structurally bound troponins are also released. This explains the sustained high troponin 
concentrations in human patients with severe cardiac disease, despite the short half-life 
(± 2 h)[3]. In human patients, the diagnostic power of cTnI and cTnT are comparable [2]. 
However, because of the wide variation in cTnI assays [4-8] in human clinical practice, 
cTnT is often the molecule of choice [2]. In equine medicine, cTnI has been reported to 
be the best biomarker to detect myocardial disease [9, 10]. Apart from a unique equine 
6-amino acid N-terminal deletion, human and equine cTnI are largely similar. Since this 
deletion lies outside the epitope region of most commercial assays, human cTnI assays 
can be used for detection of myocardial damage in horses [11]. A number of equine cTnI 
studies have established different reference values [12-17] and an equine specific half-
life (± 0.47 h) has been determined [18]. An equine reference range of 0-0.35 ng/mL was 
reported in pastured and race-trained Thoroughbred horses using the Dimension 
Immunoassay Modulea [12]. A lower reference range (<0.15 ng/mL) was found with the 
ADVIA Centaur cTnI assayb [19]. In the most recent study, a high sensitivity assayc was 
used, in which all healthy horses showed a cTnI <0.03 ng/mL [15]. CTnI assays have been 
thoroughly compared in human medicine [20, 21] and small animal veterinary medicine 
[22]. However, little is known about differences between cTnI assays in horses. 
Therefore, the first aim of this study was to compare results of two different cTnI assays 
when used in healthy horses and in horses with cardiac disease. A second aim was to 
determine a significant cut-off value with these two cTnI assays for detection of cardiac 
disease in horses. 
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Materials and methods 
Study population 
The study was approved by the ethical committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering on the 26th of February, 2013 (EC2012/57). The study 
population consisted of 23 healthy horses (group 1; age 8±4 years, height 168±5 cm, 
weight 567±55 kg) and 72 horses with cardiac disease (group 2; age 11±7 years, height 
165±10 cm, weight 503±117 kg). Group 1 included 10 mares, 12 geldings and one 
stallion. These horses were trained 2-4 times a week for 30-60 min for dressage or show 
jumping. Their medical history was determined and a thorough clinical examination was 
performed, along with echocardiography and electrocardiographyd (ECG) at rest and 
during exercise. A standardised lungeing exercise test was performed and consisted of 5 
min at walk, followed by 10 min at trot, 4 min at canter and 1 min at gallop [23].   
Horses in group 2 (n=72) were presented over a 2 year period at the Faculty of 
Veterinary Medicine (Ghent University) and diagnosed with cardiac disease. Fifty-two 
horses were diagnosed with cardiac disease based on echocardiography and 
electrocardiography. The other 20 horses were diagnosed with atypical myopathy (AM) 
based on clinical signs, blood examination and seasonality of the disease. Atypical 
myopathy is a seasonal, acute, frequently fatal rhabdomyolysis that affects skeletal 
muscles and myocardium [24-30].  
Blood sampling and laboratory analysis 
A serum sample (10 mL) was collected from each horse before exercise, using a 
vacutainer blood collection tube by puncture of the jugular vein. The tubes were 
centrifuged 30 min after collection for 10 min at 2576 g and serum was transferred into 
three cryoviale tubes and stored at -20 °C until analysis.  
Three laboratories were included for sample analysis. For each laboratory, a separate 
cryovial was used to avoid thawing-freezing cycles. Samples were transported on ice to 
each laboratory; the sample transportation time was 15-90 min. In laboratory A, all 
samples (n=95) were analysed using the Access Accu cTnIf assay (lower limit of 
detection, LOD:0.03 ng/mL). The Access Accu assay is a chemiluminescent sandwich 
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immunoassay. Monoclonal anti-cTnI antibody (conjugated to alkaline phosphatase) and 
paramagnetic particles coated with monoclonal anti-cTnI antibody are added with the 
sample in a reaction vessel. The cTnI molecule binds to the anti-cTnI antibody on the 
solid phase and binds with other antigenic sites to the anti-cTnI antibody -alkaline 
phosphatase conjugate. After incubation, the reaction vessel is held in a magnetic field, 
chemiluminescent substrate is added and the light energy is measured with a 
luminometer. Of the 95 samples which were analyzed with the Access Accu assay, 67 
were re-analysed with a STAT-Ig assay (LOD: 0.01 ng/mL) at laboratory B. Forty-three of 
these 67 samples were analysed again with the STAT-I assay at laboratory C to study the 
effect of laboratories on the test results. The STAT-I assay is also a chemiluminescent 
microparticle assay. The sample and anti-troponin-I antibody-coated paramagnetic 
microparticles are combined in step 1. After incubation and wash, anti-troponin-I 
acridinium-labeled conjugate is added in the second step and the chemiluminescent 
reaction is measured as relative light units.  
Statistical analysis 
Samples with values less than the LOD were assigned the concentration of the LOD so as 
not to underestimate the differences between groups [31]. Thus, samples under the LOD 
were reported as 0.03 ng/mL for the Access Accu assay and 0.01 ng/mL for the STAT-I 
assay. Data were analysed using commercially available computer softwareh. Based on 
the Kolmogorov-Smirnov and Shapiro-Wilk test, data were not normally distributed and 
results were reported as medians, with minimum and maximal values, unless stated 
otherwise. A non-parametric Mann-Whitney U test was used to compare cTnI values and 
ECG results in group 1 and 2. The cTnI values of healthy horses, horses with valvular 
heart disease and horses with AM were compared using a Kruskal-Wallis rank test. The 
same test was used for comparison of storage time of laboratories A, B and C. A Receiver 
Operator Characteristic (ROC) curve was established to determine the optimal cut-off 
value for the Access Accu assay and the STAT-I assay (laboratory B). The two areas under 
the ROC curve were compared with MedCalc softwarei [32]. The Spearman correlation 
and the Lin’s concordance coefficient (Rc) were calculated after log transformation. A 
further comparison between assays and between laboratory B and C was done by Bland-
Altman analysis.  
Chapter 4.1: Results _______________________________________________________  
 
82 
 
Results 
Echocardiographic and electrocardiographic examination 
All 23 horses in group 1 had normal cardiac dimensions and no or non-significant valve 
regurgitation. Mild aortic regurgitation was present in one horse and mild mitral and 
tricuspid regurgitation in another horse. The resting ECG did not show arrhythmias in 22 
horses. One healthy horse showed one atrial premature depolarization (APD) at rest. A 
normal exercise ECG was found in 21 horses. One horse had two and another three 
ventricular premature depolarisations (VPDs) during lungeing. In group 2, 
echocardiographic examination was performed in 52/72 horses. Forty-nine horses were 
diagnosed with structural heart disease; 42 horses had moderate or severe valvular 
regurgitation, five had a ventricular septal defect (VSD) and two had an aortopulmonary 
fistula. One of the horses with a VSD was also diagnosed with an abnormal pulmonary 
valve and overriding aorta. The remaining three horses had suspected myocardial 
disease based on a high number of APDs (n=1) or VPDs (n=2) at rest. An exercise ECG 
test was performed in 36/52 horses with cardiac disease. The median number of VPDs in 
these group 2 horses was significantly higher (0 per 30 min, range 0-400 per 30 min) 
compared to group 1 horses (0 per 30 min, 0-2 per 30 min; P=0.01). The median number 
of APDs was also higher in group 2 (0 per 30 min, range 0-5 per 30 min) compared to 
group 1 (0 per 30 min, range 0-1 per 30 min; P=0.030). The remaining 20/72 horses were 
diagnosed with AM on the basis of clinical signs, blood examination (creatine kinase 
mean ± standard deviation 97000 ± 84000 IU/L; lactate dehydrogenase mean ± standard 
deviation 57000 ± 39000 IU/L), seasonality of the disease (outbreak in autumn 2013) and 
contact with the toxic seeds of the sycamore tree (Acer pseudoplatanus). A systolic 
murmur was heard in three horses and one horse had a diastolic murmur.  
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Table 1. Cardiac troponin I sensitivity and specificity to detect cardiac disease   
(AUC=area under the curve, CI=confidence interval).  
 
Troponin analysis 
Access Accu assay (laboratory A)  
All samples were analysed within 6 months after collection. The median storage time 
until analysis was 2 days (range 0-180 days) and 69% of all samples of laboratory A were 
analysed within 1 week. All horses in group 1 had cTnI values ≤ 0.04 ng/mL (<0.03-0.04 
ng/mL). cTnI values were significantly higher in group 2 (median: 0.11 ng/mL, range 
<0.03-58.27 ng/mL) than in group 1 (median <0.03 ng/mL, range <0.03-0.04 ng/mL; P 
<0.001). The optimal cut-off value (0.035 ng/mL) for detection of cardiac disease was 
determined using ROC curve analysis (Figure 1; Table 1). Based on clinical diagnosis, 
horses in group 2 (n=72) could be divided into two subgroups: horses with 
cardiomyopathy (AM or myocarditis, n=23) and horses with moderate or severe valvular 
regurgitation (n=42); horses with aortopulmonary fistula (n=2) and VSD (n=5) were not 
included in these subgroups. CTnI values in horses with cardiomyopathy (median: 0.90 
ng/mL, range <0.03-58.27 ng/mL) were significantly higher than in horses with valvular 
regurgitation (median 0.05 ng/mL, range <0.03-30.92 ng/mL; P=0.001) and healthy 
horses (median <0.03 ng/mL, range <0.03-0.04 ng/mL; P <0.001). Horses with valvular 
regurgitation also showed significantly higher cTnI values than healthy horses (P=0.001; 
Fig. 2).   
Method Lab n 
Cut-off 
(ng/mL) 
Sensitivity Specificity P-value AUC 95% CI 
Access Accu A 95 0.035 70% 91% <0.001 0.83 0.70-0.97 
STAT-I B 67 0.015 55% 68% 0.11 0.64 0.47-0.81 
STAT-I C 43 0.015 30% 86% 0.30 0.59 0.42-0.77 
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Table 2. Spearman correlation coefficient between two troponin assays for cardiac 
troponin I determination in horses (*P<0.01).  
  
Access Accu 
Laboratory A 
STAT-I 
Laboratory B 
STAT-I 
Laboratory C 
Access Accu 
Laboratory A 
correlation 
coefficient 
n 
1.00 
 
95 
  
STAT-i 
Laboratory B 
correlation 
coefficient 
n 
0.454* 
 
67 
1.000 
 
67 
 
STAT-I 
Laboratory C 
correlation 
coefficient 
n 
0.475* 
 
43 
0.412* 
 
42 
1.000 
 
43 
STAT-I assay (laboratories B and C)  
As for laboratory A, the median sample storage time was 2 days in laboratories B (range 
0-34 days) and C (range 0-38 days); 91% of samples in laboratory B and 86% of samples 
in laboratory C were analysed within 1 week. Group 1 had a median cTnI concentration 
of <0.01 ng/mL (range <0.01-0.15 ng/mL; n=22) in laboratory B; the cTnI concentration 
in group 2 (n=45) was significantly higher (median 0.02 ng/mL, range <0.01-22.87 ng/mL; 
P = 0.044). A cut-off value of 0.015 was determined from the ROC curve (Figure 1; Table 
1); however, the sensitivity was low and the P value was above 0.05, which indicates 
that the assay does not have the ability to distinguish between group 1 and 2. No 
significant difference was found between cTnI in group 1 (median <0.01 ng/mL, range 
<0.01-0.13 ng/mL) and group 2 (median <0.01 ng/mL, range <0.01-12.29 ng/mL; P>0.05) 
when samples were analysed in laboratory C (n=43).  
Comparison between assays 
No significant difference in storage time was found between assays. As shown in Table 2, 
a significant association was demonstrated between the two cTnI assays (P<0.01). A 
moderate agreement was found between the Access Accu and the STAT-I assay from 
laboratory B (Rc: 0.543, bias correction (Cb): 0.837, shift: 0.607) and C (Rc: 0.496, Cb 
0.752, shift: 0.781). Despite these correlations, individual troponin values differed 
substantially and a significant difference between the areas under the ROC curve (Fig. 1) 
was found (P<0.001). The limits of agreement (Fig. 3a-c) and the mean difference were 
large between the two assays. The mean ± standard deviation difference between the 
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Access Acuu and the STAT-I was 1.18±1.08 ng/mL (laboratory A vs laboratory B) and 
0.92±3.14 ng/mL (laboratory A vs laboratory C). Fig. 3a and b demonstrate that this 
difference becomes larger as the magnitude of the measurement increased. As 
expected, the mean± standard deviation difference (0.01±0.27 ng/mL) was smaller when 
samples were analysed with the same assay in two different laboratories.  
 
 
Figure 1. Receiver Operator Characteristic (ROC) curve of the Access Accu (laboratory A) 
and STAT-I (laboratory B) assay for detection of cardiac disease (= cut-off of the Access 
Accu assay). 
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Figure 2. Box plot comparing the troponin I concentration measured with the Access 
Accu assay in healthy horses (group 1), horses with moderate or severe valvular 
regurgitation (group 2a) and horses with cardiomyopathy (group 2b). 
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Figure 3a-c. Bland-Altman analysis comparing 
two different troponin I assays and 
measurement of the STAT-I assay in two 
different laboratories (B and C).  
The mean difference between assays 
increases with a higher troponin value (group 
1: healthy horses, group 2: horses with 
cardiac disease). 
Fig. 3b 
Fig. 3c 
Fig. 3a 
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Discussion 
This study demonstrates that a large quantitative difference between two cTnI assays 
exists in horses. Cardiac troponin I reference values differed between assays and a cut-
off value for cardiac disease could only be determined for the Access Accu assay. A 
quantitatively smaller difference was found when results from the STAT-I assay were 
compared between laboratories. In agreement with previous results [33], the median 
cTnI value in group 1 was <0.03 ng/mL with the Access Accu assay. When samples were 
re-analysed with the STAT-I assay, median cTnI values of <0.01 ng/mL in laboratory B 
and <0.01 ng/mL in laboratory C were obtained. A high cTnI value (>0.10 ng/mL) was 
found in three healthy horses with the STAT-I assay in laboratory B. In a study on human 
beings comparing the same two assays, false positive results were found for the STAT-I 
assay due to the presence of heterophile antibodies. These are naturally occurring 
antibodies which have a low affinity and specificity. They are produced against poorly 
defined antigens. Therefore, they can bind between the capture and detection antibody 
of an assay [34]. The presence of these antibodies has previously been suggested in an 
equine cTnI study [16] and could also explain the conflicting results in our study. Despite 
the significant correlation between the Access Accu and STAT-I assay (Table 2), a large 
mean difference was found (Figures 3a and 3b). Since no gold standard was available, it 
could not be concluded that one cTnI assay was better than another. However, an 
optimal cut-off value was only significant for the Access Accu assay. Therefore, the 
Access Accu assay might perform better than the STAT-I assay in a clinical setting.  
Many explanations exist for the differences between these assays. The Access Accu 
assay consists of two antibodies directed against the stable NH2-region-terminus of the 
cTnI molecule (epitopes at amino acids 24-40 and 41-49) [35]. An additional capture 
antibody directed against the 87-91 amino acid region is used by the STAT-I assay. Since 
these assays recognise different target amino acids of the cTnI molecule, troponin values 
might differ. In addition, cardiac troponins can circulate as various complexes [36], 
troponin modification products after myocardial injury exist and multiple degradation 
products have been described in human beings. Thus, the detectability of all these 
products and fragments might also vary according to the used assay [37].  
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In our study, cTnI was measured in horses with several different diseases; 49 horses had 
structural cardiac disease (moderate or severe valvular regurgitation, aortopulmonary 
fistula and VSD) and 23 horses had cardiomyopathy. Significantly higher cTnI values 
were found with the Access Accu assay in horses with cardiomyopathy than in horses 
with valvular regurgitation and in horses with valvular regurgitation compared to 
healthy horses. Similar findings have been reported by Nath et al. (2012) [15] and 
demonstrate that the cTnI assay not only detects severe myocardial damage in case of 
cardiomyopathy, but is also able to demonstrate mild cTnI increase in case of severe 
valvular disease.  
When results of the STAT-I assay analysed at two different laboratories were compared, 
a smaller mean difference (0.01 ng/mL) was found than when two different assays were 
compared. However, a large standard deviation of the mean difference (0.27 ng/mL) still 
existed suggesting that laboratory differences should be taken into account.  
In agreement with medical studies, comparisons between two troponin I assays are 
difficult. It can only be advised to be aware of these assay differences, get familiar with 
one assay, develop a reference range from a large number of horses, use the same 
laboratory and learn by experience which horses are most likely to be positive for 
cardiac disease [8]. Cardiac troponin T assay differences are limited, since only one 
manufacturer has marketed a cTnT assay. The specificity of the cTnT assay has been 
questioned in the case of severe skeletal muscle injury [38] and kidney disease [39]. 
However, with newer cTnT assays, false positive results seem to be limited to primary 
skeletal muscle disease [40, 41]. Therefore, similarly to human medicine, cTnT might be 
an alternative for future troponin measurement in horses [42].  
A limited number (n=23) of healthy horses was used to determine the reference range 
for individual assays. Furthermore, our study also did not determine the coefficient of 
variation for these assays [43]. More assay-specific research is needed in a larger equine 
population. Not all 95 samples could be re-analysed and a lower number of samples 
were analysed with the STAT-I assay. However, if only samples (n=67) analysed with 
both assays were considered, the area under the ROC-curve was still higher for the 
Access Accu assay (0.837, P<0.001) than for the STAT-I assay (0.643, P=0.061).  
Echocardiographic and electrocardiographic examination was not performed in all 
horses with AM. However, the presence of cardiac disease was expected, since cTnI is 
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not present in skeletal muscle [44, 45] and because ultrasound, ECG and post-mortem 
findings from previous studies have shown that AM is associated with cardiomyopathy 
[25, 26, 28-30]. When horses with AM were not included, results from the Access Accu 
assay still showed a significant difference between healthy horses and horses with 
cardiac disease. Finally, samples were not analysed at the same time for the two assays. 
No significant difference in storage time was found between assays, or between 
laboratories, and most of the samples were analysed within the same week. The longest 
storage time (180 days; n=2) was found for the Access Accu assay, where samples had 
the highest cTnI concentrations. Since samples were stored at -20 °C according to 
manufacturer’s instructions and because it is known that cTnI or cTnT are stable for at 
least 1 year in serum samples stored at -70°C [46], an influence of sample storage on 
results is unlikely. 
Conclusion 
Troponin I assays cannot be directly compared to each other, since clinically important 
differences exist. Assay specific reference values should be used and laboratory 
differences must be considered. CTnI measurement can not only differentiate healthy 
horses from horses with cardiomyopathy in a population but also healthy horses from 
horses with moderate to severe valvular regurgitation. 
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Footnotes 
a Dimension Heterogeneous Immunoassay Module, Siemens Healthcare, Beersel, 
Belgium 
b Bayer Healthcare, Diegem, Belgium 
c ADVIA Centaur Assays TnI-Ultra, Bayer Healthcare, Diegem, Belgium 
d Televet 100, Engel Engineering Services GmbH, Offenbach, Germany 
e Cryovials, 2 mL, VWR International, Leuven, Belgium 
f Beckman Coulter Corporations, Fullerton, California 
g Abbott Diagnostics, Wavre, Belgium 
h SPSS version 22.0, Chicago, IL 
i MedCalc software version 13.2.0.0, Ostend, Belgium 
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Summary 
Cardiac troponin T (cTnT) has been used for detection of myocardial damage in horses. 
However, analytical validation of a cTnT assay has never been performed. The aims were 
to estimate the precision of a high sensitivity cTnT assay in horses and to determine the 
influence of hemolysis on the cTnT concentration. Serum samples from horses were 
mixed in three different pools. Pool 1 consisted of samples from 3 healthy horses, pool 2 
from 6 horses with valvular regurgitation or atypical myopathy and pool 3 from 10 
horses with atypical myopathy. The within- and between-day coefficient of variation 
were determined for each pool. Pool 2 and pool 3 were diluted to estimate linearity. To 
study the influence of sample hemolysis, serum was collected from four horses with a 
high cTnT concentration in which hemolysis was mechanically induced. In addition, EDTA 
blood tubes were collected from three other horses, from which hemolysate was 
prepared and added at different concentrations to plasma. The within- and between-day 
coefficient of variations of all pools were <10% and a good linearity was found. Three 
out of four hemolyzed serum samples had a decreased serum cTnT concentration. 
Plasma samples with a high hemolysis index showed a negative interference resulting in 
a lower cTnT concentration. Results of the high sensitivity cTnT assay were highly 
reproducible. Since samples from horses with musculoskeletal damage were included, 
further studies should test the possible cross reactivity between musculoskeletal and 
cTnT before the assay can be used in equine clinical practice.  
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Introduction 
Cardiac troponin I (cTnI) and T (cTnT), are used in human and small animal veterinary 
medicine to detect cardiac damage in case of acute myocardial damage [1-5]. Human 
cTnI assays have also been used in horses to detect myocardial damage [6-10], but cTnI 
assay validation studies are scarce [6]. Studies about cTnT measurement in horses are 
limited [11, 12]. Recently, equine cTnT reference intervals have been established using a 
high-sensitive cTnT (hs-cTnT) assay [13]. In human medicine, this hs-cTnT assay has an 
improved diagnostic accuracy compared to the older less sensitive troponin tests, 
especially when patients are presented with a mild troponin increase in an early phase 
of acute myocardial infarction [14]. In horses, both cTnT and cTnI have been used for 
detection of myocardial damage [13]. Many cTnI assays from different manufacturers 
exist. Because all these cTnI assays have different target peptides and use different 
antibodies, cTnI results are difficult to compare due to this lack of standardization [10, 
15]. In contrast, only one manufacturera has produced cTnT assays [2, 15, 16], which 
facilitates data interpretation. Since cTnT might be a good alternative for cTnI and data 
can be easily compared between studies due to the better standardization, it is a 
promising cardiac biomarker for use in equine veterinary medicine. However, assay 
validation is needed before cTnT results can be interpreted correctly. Therefore, the aim 
of this study was to determine the analytical performance of the hs-cTnT assay in 
horses. The second aim was to study the influence of sample hemolysis on cTnT results. 
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Materials and methods 
The study was approved by the ethical committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering, Ghent University (EC2012/57). Blood samples were 
collected from horses which were admitted to the Faculty of Veterinary Medicine 
(Merelbeke, Belgium). In a first study, the precision of the assay was determined. In a 
second study, the effect of hemolysis on the cTnT concentration was investigated.  
High-sensitive cardiac troponin T assay 
The hs-cTnT assayb is a sandwich electrochemiluminescence immunoassay and uses two 
monoclonal mouse antibodies against amino acid positions 125-131 and 136-147 of the 
human cTnT molecule [17]. Briefly, biotinylated capture antibody, ruthenium-labeled 
detection antibody and sample are incubated. After 9 minutes, streptavidin-coated 
beads are added and a second incubation is started. The mixture is then aspirated into a 
measuring cell and binds to a magnet on an electrode surface. Next, the measuring cell 
is filled with detection buffer, voltage is applied on the electrode and the emitted light 
can be measured by a photomultiplier [17].  
Study 1: analytical performance 
For study 1, blood was collected by puncture of the jugular vein using a venoject and 
serum vacutainer collection tube. After 30 minutes at room temperature, the tubes 
were centrifuged for 10 minutes at 2576 g. The serum was harvested, the samples were 
fractionated in different cryovials and stored for maximally 6 months at -20°C. One of 
these cryovials was transported to a laboratory where the cTnT or cTnI concentration 
was determined. After collection of all samples, the remaining serum was thawed and 
mixed into three pools with a low, medium or high cTnT concentration based on the 
initial cTnI or cTnT results. Samples from three healthy horses were included in pool 1 
(low cTnT concentration), samples from six horses with heart failure (due to severe 
valvular heart disease) and atypical myopathy were mixed in pool 2 (medium cTnT 
concentration), while pool 3 (high cTnT concentration) only included samples from ten 
horses with atypical myopathy. Each pool contained a minimum of 10 mL, was refrozen 
(at -20°C) and analyzed within one week. The within-day coefficient of variation (CV) was 
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determined by measuring each pool 5 times on the same day. The between-day CV was 
assessed by measuring each pool 2 times on 3 consecutive days. Dilution linearity was 
examined by serial dilution of pool 2 and pool 3. Each pool was measured undiluted and 
after 1:2, 1:4, 1:8, 1:16 and 1:32 dilution with Elecsys Diluent MultiAssaya.  
Study 2: influence of hemolysis 
For study 2, seven horses with a high serum cTnT concentration caused by atypical 
myopathy were selected to study the influence of hemolysis using two different 
methods.  
Method 1: From four horses, two blood samples were collected. In one sample of each 
horse hemolysis was mechanically induced on whole blood (before clotting) by repeated 
aspiration of the blood sample through a 21 Gauge needle. The serum was harvested 
after centrifugation and stored at -20°C until analysis. The hemolysis index (HI), (an 
objective, spectrophotometric measurement of the amount of hemolysis [18]), of each 
sample was measured on the Cobas E601 module and cTnT was compared between the 
non-hemolytic and hemolytic samples.  
Method 2: From the three other horses, two EDTA tubes were collected per horse. From 
one sample per horse, the initial plasma cTnT concentration and HI was determined. 
Next, fresh hemolysate was prepared from the other EDTA-tube on the same day 
according to the CLSI-protocol [19]. Briefly, the EDTA blood was centrifuged, the plasma 
removed and the red blood cells were washed three times with 10 mL isotonic saline. 
The cells were recovered after the final centrifugation and frozen overnight at -20°C. 
After thawing, the samples were brought to room temperature and centrifuged for 30 
minutes to remove the cellular stroma. The supernatant hemolysate was collected and 
added at seven different concentrations to the EDTA plasma sample of the same horse. 
The final HI was determined on the Cobas E601 module and the cTnT concentration was 
compared to the initial cTnT concentration.   
Statistical analysis 
Data analysis was performed with SPSS statistics 21.0c. The CV was calculated as follows: 
CV (%) = 

	
× 100 (SD=standard deviation)  
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Simple linear regression analysis was used to compare the measured cTnT levels with 
the expected cTnT levels based on linear dilution. The expected cTnT concentration was 
determined by calculation of a 1:2 dilution of the initially observed cTnT concentration. 
The influence of the hemolysate addition on the EDTA plasma cTnT concentration 
(Method 2) was presented as interferograms, which is a graphic representation of the 
mean percent change of the cTnT concentration (y-axis) with increasing HI (x-axis). The 
percent change was calculated as follows : 


× 100 where V0 is the original cTnT value 
before hemolysis and VH is the final value obtained after hemolysis. The percentage 
change was calculated for each of the three horses, for seven different concentrations of 
hemolysate.  
Results 
Study 1: analytical performance 
The mean cTnT serum concentration of pool 1, pool 2 and pool 3 was <4.00 pg/mL, 
18.47 pg/mL and 1098.80 pg/mL, respectively. Tables 1 and 2 display the results of the 
within-day and between-day variability. Figure 1a and 1b demonstrate the regression 
lines of diluted samples of pool 2 and 3: A good linearity was found after dilution 
between the observed (measured) and expected (based on the undiluted value) cTnT 
concentrations. 
Study 2: influence of sample hemolysis 
Method 1: After mechanically induced sample hemolysis, the mean HI index increased 
from 14.6±8.2 units to 84.1±15.1 units. For three out of four serum samples a lower 
cTnT concentration was demonstrated after hemolysis (Table 3).   
Method 2: The HI of the plasma samples without hemolysate was 12, 27 and 48 units 
and the cTnT concentration of these samples was 16.03 pg/mL, 31.10 pg/mL and 223.82 
pg/mL. Increasing the HI by hemolysate addition, resulted in decreasing cTnT plasma 
concentrations (Figure 2).  
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Table 1. Within-day variability of the hs-cTnT assay of three pools with a different 
cardiac troponin T concentration (pg/mL) (SD: standard deviation, CV: coefficient of 
variation). 
 
Table 2. Between-day variability of the hs-cTnT assay of three pools with a different cTnT 
concentration (pg/mL) (SD: standard deviation, CV: coefficient of variation). 
 
  Run 1 Run 2 
Mean 
runs 
Total 
mean 
SD CV(%) 
Pool 
1 
Day 1 <4.00 <4.00 <4.00 
<4.00   Day 2 <4.00 <4.00 <4.00 
Day 3 <4.00 <4.00 <4.00 
Pool 
2 
Day 1 18.14 18.18 18.16 
18.18 0.16 0.92 Day 2 18.29 18.41 18.35 
Day 3 18.00 18.03 18.02 
Pool 
3 
Day 1 1091.00 1097.00 1094.00 
1082.33 26.50 2.45 Day 2 1057.00 1047.00 1052.00 
Day 3 1101.00 1101.00 1101.00 
 Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD CV (%) 
Pool 1 <4.00 <4.00 <4.00 <4.00 <4.00 <4.00   
Pool 2 18.39 18.36 18.66 18.45 18.50 18.47 0.12 0.64 
Pool 3 1094.00 1092.00 1100.00 1101.00 1107.00 1098.80 5.97 0.54 
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Table 3. Cardiac troponin T (cTnT), and hemolysis index (HI), before and after 
mechanically induced serum sample hemolysis (Method 1). 
 
 
 
cTnT (pg/mL) HI (units) 
Before After Before After 
Horse 1 37.46 39.94 6.5 65.0 
Horse 2 865.10 855.00 7.5 96.0 
Horse 3 3211.00 2906.50 26.5 96.5 
Horse 4 5424.00 4963.50 18.0 79.0 
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Figure 1. a-b Linear regression analysis and 95% confidence interval demonstrating the 
relationship between the expected cTnT concentration and the measured cTnT 
concentration after dilution of pool 2 (Figure 1a) and pool 3 (Figure 1b). 
Fig. 1a 
Fig. 1b 
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Figure 2. Interferogram demonstrating the graphical relationship between the mean 
percent change (final value obtained after hemolysis (VH)/ original value without 
hemolysis (V0) x 100) of the initial EDTA plasma cTnT concentration and the hemolysis 
index (Method 2) of horse 1, horse 2 and horse 3. 
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Discussion 
In human medicine, the guidelines suggest that the CV should be <10% at the 99th 
percentile cTnT concentration [20]. In our study, the within-day and between-day CV 
was less than 10% for all sample pools which indicates that the cTnT assay has a good 
precision for measurement of cTnT in equine blood serum. Analytical validation was also 
performed for one cTnI assay in horses [6] but showed a substantially higher inter-assay 
CV than for the hs-cTnT assay. However, validation studies of other cTnI assays are still 
needed. A high regression coefficient (R2) was found for both pool 2 and pool 3. 
Therefore, a good linear agreement was found between the observed and expected 
serum cTnT concentrations. However, the influence of sample hemolysis should be kept 
in mind. Sample hemolysis is an important cause of laboratory errors and an incidence 
of 2.5-5% has been reported in human medicine [21, 22]. A free hemoglobin 
concentration of 2 mg/dL and 5 mg/dL is normal in human plasma and serum samples, 
respectively [23]. In our study, plasma samples with a high HI had a lower cTnT 
concentration (Figure 2). This has also been described in two previous studies [18, 24] in 
which hemolysate was added to human cTnT serum samples. The exact reason remains 
unknown, but the hemolysis effect is possibly independent of the 
electrochemiluminescence technique [25] as pre-analytical alterations of the cTnT 
molecule by hemolysis have been proposed [18]. Sample hemolysis might cause the 
release of protease enzymes such as cathepsins from the erythrocytes, which can cleave 
the cTnT molecule and thus destroy the antigenic binding sites of the antibodies used in 
the hs-cTnT assay [26]. Although the influence of hemolysis on plasma samples was clear 
(Method 2, Figure 2), the difference between serum samples before and after 
mechanically induced hemolysis was less pronounced (Method 1, Table 3). The maximal 
HI in these samples was 96.5 units, while plasma samples with hemolysate had a 
maximal HI of more than 1500 units. Since a HI of 500 units is equivalent to a 
hemoglobin concentration of 500 mg/dL, and hemolysis can be visible from 30-50 mg/dL 
free hemoglobin, the severity of hemolysis in these plasma samples was high and would 
be clearly visible [23]. Therefore, a decreased cTnT concentration can be expected in 
samples with an obvious pink to red discoloration.  
A limitation of our study was that the freshly prepared hemolysate, resulting in the 
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highest HI, was only added to the EDTA plasma samples and not to the serum samples. 
In human medicine, a good correlation between the serum and EDTA plasma cTnT 
concentration has been described [17]. Therefore, severe hemolysis probably causes a 
decreased cTnT concentration in both serum and plasma. Secondly, the mean cTnT 
concentration of pool 1 was under the limit of detection of the assay. Therefore, the 
exact CVs of these samples could not be determined. In human serum, a between-day 
CV of 10% has been reported in samples with a cTnT concentration around 10 pg/mL but 
a higher CV was found in samples with a lower cTnT concentration. Therefore, the 
between-day CV might be higher in samples from healthy horses. Thirdly, besides 
myocardial damage, horses with atypical myopathy also have severe skeletal muscle 
damage [27, 28]. Previous studies demonstrated that musculoskeletal troponin T might 
cross react with cTnT in first generation assays [29, 30]. However, in newer generation 
cTnT assays, such as the one used in our study, this cross reactivity is counteracted by 
using a more specific cardiac troponin antibody [29, 31]. Thus, although further 
investigation is needed, the influence of musculoskeletal troponin T on our results is 
probably limited. Finally, the limit of blank or limit of detection was not calculated for 
equine cTnT and should be determined in order to fully validate the test. In conclusion, 
the hs-cTnT assay demonstrates a good precision for diagnostic use in the horse. Severe 
sample hemolysis can cause a decrease in the cTnT concentration, thus appropriate 
sample collection and handling is recommended.  
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Footnotes 
a Roche Diagnostics, GmbH, Indianapolis, IN  
b Cobas E601 module, Roche Diagnostics, GmbH, Indianapolis, IN  
c SPSS Statistics 21.0, Chicago, IL 
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Summary 
Different cardiac troponin I (cTnI) assays give different results. Only 1 manufacturer has 
marketed troponin T (cTnT) assays. Therefore, cTnT often is preferred for detection of 
myocardial infarction in human patients. Studies of cTnT in horses studies are limited. 
CTnI and cTnT were determined in 35 healthy horses (group 1), 23 horses suspected to 
have primary myocardial damage (group 2a) and 41 horses with secondary myocardial 
damage caused by structural heart disease (group 2b). All cTnI samples were analyzed at 
laboratory A (limit of detection [LOD]:0.03 ng/mL), whereas cTnT samples were analyzed 
at 2 laboratories with the same hs-cTnT assay (laboratory B, LOD: 10.0 pg/mL; laboratory 
C, LOD: 4.0 pg/mL).The median cTnI concentration in group 2a (0.90 ng/mL; range 0.03-
58.27 ng/mL) was significantly higher (P<0.001) than in group 1 (0.03 ng/mL; range 0.03-
0.09 ng/mL) or group 2b (0.05 ng/mL; range 0.03-30.92 ng/mL) and the optimal cut-off 
for detection of primary myocardial damage was 0.095 ng/mL (sensitivity: 90.5%, 
specificity: 100%). Using an LOD of 10.0 pg/mL for all cTnT samples, a cut-off value of 
10.5 pg/mL was found, but sensitivity was low (42.9%). When only samples analyzed at 
laboratory C (n=58) were included, a cut-off of 6.6 pg/mL was found (sensitivity: 81%, 
specificity: 100%). Despite large quantitative differences, cTnI and cTnT are both useful 
for detection of myocardial damage in horses. 
 Chapter 4.3: Cardiac troponin I compared to cardiac troponin T 
 
115 
 
Introduction 
Cardiac troponin I (cTnI) and troponin T (cTnT) have proven to be excellent cardiac 
biomarkers for diagnosis of myocardial injury in human medical practice [1]. They have 
replaced the less sensitive lactate dehydrogenase (LDH) and creatine kinase-myocardial 
band (CK-MB) enzymes since the 1990’s and are routinely used in human patients for 
detection of acute myocardial infarction [2, 3]. Although cTnI and cTnT have comparable 
diagnostic efficacy, cTnT often is preferred in human medicine [3]. The existence of a 
wide variety of cTnI assays from different manufacturers complicates interpretation and 
comparison of cTnI data [4]. In contrast, only Roche Diagnosticsa has marketed cTnT 
assays [1, 5]. The troponin structure is very conserved among species. Therefore, assays 
intended for humans can be used in horses and other animals [6, 7]. Over the last 15 
years, measurement of cTnI has been introduced in equine veterinary medicine and 
several cTnI reference ranges have been determined using different assays [8-13]. 
Studies of cTnT measurement in horses are limited [14-16]. Normal concentrations for 
cTnT were obtained in foals with a third generation Elecsys 2010b immunoassay [16] and 
in 20 healthy horses using a qualitative cTnT assayc and a quantitative cTnT enzyme-
linked immunosorbent assayd [15]. In this last study, cTnT was increased in horses with 
cardiac diseases such as valvular insufficiency, endocarditis and atypical myopathy. 
However, many horses with cardiac disease still had cTnT concentrations under the limit 
of detection (LOD) of the assay (<40 pg/mL). Since 2010, Roche Diagnostics has 
marketed a new hs-cTnT assay [17]. Due to its higher sensitivity and increased precision, 
this hs-cTnT assay may be a good alternative for cTnI measurement in horses. 
Laboratories often only provide cTnI or cTnT analysis. Therefore, additional cTnT studies 
in horses are needed to determine the applicability of cTnT measurement for the 
diagnosis of myocardial damage in horses. The aim of this study was to establish 
reference ranges for hs-cTnT in normal horses and to compare a cTnI with a hs-cTnT 
assay in healthy horses and horses with confirmed cardiac disease.  
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Figure 1. Schematic representation of sample analysis in the different laboratories (LOD 
= limit of detection, group 1= healthy horses, group 2a= horses with primary myocardial 
damage, group 2b= horses with secondary myocardial damage). 
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Materials and Methods 
Study population 
This study was approved by the ethical committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering (EC2012/57). All horses were privately owned and examined 
with the owners’ informed consent. In order to be included as control horses (group 1, 
n=35) horses had to be healthy and in training and had to be free of cardiac disease 
based on cardiac examination including echocardiography, electrocardiography (ECG) at 
rest and during exercise (Televet 100e) [18]. Horses of group 2 (n=64) were presented at 
the Faculty of Veterinary Medicine with cardiac disease. 
Data collection and analysis 
Blood was collected before exercise by jugular venipuncture using a vacutainer 
collection tube. Samples were left at room temperature for 30 min to allow clotting. 
Next, they were centrifuged for 10 minutes at 2576 g. The serum was transferred into 3 
cryovial tubesf and stored at -20°C until sample analysis. Samples were transported on 
ice to 3 different laboratories (A, B and C; Figure 1). In laboratory A, all samples were 
analyzed with the Beckman Access Accu cTnI assayg. The LOD of this assay was 0.03 
ng/mL. Samples from all 99 horses also were analyzed with the hs-cTnTh assay: 47 
samples (21 healthy horses and 26 horses with cardiac disease) were analyzed in 
laboratory B with the Cobas E602 analyzer and 58 samples (20 healthy horses and 38 
horses with cardiac disease) were analyzed in laboratory C with the Cobas E601 analyzer 
(Figure 1). Six samples from healthy horses were analyzed both in laboratories B and C. 
In laboratory B, a LOD of 10.0 pg/mL was used. Although the same assay was used, the 
LOD of laboratory C was 4.0 pg/mL. 
Statistical analysis 
Statistical analysis was performed using commercially available computer software 
(SPSSi and MedCalcj). Based on the Kolmogorov-Smirnov and Shapiro-Wil test, data were 
not normally distributed and all results were reported as median and range (minimum, 
maximum), unless stated otherwise. Samples with a cTnI or cTnT concentration under 
the LOD (e.g., <10.0 pg/mL) were assigned the concentration of the LOD (e.g., 10.0 
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pg/mL). This allowed inclusion of all samples for further statistical analysis. Because 
these samples probably had a lower troponin concentration than assigned, differences 
among groups were likely not overestimated, but rather underestimated. Initially, we 
chose to report all cTnT samples, including samples of laboratory C, with an LOD of 10.0 
pg/mL. Secondly, only cTnT samples of laboratory C were considered, allowing an LOD of 
4.0 pg/mL. The storage time difference between laboratories was compared by the non-
parametric Friedman test. A non-parametric Mann Whitney U test was used to compare 
the horses’ age, weight, height. The troponin concentrations of group 1, 2a and 2b were 
compared by the Kruskal Wallis and the post-hoc Dunn’s test. The cTnI and hs-cTnT 
assays were compared after log transformation with the Spearman correlation test. A 
Receiver Operator Characteristic (ROC) curve was established to determine the optimal 
cut-off value for detection of myocardial damage for both assays. 
 
Figure 2. Comparison of the log cardiac troponin I (n= 99, laboratory A) and T (n=58, 
laboratory C) concentration in healthy horses (group 1), horses with primary myocardial 
damage (group 2a) and horses with secondary myocardial damage caused by structural 
heart disease (group 2b). The cut-off concentration for primary myocardial damage 
(cTnI: 0.095 ng/mL, cTnT: 6.6 pg/mL) is demonstrated by the horizontal dotted line. The 
median troponin concentration within each group is indicated by a black horizontal bar.
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Results 
Clinical, echocardiographic and electrocardiographic examination 
Group 1 (age: 8±4 years; weight: 540±61 kg; height: 165±6 cm) consisted of 13 geldings, 
20 mares and 2 stallions; 24 Warmbloods, 10 Trotters and 1 pony. Group 2 (age: 10±7 
years; weight: 507±97 kg; height: 163±10 cm) consisted of 33 geldings, 28 mares and 3 
stallions; 39 Warmbloods, 4 mixed breeds, 5 ponies, 4 Friesians, 3 Trotters, 2 draft 
horses, 2 Quarter horses, 2 Spanish horses, 2 Arabian horses and 1 Halflinger horse. No 
significant differences in age, weight or height were found between horses of groups 1 
and 2. Based on clinical and cardiac examination, horses of group 2 were divided into 2 
subgroups: horses with primary myocardial disease (inflammatory, toxic or ischemic 
myocardial damage) and horses with secondary myocardial disease caused by structural 
heart disease (valvular heart disease, ventricular septal defects or aortopulmonary 
fistula).   
Of the 64 horses with cardiac disease, 23 were diagnosed with primary myocardial 
disease and included in group 2a. Twenty-one horses were suspected to have atypical 
myopathy based on the seasonality of the disease, the presence of Maple trees (Acer 
pseudoplatanus) around the pastures, extremely increased muscle enzymes activity 
(creatine kinase: median 69750 mU/mL, range 1200-309000) and necropsy [19, 20]. The 
remaining 2 horses in group 2a were suspected to have primary myocardial disease 
based on the presence of a large number of ventricular premature depolarizations 
(>14/minute) on ECG and lack of echocardiographic evidence of valvular, pericardial or 
vascular disease. One of these horses also had ataxia, fever and decreased systolic 
function of the left ventricle. Forty-one horses of group 2 were diagnosed with structural 
heart disease and therefore included in group 2b. The severity of valvular regurgitation 
in these horses was graded subjectively on a scale from 1-9 [21]. Grade 1-3 was 
classified as trivial regurgitation, grade 4-5 as mild, grade 6-7 as moderate and grade 8-9 
as severe valvular regurgitation, only horses with moderate or severe valvular 
regurgitation were selected. Fourteen horses had moderate regurgitation and 27 horses 
severe regurgitation of ≥1 valves. Within this group, 3 horses also had an 
aortopulmonary fistula and 4 horses had a ventricular septal defect.   
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Troponin analysis 
All samples were stored at -20°C according to the manufacturer’s instructions and 
thawed only once. A maximum storage time of 6 months at -20°C was recommended by 
the manufacturer for the Access Accu cTnI assay. The median time until analysis for this 
assay was 2 days (range 0-165 days). The maximum recommended storage time for the 
hs-cTnT assay was 12 months at -20°C. The median time until analysis was 5 days (range 
0-38 days) in laboratory B and 3 days (range 0-183 days) for the hs-cTnT assay in 
laboratory C. The storage time of samples for laboratory A (P=0.002) and C (P=0.005) 
was significantly shorter than that of samples for laboratory B. No significant difference 
in storage time was found between laboratory A and laboratory C.   
Most healthy horses had cTnI and cTnT concentrations under the LOD (cTnI: 0.03 ng/mL; 
cTnT: 10.0 pg/mL). The median (range) cTnI concentrations in horses of group 1, 2a and 
2b were 0.03 (0.03-0.09) ng/mL, 0.90 (0.03-58.27) ng/mL and 0.05 (0.03-30.92) ng/mL, 
respectively. Horses of group 2a had significantly higher cTnI concentrations compared 
to horses of group 1 (P<0.001) and group 2b (P<0.001). Horses with secondary 
myocardial disease caused by structural heart disease (group 2b) also had significantly 
higher (P=0.003) cTnI concentrations than healthy horses (group 1; Figure 2). Based on 
the ROC curve (Figure 3), an optimal cut-off value for detection of primary myocardial 
damage was determined for cTnI (0.095 ng/ml; area under the curve [AUC]: 0.94; 95% 
confidence interval: 0.86-1.00; P<0.001; sensitivity: 90.5%; specificity: 100%). No 
significant (P=0.051) cut-off value (0.045 ng/mL) could be determined for detection of 
secondary myocardial damage.  
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Figure 3. Receiver Operator Characteristic (ROC) curve of the Access Accu troponin I 
(cTnI) assay of laboratory A ( cut-off = 0.095 ng/mL), the high sensitive troponin T 
(cTnT) assay of laboratory B and C together (cut-off= 10.5 pg/mL) and of laboratory C 
separately  (cut-off= 6.6 pg/mL) for detection of primary myocardial damage. 
The median (range) cTnT concentration also was significantly (P=0.001) higher in group 
2a (10.0, 10.0-2010.0 pg/mL) compared to group 1 (10.0, 10.0-10.0 pg/mL; P<0.001) and 
group 2b (10.0, 10.0-570.0 pg/mL; P=0.010) for samples of laboratories B and C. No 
significant difference was found between group 1 and group 2b. The cut-off value for 
detection of primary myocardial damage was 10.5 pg/mL (AUC: 0.71; 95% confidence 
interval; 0.55-0.88, P=0.019). However, a low sensitivity was found (42.9%; specificity: 
100.0%). No significant (P=0.361) cut-off value for secondary myocardial disease could 
be determined. The cTnT concentrations of the 6 healthy horses which were analyzed in 
both laboratories all were below the LOD of laboratories B (10.0 pg/mL) and C (4.0 
pg/mL).  
When only samples analyzed in laboratory C (n=58) were considered, the median cTnT 
was 4.0 pg/mL (range, 4.0-6.0 pg/mL) in healthy horses (n=20) and a significantly higher 
(P<0.001) cTnT concentration was found in horses with primary myocardial damage 
(42.2; 4.0-1341.0 pg/mL). The median cTnT concentration in horses with primary 
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myocardial damage was also significantly higher (P=0.004) than that in horses with 
secondary myocardial damage (4.0; 4.0-13.22 pg/mL). No significant difference was 
found between healthy horses or horses with secondary myocardial damage (Figure 2). 
Based on the ROC curve (Figure 3), a significant (P=0.001) cut-off (6.6 pg/mL) could be 
determined for detection of primary myocardial damage (AUC: 0.89; 95% confidence 
interval: 0.78-1.00; sensitivity: 81%; specificity: 100%).  
Comparison of cTnI and cTnT values 
A significant correlation between log cTnI and log cTnT was found (Figure 4). The 
Spearman correlation coefficient between the cTnI and hs-cTnT concentrations was 
0.621 (P=0.01). Thirty-six of all samples had a cTnI value above the cut-off.  
When only samples analyzed in laboratory C were considered, the Spearman correlation 
coefficient between the cTnI and hs-cTnT assays increased to 0.801. The AUC was not 
significantly different between the cTnI and the cTnT ROC curves (P=0.376). Twenty-
three of the 58 samples had a cTnT concentration above the cut-off (6.6 pg/mL, Table 1). 
Four horses were positive for myocardial damage based on the cTnI results, whereas the 
cTnT concentration was below the cut-off. Three of these horses had atypical myopathy 
and the last horse had severe mitral valve regurgitation with atrial dilatation caused by 
rupture of the chordae tendineae. Two horses had high cTnT concentrations with 
normal cTnI concentrations of which 1 had severe aortic regurgitation and the other 
atypical myopathy.  
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Figure 4. A significant correlation (r=0.621) between the log troponin I value of the 
Access Accu cardiac troponin I assay and the log troponin T value of the high sensitive 
troponin T assay of horses of group 2 was found (P=0.01). 
 
Table 1. Cross tabulation comparing the high sensitive troponin T assay of laboratory C 
(cut-off: 6.6 pg/mL, limit of detection: 4.0 pg/mL) and the Access Accu troponin I assay 
of laboratory A (cut-off: 0.095 ng/mL, limit of detection: 0.03 ng/mL) for detection of 
myocardial disease. 
 
hs-cTnT 
Total 
Negative Positive 
cTnI 
Negative 31 (53%) 2 (3%) 33 (57%) 
Positive 4 (7%) 21 (36%) 25 (43%) 
Total 35 (60%) 23 (40%) 58 (100%) 
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Discussion 
CTnI is routinely used in equine clinical practice, but different assays produce different 
results. No such variations exists for cTnT assays because only 1 manufacturer produces 
these assays. For this reason, a number of laboratories in human medicine might switch 
from cTnI to the new hs-cTnT assay for detection of cardiac disease, which might 
decrease the availability of cTnI measurement in clinical practice [14]. Because limited 
information about cTnT is available in horses [15, 16], the aim of this study was to 
compare cTnI and cTnT concentrations in horses with and without cardiac disease.  
CTnI was measured with the Access Accu assay in one laboratory (laboratory A). 
Measurement of cTnT was performed in two laboratories (B and C) with the LOD set at 
10.0 pg/mL and 4.0 pg/mL in laboratories B and C, respectively (Figure 1). Reference 
results for cTnI and cTnT were obtained by blood sample analysis of healthy horses and, 
for both cTnI and cTnT, a significant difference was found between the healthy horses 
and those with primary myocardial damage. An optimal cut-off value could be 
established for both cTnI and cTnT. In a previous study, an older, less sensitive cTnT 
assay was used with an LOD of 40 pg/mL [15]. All healthy horses had a cTnT 
concentration under this LOD. However, in our study, a 10-fold more sensitive cTnT 
assay was used and showed that the cTnT concentration in healthy horses was much 
lower than 40 pg/mL. Although an optimal cut-off concentration for primary myocardial 
disease was established, sensitivity was low when the LOD of both laboratories B and C 
was set at 10.0 pg/mL. However, when only samples analyzed at laboratory C were 
included with the LOD set at 4.0 pg/mL, the optimal cut-off was lower and the AUC of 
the cTnT assay approached the AUC of the cTnI assay. This cTnT cut-off concentration 
provided similar results to categorize horses in different groups as the cTnI cut-off 
concentration (Table 1). Therefore, cTnI and cTnT both were able to differentiate 
healthy horses from horses with primary myocardial damage.   
Although a significant correlation between cTnI and cTnT was found (Figure 4), 
quantitative differences existed: the optimal cTnI cut-off concentration for primary 
myocardial disease (0.095 ng/mL or 95 pg/mL) was more than 10 times higher than the 
cTnT cut-off concentration (6.6 pg/mL). Because qualitative results are comparable 
(Table 1), the quantitative assay difference seems less important for diagnosis of 
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myocardial damage and only demonstrates that the same assay has to be used if 
troponins are re-analyzed for patient re-evaluation.   
Similar to the situation in human medicine, it seems that the diagnostic efficacy of cTnI 
and cTnT is comparable in horses [3]. In our study, 4 horses had high cTnI 
concentrations, whereas the cTnT assay result was low: 3 of these horses had atypical 
myopathy whereas the other horse had severe valvular regurgitation. Conversely, 2 
horses had high cTnT concentrations with a low cTnI concentration. Because extensive 
post-mortem examination was not performed on the horses that were determined to be 
clinically normal with either test, it could not be determined whether cTnI or cTnT 
performed better to detect cardiac disease.   
Despite the good sensitivity of the hs-cTnT assay, the LOD was set at 10.0 pg/mL in 
laboratory B and 4.0 pg/mL in laboratory C. According to laboratory B, this higher LOD 
was chosen as a safety margin. In human medical practice, cardiac troponins are mostly 
measured for the early diagnosis of myocardial infarction. One benefit of high sensitive 
assays is their improved diagnostic accuracy in the case of early presentation of patients 
with chest pain. Patients with a cTnT concentration above the 99th percentile of a large 
reference population are diagnosed with acute myocardial infarction and a hs-cTnT cut-
off concentration of 14.0 pg/mL has been determined [22]. Therefore, even with an LOD 
of 10.0 pg/mL, the hs-cTnT assay still is useful for detection of myocardial injury in 
human patients. However, myocardial infarction is very rare in equine medicine and 
valvular heart disease is most commonly diagnosed [23]. Of a total of 555 horses with 
various cardiac diseases, Gehlen et al. (2007) [24] diagnosed valvular heart disease in 
approximately 65% of the patients. In our study, most of the horses with suspected 
primary myocardial damage (n=23), such as myocarditis or atypical myopathy due to 
Acer pseudoplatanus intoxication, had cTnI (0.90 ng/mL, 0.03-58.27) and cTnT (42.2 
pg/mL, 4.0-1341.0) concentrations that were well above the established cut-off 
concentrations. Horses with secondary myocardial disease caused by structural heart 
disease had significantly lower cTnI and cTnT concentrations. No significant cut-off 
concentration for structural heart disease could be determined. However, the cTnI 
concentration in horses with secondary myocardial damage was significantly higher than 
that in healthy horses. Thus, horses with structural heart disease also could have minor 
increases in troponin concentrations. Two of the 3 horses with aortopulmonary fistulas 
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had acute clinical signs and a cTnI increase (0.26 and 1.98 ng/mL) of greater extent than 
most of the other horses in group 2b. In contrast to valvular heart disease, 
aortopulmonary fistulation often is an acute event, which might cause a sudden and 
extensive release of cTnI.  
One limitation of our study was that not all cTnT samples could be analyzed at the same 
laboratory. Not only the LOD, but also other laboratory characteristics could have 
influenced results. A large study in which the same samples are analyzed with the same 
assay in different laboratories could elucidate variation among laboratories. Samples for 
cTnI and cTnT also were not analyzed at the same time. However, all samples were 
stored at -20°C, analyzed within the time recommended by the manufacturer, and only 
thawed once. CTnT is known to be stable for 3 months at -20 °C and only 9/99 samples 
were stored >3 months (maximum 5.5 months). Therefore, the influence of storage on 
our results is most likely minimal [25]. Thirdly, it could be argued that extensive muscle 
damage caused troponin increase in horses with atypical myopathy. However, skeletal 
muscle damage has no impact on cTnI concentrations and only has an influence on first 
generation cTnT assays [26, 27]. Cardiac damage in atypical myopathy previously has 
been identified by echocardiography, ECG and necropsy findings [19, 20] and was 
thought to be the source of the troponin increase in our study. Finally, it could not be 
ruled out that the troponin increase in horses with structural heart disease was caused 
by additional primary myocardial damage. However, no myocardial abnormalities were 
seen in these horses during echocardiographic examination.  
Conclusion 
Both cTnI and cTnT can distinguish healthy horses from horses with myocardial disease 
and have comparable diagnostic value. However, absolute cTnI and cTnT differences 
exist, which indicates that the same assay should be used for patient re-evaluation. 
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Footnotes 
a Roche Diagnostics GmbH, Indianapolis, IN 
b Elecsys 2010, Roche Diagnostics GmbH, Indianapolis, IN 
c Trop T Sensitive Rapid Assay, Roche Diagnostics GmbH, Indianapolis, IN 
d ELISA Troponin T, Boehringer, Manheim Germany, now Roche Diagnostics 
e Engel Engineering Services GmbH, Offenbach, Germany 
f Cyrovials 2 mL, VWR International, Leuven, Belgium 
g Beckman Coulter Inc, Fullerton, California 
h Troponin T hs, Roche Diagnostics, GmbH, Indianapolis, IN 
i SPSS Version 22.0, Chicago, IL 
j MedCalc software, version 13.2.0.0, Ostend, Belgium  
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Summary 
Studies about the use of atrial natriuretic peptide (ANP) as a biomarker for left atrial 
dilatation in horses have produced variable results. Only a few studies have been 
performed and the results may have been influenced by ANP instability, differences in 
sampling protocol and changes in the assay over time. N-terminal proANP (NT-proANP), 
a more stable molecule, might be a good alternative for clinical use. To compare ANP 
and NT-proANP in terms of the detection of left atrial dilatation and to determine the 
influence of sample storage at temperatures of -80°C and -20°C.  
 A comparison was made between ANP and NT-proANP concentrations in healthy horses 
(group 1, n=20), horses with mitral valve regurgitation and a normal atrial size (group 2, 
n=11) and horses with mitral valve regurgitation associated with left atrial dilatation 
(group 3, n=16). The ANP concentration was measured with an equine enzyme-linked 
immunosorbent assay (ELISA), the NT-proANP concentration with an ELISA developed 
for use in human patients. Samples were stored at -20°C and -80°C and analyzed within 
7 months. The NT-proANP concentrations were not significantly different between the 
groups. Horses in group 3 had a significantly higher ANP concentration (median 366, 
interquartile range (IQR): 74-2000 pg/mL) compared to horses in groups 1 (median 31, 
IQR: 31-333 pg/mL) or 2 (median 31, IQR: 31-1152 pg/mL, P=0.015). The ANP cut-off 
value for detection of left atrial dilatation was 52 pg/mL (sensitivity: 81%, specificity: 
84%) for sample storage at -80°C, and 44 pg/mL (sensitivity: 69%, specificity: 84%) for 
storage at -20°C. A larger decrease in ANP (45±126 pg/mL) as compared to NT-proANP 
(10±31 pg/mL) was found when the samples were stored at -20°C instead of -80°C. 
 ANP, but not NT-proANP, can detect left atrial dilatation in horses. ANP is less stable 
than NT-proANP when samples are stored at -20°C. ANP is more suitable than NT-
proANP for the assessment of left atrial dilatation in horses. 
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Introduction 
Natriuretic peptides (NPs) are a family of cardio-protective hormones which cause 
natriuresis, diuresis and vasodilation in the case of cardiac overload [1]. The NP family 
consists of two main members: atrial NPs and B-type NPs, of which the diagnostic value 
has already been extensively proven in human and small animal veterinary medicine [2-
11]. In human medical practice, NPs are useful for diagnosis of congestive heart failure 
and are often determined in the emergency department for rapid diagnosis of acute 
dyspnea. NPs are also useful prognostic indicators for survival and for treatment follow-
up [2, 3, 12]. A limited number of studies in small animals are available. First results 
show that NPs can also distinguish cardiac from non-cardiac related dyspnea [4], that a 
relationship with severity of cardiac disease also exists [7, 8] and that NPs can be 
successfully used as screening test for cardiac enlargement [9-11]. Both NPs are space-
stored as prohormones (proANP and proBNP) in numerous granules within the cardiac 
myocytes. These prohormones are released in response to an increased cardiac volume 
and cleaved into an N-terminal inactive, stable molecule (NT-proANP and NT-proBNP) 
and an active, unstable molecule (ANP and BNP) [13]. The half-life of human BNP (12.1 
min) and NT-proBNP (24-120 min) is longer than that of ANP (2-5 min) and NT-proANP 
(55-60 min). Therefore, BNP and NT-proBNP are better targets for diagnostic testing in 
clinical practice [14-18]. Unfortunately, BNP and NT-proBNP vary considerably in genetic 
terms between species, which explains why a test developed for human patients cannot 
be used in veterinary medicine [19]. An NT-proBNP assay is available for dogs and catsa. 
Since an equine NT-proBNP assay does not exist, only ANP and NT-proANP have been 
studied in horses [20-24]. In contrast to BNP and NT-proBNP, the amino-acid sequence 
of ANP and NT-proANP is largely conserved between species; 100% homology has been 
reported between human and equine ANP [25]. NT-proANP is more species specific with 
a homology of 80-90% between the human and equine peptides [25]. The sequence 
similarity suggests that assays from human medical practice can be used in horses. 
Therefore, a radioimmunoassayb (RIA), which was validated for human ANP, was used to 
examine the diagnostic value of ANP to detect atrial dilatation in three equine studies 
[20, 21, 24]. No relationship was seen between ANP and atrial dilatation in the first 
study [21]. In contrast, a significant correlation between ANP and left atrial dilatation 
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was suggested in the two subsequent studies [20, 24]. Recently, a correlation between 
ANP and the pulmonary capillary wedge pressure has been demonstrated at rest and 
after exercise, suggesting a relationship between the ANP concentration and the left 
atrial pressure in horses [20]. For the first time, a cut-off value to identify horses with 
mitral valve regurgitation and left atrial enlargement was proposed, using the ANP 
concentration that was measured 5 (455 pg/mL) or 10 minutes (332 pg/mL) after a 
standardized treadmill-exercise test [20]. Although the number of horses (n=7) was 
limited, this study showed that ANP could be used to document the presence of mitral 
valve regurgitation with left atrial dilatation after a treadmill test. However, the poor 
analytic performance of the test and the complicated sample processing and storage 
might limit its future use in clinical practice [26]. The larger and more stable NT-proANP 
molecule probably requires a less strict sampling protocol [27] and might therefore be a 
better target for clinical testing. NP determination will never fully replace 
echocardiography in horses. However, echocardiographic examination is expensive and 
not always available, especially in first-line care, and even with a full cardiac 
examination, estimation of prognosis remains difficult in some cases. Therefore, NPs 
might be helpful to establish correct diagnosis, prognosis and follow-up of cardiac 
disease in horses.  
The objectives of this study were (1) to compare ANP and NT-proANP as detectors of left 
atrial dilatation and (2) to study if sample storage at -20°C versus -80°C influences the 
results.  
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Materials and methods 
Study population 
The study was approved by the ethical committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering (Ghent University, Belgium). All horses were privately owned 
and clinical examination, echocardiography as well as electrocardiography (ECG) were 
performed with the owners’ consent. Group 1 consisted of 20 healthy, adult Warmblood 
horses that were used as dressage or jumping horses and were trained 2-4 times per 
week: 10 geldings, 9 mares and 1 stallion (age: 8±4 years, weight: 566±56 kg, height: 
168±5 cm). Horses with a decreased performance or any indication of cardiorespiratory 
disease were also excluded from group 1. The second and third groups consisted of 
horses of various breeds in which moderate or severe mitral valve regurgitation had 
been diagnosed. Horses without left atrial dilation were classified in group 2 and horses 
with atrial dilatation in group 3.  
Echocardiographic measurements 
The echocardiographic examination included standardized transthoracic two-
dimensional B-mode, M-mode and Doppler images using an ultrasound unitc with a 
phased-array transducerd at a frequency of 1.7/3.4 MHz (second order harmonic 
frequency). A modified base-apex ECG was recorded simultaneously and at least 3 
cardiac cycles from each view were stored. An off-line analysis was performed using 
dedicated softwaree. For each variable, the average of three cardiac cycles was used. A 
right parasternal short-axis view of the left atrium was stored for measuring both the 
end-systolic left atrial-to-aortic diameter ratio (LAD/AoD) and the left atrial-to-aortic area 
ratio (LAA/AoA). The LAD/AoD was measured as follows: callipers were placed in a line 
extending from and parallel to the commissure between the non-coronary and left 
coronary aortic valve cusps to the distant margin of the left atrium for assessment of the 
internal short-axis diameter of the LA. The internal short-axis diameter of the aorta at 
valvular level was determined by placing callipers along the commissure between the 
non-coronary and right coronary aortic valve cusps [28]. The LAA/AoA was measured as 
previously described [29]. Horses with a LAD/AoD larger than 1.25 were considered to 
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have left atrial dilatation and therefore categorized in group 3. Mitral valve regurgitation 
was subjectively graded on a scale from 1-9 taking into account the duration of the jet, 
the number of images in which the jet was visible, and the area of the chamber covered 
by the jet [30]. Grade 1-3 was classified as trivial regurgitation, grade 4-5 mild, grade 6-7 
moderate and grade 8-9 severe valvular regurgitation.   
Of the 27 horses with moderate or severe mitral valve regurgitation, 11 horses had a 
LAD/AOD<1.25 and were therefore categorized in group 2. Group 2 consisted of 10 
Warmblood horses and 1 Arabian horse; 7 geldings and 4 mares (age: 13±7 years, 
weight: 584±71 kg, height: 169±11 cm). The remaining 16 horses had a LAD/AoD>1.25 
and were included in group 3. This group consisted of 12 Warmblood horses, 2 Spanish 
horses, 1 Friesian and 1 mixed breed; 10 geldings and 6 mares (age: 13±7 years, weight: 
519±140 kg, height: 162±16 cm).  
Blood sampling and laboratory analysis 
Two EDTA-blood tubesf with aprotinin were used to improve the sample stability of the 
ANP samples. To measure the more stable NT-proANP molecule, two EDTA-tubesg 
without aprotinin were utilized. Aprotinin is a proteinase inhibitor which has been 
shown to maintain sample stability of ANP but has no influence on NT-proANP results 
[31]. Blood samples were collected by jugular vein puncture and all tubes were 
immediately stored on ice and centrifugally cooled within 30 minutes (1000 g, 15 min, 2-
8 °C). Subsequently, plasma was transferred to four cryotubesh: two were stored at -
80°C and two at -20°C for later analysis. Samples were analyzed within 7 months using a 
commercially available ANPi and NT-proANPj enzyme-linked immunosorbent assay 
(ELISA) following the manufacturer’s instructions. The ANP ELISA was an equine assay, 
while the NT-proANP ELISA was developed for use in human medicine. On the day of 
analysis, ANP and NT-proANP were determined simultaneously on the -20°C and -80°C 
samples in order to study the influence of the temperature variation. As such, the 
storage times of the -20°C and -80°C samples for each horse were identical. In order to 
account for intra-assay variation, each individual sample was measured in duplicate 
within the same assay and the calculated average of these two measurements was used 
for further data analysis. In order to avoid the influence of inter-assay variation, which 
was <12% according to the manufacturer’s datasheet, the -20°C and -80°C samples from 
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each horse were always measured within the same assay. In total, throughout the study, 
three different ANP and NT-proANP ELISA plates were developed, using the same ANP 
and NT-proANP ELISA. The detection range of the ANP and NT-proANP test was 31-2000 
pg/mL and 39-2500 pg/mL, respectively.  
Statistical analysis 
The data analysis was performed using commercially available computer softwarek. 
Based on the Kolmogorov-Smirnov and Shapiro-Wilk test, data were not normally 
distributed. Data are expressed as median and interquartile range: (25th percentile 
value-75th percentile value), unless stated otherwise. Groups were compared by means 
of a Kruskal-Wallis a Dunn’s post hoc test for multiple comparisons. An ANP cut-off value 
for detection of left atrial dilatation was established by calculating a Receiver Operator 
Characteristic (ROC) curve. Correlations between ANP and NT-proANP values and 
echocardiographic measurements were examined by the Spearman correlation 
coefficient. Finally, the influence of the storage temperature was studied by means of 
Bland-Altman analysis. 
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Figure 1a and b. Atrial natriuretic peptide (ANP, Figure 1a) and N-terminal proANP (NT-
proANP, Figure 1b) concentration in healthy horses (group 1, n=20), horses with valvular 
regurgitation without atrial dilatation (group 2, n=11) and horses with valvular 
regurgitation and left atrial dilatation (group 3, n=16). A significantly higher (*) ANP 
concentration was found in group 3 as compared to group 1 (P<0.001) and group 2 
(P=0.015). No significant difference was found for NT-proANP. 
Fig. 1a 
Fig. 1b 
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Results 
Clinical examination 
No significant differences were found in weight or height between groups. Horses in 
group 3 (13±7 years; P=0.048) were significantly older than horses in group 1 (8±4 
years). No age difference was found between the other groups. A systolic heart murmur 
was detected in 10/11 horses of group 2 (grade: 1-5/6) and 15/16 horses of group 3 
(grade: 2-5/6). In addition to the systolic murmur, two horses of group 2 presented a 
diastolic murmur (grade: 4-5/6). Both remaining horses of groups 2 and 3 only had 
diastolic murmurs (grade: 2-4/6). Mild ventral edema was present in 2 horses of group 3. 
Echocardiography 
No significant valvular regurgitation was observed in the horses of group 1. Trivial mitral 
valve regurgitation was present in three horses and none of the other horses had an 
affected mitral valve. In group 2, seven horses had moderate, and four horses severe 
mitral valve regurgitation. In group 3, moderate mitral valve regurgitation was present in 
ten and severe mitral valve regurgitation in six horses. Moderate or severe regurgitation 
of the other valves was also found in 6/11 horses of group 2 and 7/16 horses of group 3. 
Four horses in group 2 and three horses in group 3 suffered from aortic regurgitation, 
two horses in group 2 and six in group 3 from tricuspid regurgitation, and two horses in 
group 2 and group 3 from pulmonary valve regurgitation.   
A median LAD/AoD and LAA/AoA of 1.15 (1.14-1.24) and 1.85 (1.54-2.12) was observed in 
group 1. Horses in group 2 had a LAD/AoD of 1.19 (1.10-1.24) and a LAA/AoA of 2.07 (1.78-
2.63). In the group of horses with dilatation (group 3), a LAD/AoD of 1.43 (1.31-2.41) and 
LAA/AoA of 2.90 (2.51-8.01) was demonstrated. In comparison to group 1, group 3 had a 
higher LAD/AoD (P<0.001) and LAA/AoA (P=0.003).  
Electrocardiography 
No significant abnormalities were seen at rest or during exercise in the horses of group 
1. An ECG at rest was performed in all horses of groups 2 and 3. Two horses of group 2 
and six horses of group 3 had atrial fibrillation (AF). An exercise ECG was performed in 
10/11 horses of group 2 and 9/16 horses of group 3. Two horses in group 2 and six 
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horses in group 3 showed a normal exercise test without dysrhythmia. Within group 2, 
atrial premature depolarizations (APDs per 30 min : 0, 0-20) were found in three and 
ventricular premature depolarizations (VPDs per 30 min: 0, 0-4) in seven horses. In two 
horses APDs as well as VPDs were detected. In group 3, the median number of APDs and 
VPDs was 0 (0-5) and 0 (0-5) per 30 min, respectively. 
ANP and NT-proANP comparison between groups  
The sample storage time for group 1 (1, 1-3 days, P<0.001) and group 2 (9, 1-210 days, 
P=0.027) was significantly shorter than for group 3 (52, 12-212 days). When samples 
were stored at -80°C (ANP-80 and NT-proANP-80), a median ANP-80 concentration of 31 
(31-333) pg/mL was found in group 1 (Figure 1a). 17/20 horses within this group had 
values under the limit of detection (31 pg/mL) and a high ANP concentration was found 
in two healthy horses. The median ANP-80 concentration in group 2 was 31 pg/mL (31-
1152 pg/mL). There was no significant difference between the ANP-80 concentration in 
healthy horses and that of horses with regurgitation without left atrial dilatation. 
However, the median ANP-80 concentration in group 3 (366, range 74-2000 pg/mL) was 
significantly higher than that of group 1 (P<0.001) and group 2 (P=0.015) (Figure 1a). A 
ROC analysis demonstrated that an ANP-80 cut-off value of 52 pg/mL (sensitivity: 81%, 
specificity: 84%) can be applied for the detection of left atrial dilatation in horses (Figure 
2).  
No significant differences between the groups were demonstrated for NT-proANP-80. 
18/20 healthy horses had NT-proANP-80 values under the limit of detection (39 pg/mL) 
and a high NT-proANP-80 concentration was found in the same 2 healthy horses that also 
had high ANP values. The median NT-proANP-80 was 39 pg/mL in group 2 (39-2500 
pg/mL) and in group 3 (39-2500 pg/mL).  
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Figure 2. Receiver Operator Characteristic curve of atrial natriuretic peptide (ANP) and 
N-terminal proANP (NT-proANP) stored at -20°C (ANP-20 and NT-proANP-20) and -80°C 
(ANP-80 and NT-proANP-80). In contrast to NT-proANP, a cut-off value for the detection of 
left atrial dilatation could be established for ANP. 
Correlation with echocardiographic variables (Table 1)  
A significant correlation was found between the ANP-80 concentration, LAD/AoD and 
LAA/AoA. Although the ANP-80 and NT-proANP-80 concentrations were correlated, no 
association was found between NT-proANP-80 and echocardiographic measurements.  
The influence of sample storage temperature   
ANP sample storage at -20°C (ANP-20) still resulted in a significant difference between 
group 1 and group 3 (P=0.001). However, no difference was found between groups 2 
and 3. The median ANP-20 concentration was 31 (31-352) pg/mL, 31 (31-1038) pg/mL 
and 178 (31-1581) pg/mL in group 1, 2 and 3, respectively. A correlation between ANP-20 
and echocardiographic variables was present (Table 1). The ANP-20 cut-off value (44 
pg/mL) was slightly lower than for ANP-80. Although the specificity did not change (84%), 
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a lower sensitivity was found (69%). Similarly as for NT-proANP-80, the median NT-
proANP-20 was 39 (39-270) pg/mL, 39 (39-2500) pg/mL and 39 (39-2500) pg/mL in group 
1, 2 and 3.   
When compared to storage at -80°C, storage at -20°C resulted in lower ANP and NT-
proANP values (Figure 3a and Figure 3b). Figure 3 shows that this decrease is smaller for 
NT-proANP than for ANP. A mean difference of 45±126 pg/mL was found for ANP-80-ANP-
20, while the mean difference was only 10±31 pg/mL for NT-proANP-80-NT-proANP-20. 
 
Table 1. Spearman correlation coefficient between atrial natriuretic peptide (ANP) and 
N-terminal proANP (NT-proANP) concentration stored at -80°C (ANP-80 and NT-proANP-
80) and -20°C (ANP-20 and NT-proANP-20). *Correlation is significant at the 0.01 level. 
 
 ANP-80 ANP-20 NT-proANP-80 NT-proANP-20 LAD/AoD LAA/AoA 
ANP-80 1.000      
ANP-20 0.913
* 1.000     
NT-proANP-80 0.428
* 0.461* 1.000    
NT-proANP-20 0.530
* 0.555* 0.933* 1.000   
LAD/AoD 0.605
* 0.526* 0.079 0.156 1.000  
LAA/AoA 0.559
* 0.475* 0.097 0.147 0.862* 1.000 
 
 
.  
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Figure 3a and b. Bland-Altman curve showing the relationship between the difference 
(ANP-80-ANP-20) of atrial natriuretic peptide (ANP-80-ANP-20; Figure 3a) on the one hand 
and N-terminal proANP (NT-proANP-80-NT-proANP-20; Figure 3b) on the other, relative to 
the mean ANP or NT-proANP concentration when samples that were stored at -80°C and 
-20°C were analyzed at the same time (group 1= healthy horses; group 2= horses with 
regurgitation without atrial dilatation; group 3= horses with regurgitation and left atrial 
dilatation; ANP-80: atrial natriuretic peptide concentration stored at -80°C; ANP-20: ANP 
stored at -20°C; NT-proANP-80: N-terminal proANP stored at -80°C; NT-proANP-20 : NT-
proANP stored at -20°C). 
Fig. 3b 
Fig.3a 
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Discussion 
This study demonstrates that ANP, not NT-proANP, increases in case of left atrial 
dilatation. A correlation between ANP and left atrial size was demonstrated and an ANP-
80 cut-off value of 52 pg/mL was established for the detection of atrial dilatation. 
Therefore, ANP might be better than NT-proANP to assess the severity of mitral valve 
disease. These results confirm preceding studies [20, 24] which showed that ANP 
increases in case of atrial stretch. Also in man, ANP was mainly related to atrial 
pathologies [13].   
 In our study, two healthy horses had high ANP and NT-proANP values in the absence of 
cardiovascular abnormalities and three horses with left atrial dilatation had low ANP 
values. An influence of extra-cardiac factors such as pulmonary disease, liver and renal 
failure, age, sex, body weight and sampling time on natriuretic peptides has been 
described [32-35]. Therefore, results should always be interpreted with caution. Both 
healthy horses with increased ANP and NT-proANP were mares, sampled in May, but it 
was not assessed whether they were in oestrus. In women, increased estrogen levels 
have been associated with increases in ANP. Similarly, in normal horses, stallions were 
shown to have significantly lower ANP and NT-proANP levels than geldings (P<0.001) or 
mares (P<0.05) [36].   
In contrast to earlier studies, an equine ANP ELISAi was chosen instead of a human ANP 
radioimmunoassay testb. The latter test has already been validated in horses [20, 21, 
24], but contradictory results were found: no correlation between ANP and 
echocardiographic measurements was demonstrated by Gehlen et al. (2007)[21], 
whereas Trachsel et al. (2012) found not only a relation between ANP and atrial 
dimensions [24], but also a partial correlation with the pulmonary capillary wedge 
pressure [20]. These inconsistent results could be caused by differences in study 
population, sample processing or changes of the assay over time [20]. A limitation of the 
ANP ELISA is the low sensitivity with a detection limit of 31 pg/mL. Since most healthy 
horses had ANP values under the limit of detection, an exact ANP value could not be 
determined in this group. The ANP concentrations in healthy horses in the studies 
mentioned above [21, 24] were also lower than 31 pg/mL. However, in our study, much 
higher ANP concentrations than previously reported were found in horses with atrial 
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enlargement at rest. The median ANP value in group 3 was 366 pg/mL, while ANP values 
of this order of magnitude could only be obtained in horses with mitral regurgitation 
after exercise (455 pg/mL 5 min post-exercise and 332 pg/mL 10 min post-exercise) [20]. 
Lower ANP values were reported in older studies [23, 37-39]. A direct comparison 
between the assays is needed to study possible explanations for these assay differences. 
However, the use of an equine ANP assay instead of a human assay might, at least in 
part, explain the differences in results. Although 100% homology has been described 
between human and equine ANP [25], structural differences could still exist [40] and 
could explain antibody affinity differences between a human and equine assay. Cross-
reactivity with other molecules might also differ between assays and explain the high 
ANP values obtained in our study. However, according to the manufacturer’s 
instructions, no cross-reactivity exists between the used recombinant equine ANP 
molecule and equine BNP or NT-proANP. Since no equine NT-proANP assay is available 
and 80-90% homology exists between human and equine NT-proANP, an ELISAj 
developed for human NT-proANP measurement was used for equine NT-proANP 
measurement [36]. As the human NT-proANP assay was not validated in horses, one 
could hypothesize that not NT-proANP, but another molecule was detected. However, 
antibodies against the human NT-proANP-fraction have been successfully used 
previously for the detection of proANP in equine atria [25]. In addition, our data show a 
clear correlation between ANP and NT-proANP (Table 1). Also, equine NT-proANP 
reference values have been determined previously using an NT-proANP RIA validated in 
humans [23]. Reference values for normal individuals in our study were generally under 
the limit of detection (<39 pg/mL or <3.5 pmol/L) and were much lower than previously 
reported (mean 208±22 pmol/L) [23]. Unfortunately, NT-proANP did not seem useful for 
detection of left atrial dilatation in our study. It remains to be determined whether an 
assay using horse-specific antibodies against NT-proANP would result in higher values 
and would allow for the differentiation of horses with and without atrial dilatation. The 
advantage of using NT-proANP over ANP is that this molecule has proved to be more 
stable. Indeed, in our study, only a mean NT-proANP difference of 10±31 pg/mL was 
found between sample storage at -80°C and at -20°C. This was smaller than for ANP, 
where the difference was 45±126 pg/mL.   
One of the limitations of our study was the variation in sample storage time between 
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groups. The samples were collected from horses admitted at our clinic and had to be 
stored until enough samples were obtained to run one ELISA. Therefore, the samples 
were not analyzed within the same time frame. However, to allow for comparison of 
ANP and NT-proANP levels, for each horse both molecules were always determined on 
the same day. Since sample storage time was variable, the decrease caused by sample 
instability could vary between groups. In humans, it has been reported that ANP is stable 
for 6 months when stored at -80°C [26, 41]. However, some authors disagree [42] and 
no studies have been performed in horses. Samples from group 3 were stored longer 
than samples from groups 1 and 2. Therefore, one would expect that the decrease in 
ANP concentration caused by sample instability would be larger in group 3 than in group 
1. Still, group 3 showed significantly higher values. Although storage could have a more 
pronounced negative effect on the unstable ANP molecule, ANP remained superior to 
NT-proANP for the assessment of left atrial dilatation.   
Secondly, the intra-assay and inter-assay coefficient of variations (CVs) were taken from 
the manufacturer’s datasheet and were not based on our own measurements. A large 
inter-assay CV has previously been demonstrated in horses [20, 43] and complicates 
interpretation of clinical values. Therefore, future research should be performed to 
determine if the intra- and inter-assay CV corresponds to the manufacturer’s datasheet. 
A third limitation was the significant age differences between groups 1 and 3. In 
humans, it has been reported that ANP and NT-proANP are related to age [35]. The 
higher ANP values in horses from group 3 could be influenced by their older age. 
Although no studies have been performed in horses, the influence of age is probably 
limited. The age difference between groups 2 and 3 was also very small, yet a significant 
difference in ANP was found between these groups. Therefore, age could only partially 
explain the ANP increase in group 3. The presence of different breeds in groups 2 and 3 
could also have an influence on ANP. As the majority of horses of group 2 and 3 were 
Warmbloods, the influence of breed differences on the obtained data was of minor 
importance. 
Finally, the effect of ventricular changes was not examined in this study. Although 
Mifune et al. (1991) [44] could only find ANP granules in healthy equine atrial, not 
ventricular myocytes, ventricular contribution to ANP levels in diseased horses is still 
unknown. Similar to BNP, an ANP up-regulation in the ventricles might occur in patients 
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with cardiac disease [45]. Further research about the ANP distribution in diseased 
equine myocardium is definitely needed. An up-regulation might also occur in horses 
with AF: a high ANP concentration has been reported in patients with acute atrial 
fibrillation. This ANP concentration can decrease in case of long-standing AF [46]. No 
association between NPs and AF was found in our study (unpublished data). This could 
be due to the chronicity of AF or the small number of horses in the study.  
Conclusion 
An ANP rise can be detected in horses with left atrial dilatation. Although NT-proANP 
was more stable than ANP, it did not turn out to be useful in horses.  
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Footnotes
a Cardiopet proBNP, IDEXX Europe, Hoofddorp, The Netherlands 
b RIA kit 2011, Peninsula Laboratories, member of the Bachem group, San Carlos, USA 
c GE Vivid 7 Dimension, GE Healthcare, Diegem, Benelux 
d 3S Phased Array Transducer, GE Healthcare, Diegem, Benelux 
e EchoPAC software version 12, GE Healthcare, Diegem, Benelux 
f Vacutainer 1.6 mg KD EDTA and 50 KIU aprotinin/mL blood, BD Diagnostics, 
Erembodegem, Belgium 
g Vacutest 1.8 mg KD EDTA/mL blood, Arzergrande, Italy 
h Cryovials 2 mL, VWR International, Leuven, Belgium 
I E90225EQ, USCN, Wuhan, China 
j E90484Hu, USCN, Wuhan, China 
k SPSS Statistics 21.0, Chicago, IL 
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Summary 
Equine atrial natriuretic peptide (ANP) plasma concentrations are correlated with left 
atrial size. However, species specific assays are lacking and the results from human 
assays are poorly reproducible. A new methodology called processing independent 
analysis that measures the total proANP product in plasma has proven to be successful 
in human medicine, but has never been used in horses. The aims were to establish an 
equine proANP reference interval by measurement of the total proANP product and to 
examine the proANP concentrations in horses with atrial dilatation. Sample stability was 
studied by comparison of storage at -80°C and -20°C. Plasma samples were obtained 
from 23 healthy horses, 12 horses with cardiac disease without atrial dilatation and 42 
horses with cardiac disease and atrial dilatation. The proANP concentration was 
significantly (P<0.001) higher in horses with atrial dilatation (761.4 (442.1-1859.1) 
pmol/L) than in healthy horses (491.6 (429.5-765.9) pmol/L; P<0.001) or horses with 
cardiac disease but without atrial dilatation (544.4 (457.0-677.6) pmol/L). A cut-off value 
(573.8 pmol/L) for detection of atrial dilatation was calculated. Sample storage at -80°C 
did not differ from sample storage at -20°C. Measurement of total proANP in plasma 
detects atrial dilatation in horses and may be useful for clinical evaluation in equine 
medicine. 
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Introduction 
Equine and human atrial natriuretic peptide (ANP) have 100% homology. Therefore, 
human assays have been used in horses [1] and a significant correlation between the 
ANP plasma concentration and left atrial dilatation has been reported [2-5]. However, 
plasma ANP is labile and the methods often not validated [2, 6, 7]. A recent study [4] 
with different human ANP assays showed that assays are poorly comparable with a 
troublesome high degree of analytical variation. The poor precision of human assays 
used in equine veterinary science might also be caused by species differences in ANP 
expression and post-translational processing, or in peripheral elimination [8]. The 
antibody affinity towards circulating equine ANP and NT-proANP fragments in plasma 
depends on the human ANP and NT-proANP calibrator peptides of the human assays. 
Different assays may have different calibrator peptides, thus the antibody affinity 
against these equine fragments could be variable. An equine specific ANP assay might 
perform better [5]. However, further assay validation studies are needed. Recently, a 
technique called processing independent analysis has been applied in humans, pigs and 
dogs [9]. This technique measures a stable part of the proANP molecule, which is not 
modified after release into the circulation and is thus independent of species differences 
in expression, post-translational processing or elimination [9, 10]. Before sample 
analysis, samples are incubated with trypsin, which ensures that the selected epitope is 
fully exposed for antibody binding and that fragments of the same size are released 
from unprocessed or partially processed proANP fragments [9]. A higher proANP 
concentration has been found in dogs and humans with congestive heart failure [9, 11], 
but the applicability in horses remains untested. The first aim of this study was to 
determine reference values for proANP in horses and to establish a cut-off value for 
detection of atrial dilatation. Secondly, the stability of proANP samples was examined by 
comparison of storage at -80°C and -20°C. 
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Materials and methods 
Study population 
The study was approved by the ethical committee of the Faculty of Veterinary Medicine 
and Bioscience Engineering, Ghent University (EC2012/57). All horses were privately 
owned and all examinations were performed with owner’s informed consent. Part of the 
horses (n=30) were also used in a previous study [5]. The study population consisted of 
23 healthy horses (group 1) and 54 horses with cardiac disease (group 2). In order to be 
included, horses of group 1 had to be healthy, free from cardiorespiratory disease and 
trained on a regular basis. All horses of group 1 underwent a thorough examination 
including clinical examination, echocardiography and electrocardiography (ECGa) at rest 
and during exercise. An ECG during a standardized lungeing exercise test was recorded 
in all healthy horses. The exercise test consisted of 5 minutes walk, followed by 10 
minutes trot, 4 minutes canter and one minute gallop [12].  
Horses of group 2 were presented for cardiac examination at the Faculty of Veterinary 
Medicine (Merelbeke, Belgium). Only horses with moderate or severe regurgitation of 
one or more valves were selected. These horses also underwent clinical examination, 
echocardiography and ECG. Based on echocardiographic measurements, horses of group 
2 were categorized in 2 subgroups: horses with regurgitation of one or more valves 
without atrial dilatation were classified as group 2a, while horses with atrial dilatation 
were classified as group 2b. 
Blood sampling  
Two EDTA blood tubesb were collected by puncture of the jugular vein with a venojectc. 
The blood tubes were immediately stored on ice-packs and centrifuged (1000g, 15 min) 
within 30 min at a temperature of 4°C. After centrifugation, plasma samples were 
transferred into cryovialsd. One cryovial was stored at -80°C and another one at -20°C. 
Samples were transported on dry ice in three batches from the Faculty of Veterinary 
Medicine (Ghent University, Belgium) to the Department of Clinical Biochemistry at 
Copenhagen University (Denmark) and stored at -20°C and -80°C until analysis.  
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Assay optimization and sample analysis 
The assay was mainly performed as earlier described [9] and only the incubation of 
samples was changed. Briefly, polyclonal antibodies against proANP1-16 were mixed with 
trypsin treated diluted plasma samples. After 48 hours of incubation at 4°C, a iodinated 
tracer peptide (porcine proANP1-16) was added and samples were further incubated for 
48 hours before separation was performed. All plasma samples were ethanol extracted 
and trypsin treated before measurement and a total of 150 µL was used per 
measurement. All samples were measured in duplicate.  
Echocardiographic measurements 
Echocardiographic examination included standardized transthoracic two-dimensional B-
mode, M-mode and Doppler images using an ultrasound unite with a phased-array 
transducerf at a frequency of 1.7/3.4 MHz. A modified base-apex ECG was recorded 
simultaneously and at least three cardiac cycles from each view were stored. Off-line 
analysis was performed using dedicated softwareg. For each variable, the average of 
three cardiac cycles was used. Left atrial size was evaluated by the measurement of the 
end-systolic left atrial-to-aortic root diameter ratio (LAD/AoD) from a short axis image as 
described previously [13]. If the LAD/AoD was >1.50, horses were diagnosed as having 
atrial dilatation and thus categorized in group 2b. The right atrium was subjectively 
assessed on a long axis four chamber view. If the right atrium was dilated, horses were 
also categorized in group 2b. The level of valvular regurgitation was graded on a scale 
from 1-9 [14]; grade 1-3 was classified as trivial regurgitation, grade 4-5 mild, grade 6-7 
moderate and grade 8-9 severe valvular regurgitation.  
Statistical analysis  
The statistical analysis was performed using commercially available softwareh. Based on 
the Kolmogorov-Smirnov and Shapiro-Wilk test, data were not normally distributed. 
After logarithmic transformation, data remained skewed, thus a non-parametric 
approach was chosen and all data were expressed as median and range (minimum-
maximum value). Age, weight, sex and proANP concentration were compared between 
groups with a Kruskal Wallis test. A proANP cut-off value for detection of atrial dilatation 
was calculated using a Receiver Operator Characteristic (ROC) curve. The Spearman 
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correlation coefficient was calculated to investigate the relationship between the 
proANP concentration and echocardiographic measurements. Sample storage 
temperature at -20°C and -80°C was compared with a Wilcoxon-Signed Rank test and a 
Bland-Altman plot was used to study the correlation between the two temperatures. 
The intra-assay coefficient of variation was calculated according to the following 
formula: 
∑= N
d
s
²
. 
 
Table 1. Distribution of the level of moderate or severe valvular regurgitation in horses 
of group 2a (horses with regurgitation without atrial dilatation) and group 2b (horses 
with regurgitation and atrial dilatation). 
 
mitral 
regurgitation 
tricuspid 
regurgitation 
aortic 
regurgitation 
pulmonary 
regurgitation 
moderate severe moderate severe moderate severe moderate severe 
group 2a 9 1 1 0 8 1 1 0 
group 2b 18 10 7 8 7 10 6 4 
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Results 
Echocardiographic and electrocardiographic examination 
No significant difference in weight, age, height or sex was found between groups. Group 
1 (8±4 years; 567±54 kg; height: 168±5 cm) consisted of 12 geldings, 10 mares and 1 
stallion, all Warmblood horses. No significant valvular regurgitation was present in 
horses of group 1. Three horses had mild tricuspid regurgitation, one horse mild mitral 
valve regurgitation and two horses mild aortic regurgitation. One atrial premature 
depolarization (APD) was present during the lungeing exercise test of three healthy 
horses. One other horse had two ventricular premature depolarizations (VPDs) during 
exercise. 
Sixteen horses of group 2 had a LA/Ao of ≤ 1.50 cm and were therefore categorized in 
group 2a. Group 2a (14±7 years; 517±98 kg; 165±10 cm) consisted of one stallion, eleven 
geldings and four mares. Table 1 demonstrates the distribution of the level of valvular 
regurgitation. One of the horses also had a ventricular septal defect (3 cm, maximal 
shunt velocity: 5 m/s) which was partly closed by a prolapsed aortic valve. An exercise 
ECG was performed in 14 horses: four horses had between one and twenty APDs and 
five horses between one and four VPDs during exercise. None of the horses had atrial 
fibrillation. Of the remaining 38 horses of group 2, 36 horses had a LA/Ao>1.50 and were 
diagnosed as having left atrial dilatation. The other two horses had a markedly enlarged 
right atrium based on the long axis four chamber view and were also categorized in 
group 2b. Group 2b (11±7 years; 522±121 kg; 162±14 cm) consisted of two stallions, 21 
geldings and 15 mares. The mitral valve was mostly affected (Table 1). Six horses of this 
group had a ventricular septal defect (between 1.7 and 4.8 cm) and five horses an 
aortopulmonary fistula. One horse was diagnosed with a tetralogy of Fallot. Atrial 
fibrillation was present in 20 horses. An exercise ECG was recorded in 16 horses: 9 of 
these horses had atrial fibrillation, 4 of these horses had between one and five APDs and 
5 horses between one and five VPDs.   
The median LAD/AoD in horses of group 1 was 1.33 (1.13-1.49). No significant difference 
was found with the LAD/AoD of horses of group 2a (1.40 (1.26-1.49)). Horses of group 2b 
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had a significantly higher LA/Ao (1.76 (1.38-3.09)) than horses of group 1 (P<0.001) or 
group 2a (P<0.001). 
Comparison of proANP between groups 
The intra-assay coefficient of variation was 11.9%. The median time until sample analysis 
was 769 (307-804) days for horses of group 1, 749 (442-806) days for horses of group 2a 
and 598 (147-811) days for horses of group 2b. Sample storage for horses of group 2b 
was significantly shorter than for horses of group 1 (P<0.001). For samples stored at         
-80°C, the median proANP concentration of group 2b was significantly (P<0.001) higher 
than of group 1 (Table 2). The proANP concentration of group 2a was not significantly 
different from group 1 (P=0.92) and group 2b (P=0.10).  
Based on the proANP-80 concentration, a cut-off value of 573.8 pmol/L could be 
determined for detection of atrial dilatation (Figure 1). The sensitivity and specificity for 
this cut-off value were 78.1% and 81.2%, respectively (P<0.001, area under the curve 
(AUC): 0.79; 95% confidence interval: 0.67-0.91). The proANP-80 concentration was 
significantly correlated with the LAD/AoD and the level of valvular regurgitation (Table 3).  
Table 2. ProANP plasma concentration in healthy horses (group 1), horses with cardiac 
disease without atrial dilatation (group 2a) and horses with cardiac disease and atrial 
dilatation (group 2b) when samples are stored at -80°C and -20°C. Different letters 
indicate significant differences. 
Sample storage at -80°C Sample storage at -20°C 
 Median Minimum Maximum Median Minimum maximum 
Group 1 491.6a 429.5 765.9 509.1a 420.4 832.9 
Group 2a 544.4a,b 457.0 677.6 521.8a,b 378.6 661.7 
Group 2b 761.4b 442.1 1859.1 786.2c 449.3 2181.6 
 
Comparison of sample storage temperature 
The proANP concentration of samples stored at -20°C (proANP-20; 578.2 (378.6-2181.6) 
pmol/L) was not significantly different from those stored at -80°C (567.6 (429.5-1859.1) 
pmol/L). Similar to proANP-80, a significant (P<0.001) difference was found between the 
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proANP-20 concentration from group 1 and 2b and a correlation with echocardiographic 
variables could be demonstrated (Table 2 and 3). Horses from group 2b also showed a 
significantly higher proANP-20 concentration than horses from group 2a (P<0.001). The 
optimal cut-off for atrial dilatation was 568.1 pmol/L (P<0.001, AUC: 0.88 (0.80-0.971)) 
with similar sensitivity (84.4%) and specificity (78.1%) as for proANP-80. Bland-Altman 
analysis of proANP-80 and proANP-20 (Figure 2) demonstrates a mean difference between 
proANP-80 and proANP-20 of -3.14±159.05 pmol/L.  
Table 3. Spearman correlation coefficient between the proANP concentrations stored at 
-80°C (proANP-80) and -20°C (proANP-20), the grade of mitral (MR), tricuspid (TR), aortic 
(AR) and pulmonary valve (PR) regurgitation and the left atrial-to-aortic root diameter 
ratio (LAD/AoD, *= P<0.05; **=P<0.01). 
 proANP-80 proANP-20 MR TR AR PR 
proANP-80 1.000      
proANP-20 0.713** 1.000     
MR 0.423** 0.455** 1.000    
TR 0.407** 0.512** 0.391** 1.000   
AR 0.418** 0.281* 0.192 0.063 1.000  
R 0.363** 0.289* 0.398** 0.297** 0.440** 1.000 
LAD/AoD 0.532** 0.623** 0.644** 0.365** 0.376** 0.339** 
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Figure 1. Receiver Operator Characteristic curve of the proANP-80 and proANP-20 
concentration (= cut-off value proANP-80; = cut-off value proANP-20). 
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Figure 2. Bland Altman analysis: difference between storage at -80°C (proANP-80) and 
storage at -20°C (proANP-20). 
Chapter 5.2: Discussion  
  
168 
 
Discussion 
This study is the first to use processing independent analysis for proANP measurement 
in horses. The proANP concentration of healthy horses (491.6 (429.5-765.9) pmol/L) was 
much higher than that of healthy human patients (276 (272-311) pmol/L), which 
probably reflects differences in human and equine physiology [8, 9]. These differences 
have also been demonstrated on microscopic level: in comparison to other species, 
horses have fewer and smaller ANP granules [15], which might be correlated to a higher 
ANP metabolism [8, 16]. The median proANP value of 491.6 pmol/L in healthy horses is 
much higher than the normal ANP values (13 pg/mL or 4.22 pmol/L [2]; 21 pg/mL or 6.81 
pmol/L [6]) measured with human assays. As mentioned above, this might be caused by 
differences in equine and human post-translational modification of ANP. In contrast to 
ANP, samples for processing independent analysis are also pretreated with an 
endoprotease (trypsin), which exposes epitopes from fragments which are normally not 
fully processed [17].   
Because atrial dilatation resulted in significantly increased proANP values and because 
proANP was correlated with atrial size determined by cardiac ultrasound, measurement 
of this biomarker might be useful to detect atrial dilation, as in human medicine. The 
instability of ANP requires storage at -80°C [5, 18] which is not always available under 
clinical circumstances. Interestingly, proANP seems to be equally stable whether stored 
at -20°C or -80°C, which makes measurement of the total proANP product by processing 
independent analysis better suited for clinical use. A significant difference was even 
found between horses with valvular regurgitation with and without atrial dilatation 
when samples were stored at -20°C.   
One limitation of our study was that not all samples were stored for the same period of 
time: samples from group 2b were stored for a significantly shorter period of time than 
samples from group 1 or 2a. A longer storage time might be associated with a higher 
peptide degradation and might therefore explain the lower proANP concentration in 
samples from group 1 and 2a. However, as mentioned above, proANP seems to be a 
stable molecule, which even requires trypsin treatment before sample measurement. 
Therefore, it is unlikely that sample degradation has caused the lower proANP values in 
horses of group 1 or 2a. A second limitation of the study was that the influence of age or 
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sex could not be examined. In human medical practice, sex and age influences on NP 
levels have previously been demonstrated [9, 19-22]: females and elderly people usually 
have higher ANP levels. In stallions, one author described lower ANP and NT-proANP 
levels (n=6) [23]. The healthy mares (n=10; proANP-80: 542.3 (429 – 765.9) pmol/L) from 
our study did have higher proANP concentrations than the geldings (n=12; proANP-80: 
431.-641.2) pmol/L), but the difference was not significant. A significant correlation (r=   
-0.429; P<0.05) between age and proANP-80 concentration was found, but surprisingly, 
younger horses showed higher proANP-80 concentrations. Since a lot of young horses 
were mares, these findings should be interpreted cautiously. A new study with a higher 
number of healthy horses of different age and sex should be performed to determine if 
age or sex dependent reference values should be used in horses. Finally, a lot of horses 
in this study had regurgitation of more than one valve and dilatation of the ventricle 
might also has have influenced the proANP concentration. One horse of group 2a had 
left ventricular dilatation and a proANP concentration above the cut-off value (614.4 
pmol/L), thus the influence of the ventricle should be examined further. 
Conclusion  
The total proANP product in plasma can be successfully measured in horses and seems 
to be a good technique for detection of atrial dilatation. The reliability of the technique 
and stability of the total proANP product makes this technique suitable for future use in 
equine clinical practice. 
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Footnotes
a Televet 100, Engel Engineering Services, GmbH, Offenbach, Germany 
b Vacutest 1.8 mg K3 EDTA/mL blood, Arzergrande, Italy 
c Venosafe, Terumo Europe, Leuven, Belgium 
d Cryovials, 2 mL, VWR international, Leuven, Belgium 
e GE Vivid 7 Dimension, GE Healthcare, Diegem, Benelux 
f 3S Phased Array Transducer, GE Healthcare, Diegem, Benelux 
g EchoPAC, software version 12, GE Healthcare, Diegem, Benelux 
h SPSS Statistics, version 22, Chicago, IL 
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Summary 
B-type natriuretic peptide (BNP) is used in human medicine for the diagnosis of 
congestive heart failure. Since BNP is species specific and no equine assay is available, 
BNP has never been determined in horses. Because there is more than 90% homology 
between porcine and equine BNP, a porcine BNP enzyme-linked immunoassay (ELISA) 
was used in the present study to measure BNP in plasma of healthy horses (group 1; 
n=20), horses with cardiac disease without (group 2a; n=8) and with atrial dilatation 
(n=8), ventricular dilatation (n=1) or both (n=1) (group 2b; n=10). Samples were stored 
at -20°C and -80°C to study the influence of storage temperature. No significant 
differences were found between the BNP concentration of group 1 (77.79; 37.20-513.36 
pg/mL), group 2a (52.02; 24.69-268.37 pg/mL) or 2b (94.73; 42.88-470.66 pg/mL). 
Samples stored at -80°C showed significantly (72.19, 24.69-513.36 pg/mL; P=0.001) 
higher concentrations than samples stored at -20°C (47.35, 24.69-430.60 pg/mL). In this 
pilot study, it is suggested that the porcine BNP assay does not allow accurate detection 
of equine BNP. An equine specific BNP assay should be developed to study BNP 
concentrations in horses. 
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Introduction 
Natriuretic peptides (NPs) have become an essential aid to establish a proper diagnosis 
and prognosis and to monitor patients with heart failure [1]. Atrial and B-type NPs are 
the two most important members of the NP family, which contains a typical 17-amino 
acid ring closed by a disulfide binding between two cysteine-molecules [2]. Both atrial 
and B-type NPs are released in case of cardiac dilatation and subsequently broken down 
into a stable, inactive NH2-terminal molecule (NT-proANP and NT-proBNP) and an 
unstable, active molecule (ANP and BNP). Atrial NPs are mainly secreted in case of atrial 
dilatation [3-5], while B-type NPs are more related with ventricular pathologies [6]. Due 
to their longer half-life, B-type NPs are often preferred for the diagnosis of heart failure 
in human clinical practice [7, 8]. A half-life of 2-5 min [9] and of 55-60 min [10] has been 
reported for human ANP and NT-proANP, respectively, while BNP and NT-proBNP have a 
half-life of 12-20 min and 60-120 min, respectively [11-14].   
Human and equine ANP have 100% homology [15]. This explains why ANP has already 
been successfully determined in horses using human assays. A significant correlation 
between ANP plasma levels and left atrial dilatation has already been demonstrated [5, 
16-18]. In contrast to ANP, the molecular structure of BNP and NT-proBNP is more 
variable amongst species [15]. Recently, a new canine and feline NT-proBNP assaya has 
been developed and successfully used for the detection of cardiac disease in dogs and 
cats [19-21]. However, equine studies regarding B-type NPs are still missing. Since NT-
proBNP has a longer half-life and is currently clinically the most important molecule in 
dogs and cats [22], equine NT-proBNP measurement might be the best choice for future 
use in clinical practice. However, compared to NT-proBNP, the shorter BNP molecule 
seems to have more homology between some species [23]. Therefore, similarly to ANP, 
only for BNP, there is a chance that assays validated for other species might be useful to 
detect equine BNP. Human and equine BNP have ±75 % homology [15]. Hence, 
successful use of human BNP assays in horses seems unlikely. The difference between 
equine and porcine BNP is much smaller: only 3 of the 32 amino-acids of porcine and 
equine BNP differ [15] (Table 6, Chapter 1). Thus, a porcine assay might be suitable for 
measurement of BNP in horses. B-type NP-like activity has been demonstrated in equine 
atrial tissue using antiserum against porcine BNP [24], but a porcine BNP assay has never 
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been used to measure BNP in horse plasma. Therefore, the objectives of this pilot study 
were (1) to use a porcine BNP assay for the measurement of BNP in plasma of healthy 
horses and horses with cardiac disease and (2) to determine whether sample storage 
temperature has an important effect on analysis results. 
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Materials and methods 
Study population 
The study was approved (EC2012/57) by the ethical committee of the Faculty of 
Veterinary Medicine and Bioscience Engineering of Ghent University. All horses were 
privately owned and all examinations were performed with the owner’s informed 
consent. The study population consisted of 20 healthy horses (group 1) and 18 horses 
with cardiac disease (group 2). The horses of group 1 were subjected to a thorough 
examination, including medical assessment of case history, clinical examination, 
echocardiographic examination and registration of electrocardiography (ECG) at rest and 
during a standardized lungeing exercise test, which consisted of a five-minute walk, a 
ten-minute trot, a four-minute canter and a one-minute gallop [25]. In order to be 
included in group 1, the horses had to be healthy, trained 2-4 times a week and had to 
be free of cardiorespiratory disease.   
The horses of group 2 were presented at the Faculty of Veterinary Medicine, Ghent 
University (Merelbeke, Belgium) with a cardiac murmur. Only horses, in which moderate 
to severe regurgitation at one or more cardiac valves could be visualized by means of 
cardiac ultrasound, were included. All horses of this group underwent echocardiography 
and ECG recording. Based on echocardiographic measurements, the horses were 
classified into two subgroups: group 2a included the horses with valvular regurgitation 
without cardiac dilatation and group 2b included the horses with valvular regurgitation 
and either atrial dilatation or ventricular dilatation or both. 
Echocardiographic measurements 
Transthoracic echocardiographic examination included two-dimensional B-mode, M-
mode and color Dopplerb using a phased-array transducerc at a frequency of 1.7/3.4 
MHz. A modified base-apex ECG was recorded simultaneously and at least three cardiac 
cycles from each view were stored. Off-line analysis was performed using dedicated 
softwared. For each variable, the average of three cardiac cycles was determined. Left 
atrial size was evaluated by the measurement of the end-systolic left atrial-to-aortic root 
diameter ratio (LAD/AoD) from a short axis image. The short axis systolic diameter of the 
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left atrium (LAD) was measured by placing two calipers in a line extending from and 
parallel to the commissure between the non-coronary and left coronary aortic valve 
cusps to the distant margin of the left atrium. The internal short axis diameter of the 
aorta at valvular level was determined by placing calipers along the commissure 
between the non-coronary and right coronary aortic valve cusps [26]. If the LAD/AoD was 
> 1.25, the horses were diagnosed as having atrial dilatation and thus categorized in 
group 2b. Similarly, ventricular dilatation was evaluated by the measurement of the left 
ventricular internal diameter during diastole (LVIDd) from a short-axis M-mode view of 
the left ventricle at chordal level. Horses with a LVIDd >13.30 cm were considered having 
left ventricular dilatation [27], and therefore categorized in group 2b. A subjective 
assessment of the dimensions of the right atrium and the right ventricle was performed 
on a long axis four chamber view.  
Blood sampling and analysis 
Two ethylenediaminetetraacetic acid (EDTA) tubes with aprotinine were collected by 
puncture of the jugular vein with a venojectf. Aprotinin [28] is a proteinase inhibitor that 
might improve sample stability. From ten healthy horses, EDTA samples without 
aprotinin were also collected and stored at -80°C to study the influence of this 
proteinase inhibitor. The blood samples were directly stored on ice and centrifuged 
(1000 g, 15 min, 2-8°C) within 30 minutes. Next, the plasma was harvested and 
transferred into two cryovialsg. One cryovial was stored at -80°C and one at -20°C until 
analysis. Time until analysis was 1 (1-2) day in group 1, 7 (1-17) days in group 2a and 9 
(1-31) days in group 2b. Sample analysis was performed with a porcine competitive 
inhibition enzyme-linked immunoassayh, in which a monoclonal antibody, specific for 
porcine BNP, was pre-coated on the plate and attaches to BNP present in the sample. 
Next, biotin-labeled porcine BNP was added, which began a competition with the BNP 
present in the sample. Finally, avidin bound to horse radish peroxidase and 3.3′,5.5′-
tetramethylbenzidine (TMB) substrate was added to establish a color reaction. The 
intensity of the color reaction was reverse proportional to the BNP concentration in the 
sample. The inter-assay and intra-assay coefficient of variation (CV) was <12% and <10% 
according to the manufacturer’s instructions. The detection range was between 24.69 
and 2000.00 pg/mL. For analysis of all 76 samples (38 samples stored at two different 
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temperatures), three different ELISA plates were used. All samples were analyzed in 
duplicate and the samples from the horses of each group were included in each plate. 
For each horse, the -20°C and -80°C samples were analyzed within the same plate to 
avoid inter-assay variation in order to allow comparison of storage temperature.  
Statistical analysis 
Data analysis was performed using commercially available computer softwarei. The level 
of significance was set at P=0.05. The Kolmogorov-Smirnov and Shapiro-Wilk test were 
used to test normal distribution of data. Normally distributed data were expressed as 
mean ± standard deviation and non-parametric data were expressed as median (range). 
The mean age and weight of group 1 and 2 were compared by a student’s t-test for 
independent samples. The median BNP concentration and the storage time between 
groups were compared by a Mann Whitney U test. Comparison between the BNP 
concentration of samples stored at -20°C and -80°C and of samples with and without 
aprotinin was done by the Wilcoxon signed rank test. The influence of the storage 
temperature was further studied by Bland Altman analysis. Samples with a 
concentration under the limit of detection (<24.69 pg/mL) were assigned the value of 
the limit of detection. The association between BNP and echocardiographic 
measurements was examined by the Spearman correlation coefficient (P=0.01).  
Table 1. Spearman correlation coefficients between B-type natriuretic peptide 
concentrations stored at -80°C (BNP-80) and -20°C (BNP-20) and echocardiographic 
measurements (LAD/AoD: left atrial-to-aortic root ratio, LVIDd= left ventricle internal 
diameter during diastole, *= P<0.01). 
 BNP-80 BNP-20 LAD/AoD LVIDd 
BNP-80 1.000    
BNP-20 0.505* 1.000   
LAD/AoD 0.096 -0.300 1.000  
LVIDd 0.202 -0.112 0.123 1.000 
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Results 
Clinical, echocardiographic and electrocardiographic examination 
Group 1 consisted of 20 Warmblood horses: 10 geldings, 9 mares and 1 stallion (age: 8±4 
years, weight: 563±52 kg, height: 168±5 cm). The LAD/AoD and LVIDd was 1.15±0.05 and 
11.33±1.19 cm, respectively. The exercise ECG was normal in 18/20 horses. One horse 
had one atrial premature depolarization (APD) and another horse had two ventricular 
premature depolarizations (VPDs) during exercise.  
Group 2 consisted of 14 Warmblood horses, 1 Arabian horse, 1 Friesian, 1 Spanish horse 
and 1 mixed breed and included 8 geldings, 8 mares and 2 stallions (age: 13±6 years, 
weight: 566±90 kg; height: 167±9 cm). The mean age (P=0.006) in group 2 was 
significantly higher than the mean age in group 1. No difference in weight was found. A 
systolic murmur was detected in 13/18 horses and a diastolic murmur in 6/18 horses. 
Echocardiographic examination demonstrated a moderate or severe regurgitation of 
one (n=13) or more valves (n=5) in all of the horses. The mitral valve was mostly affected 
(n=10), followed by the aortic (n=7), tricuspid (n=4) and pulmonary valve (n=2). Two 
horses also showed a ventricular septal defect and one Friesian was diagnosed with an 
aortopulmonary fistula. Based on the LAD/AoD and the LVIDd, eight horses had normal 
left atrial and left ventricular diameters and were categorized in group 2a. One horse 
had a markedly enlarged right atrium, and was therefore classified in group 2b. The 
remaining nine horses had a LAD/AoD >1.25 (n=8) or a LVIDd>13.30 (n=2), and were 
therefore categorized in group 2b. The mean LAD/AoD and LVIDd in group 2a were 
1.16±0.06 and 12.41±0.83 cm, respectively. A mean LAD/AoD of 1.40±0.18 and LVIDd of 
12.53±1.54 was demonstrated in group 2b. Electrocardiographic examination 
demonstrated atrial fibrillation in three horses. An exercise ECG was performed in 15/18 
horses. No abnormalities were found in 4/15 horses. Six horses had between one and 
nine APDs and eight horses between one and four VPDs during exercise.  
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BNP comparison between groups 
When samples were stored at -80°C (BNP-80), the median BNP concentration in group 1 
was 77.79 pg/mL (37.20-513.36) pg/mL. The median concentration of samples from 
healthy horses analyzed on ELISA plate 1, 2 and 3 was 190.57 pg/mL (n=9, range: 95.15-
513.36 pg/mL), 42.48 pg/mL (n=9, range: 37.20-61.74 pg/mL) and 69.10 pg/mL (n=2, 
range: 44.35-93.84 pg/mL). No significant (P=0.135) difference was found between the 
BNP-80 concentration of group 2a (52.02 pg/mL, range 24.69-268.37 pg/mL) or group 2b 
(94.73 pg/mL, range 42.88-470.66 pg/mL) (Figure 1) when samples analyzed with all 
three different plates were included. When only samples from plates 2 and 3 were 
included, a significant difference was found between horses with cardiac dilatation 
(94.73 pg/mL, range: 43.77-470.66 pg/mL) and healthy horses (44.35 pg/mL, range: 
37.20-93.84 pg/mL, P=0.014) and between horses with dilatation and horses with 
valvular regurgitation without dilatation (49.56 pg/mL, range: 24.69-179.30 pg/mL, P= 
0.043). There was no correlation between the BNP-80 concentration and the LAD/AoD or 
LVIDd (Table 1). 
 
Figure 1. B-type natriuretic peptide concentrations when samples were stored at -80°C 
(BNP -80) of group 1 (healthy horses), group 2a (horses with regurgitation without atrial 
or ventricular dilatation) and group 2b (horses with regurgitation with atrial or 
ventricular dilatation) 
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Influence of sample storage temperature and aprotinin addition 
When samples were stored at -20°C (BNP-20), a significantly (P<0.001) lower BNP 
concentration (47.35 pg/mL, range 24.69-430.60 pg/mL) was found than when samples 
were stored at -80°C (72.19 pg/mL, range 24.69-513.36 pg/mL). Similarly as for BNP-80, 
no significant (P=0.792) BNP-20 difference was found between group 1 (48.84 pg/mL, 
range 24.69-139.63 pg/mL), group 2a (51.85 pg/mL, range 24.69-430.60 pg/mL) or group 
2b (40.80 pg/mL, range 24.69-409.13 pg/mL) (Figure 2). A significant correlation (P<0.01) 
existed between BNP-20 and BNP-80 (Table 1). The mean difference between the BNP-80 
and BNP-20 concentrations was 62.69±149.61 pg/mL (Figure 3). Almost all (n=32) of the 
BNP samples stored at a temperature of -80°C had a higher concentration than when 
stored at -20°C. The median BNP concentration was significantly (P=0.037) higher in 
EDTA samples with aprotinin (240.86, 95.15-513.36 pg/mL) compared than in EDTA 
samples without aprotinin (147.54, 75.27-227.98 pg/mL).   
 
 
 
 
Figure 2. B-type natriuretic peptide concentrations when samples were stored at -20°C (BNP-20) of 
group 1 (healthy horses), group 2a (horses with regurgitation without atrial or ventricular dilatation) 
and group 2b (horses with regurgitation with atrial or ventricular dilatation). 
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Figure 3. Bland-Altman plot showing the relationship between the difference (BNP-80
- BNP-20) of B-type natriuretic peptide (BNP) relative to the mean BNP concentration 
when samples stored at -80°C and -20°C were analyzed at the same time (group 1= 
healthy horses; group 2a= horses with regurgitation without atrial/ventricular 
dilatation; group 2b= horses with regurgitation and atrial or ventricular dilatation; 
BNP-80: BNP concentration stored at -80°C; BNP-20: BNP stored at -20°C). 
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Discussion 
Human assays have been used for equine ANP [5, 16, 17] and NT-proANP measurement 
[29] based on the interspecies sequence homology between molecules [5, 16, 17]. A 
sequence homology of 100% and 80-90% has been described for equine ANP [30] and 
NT-proANP [31], respectively. Since BNP and NT-proBNP are species specific molecules, 
and no equine BNP or NT-proBNP test exists, the determination of B-type NPs in horses 
remains impossible. However, B-type NPs determination might be helpful as screening 
or follow-up test for cardiac disease in horses, especially if cardiac ultrasound is not 
available. Since equine and porcine BNP have more than 90% homology [23], a 
competitive porcine BNP ELISA was used in an attempt to measure equine BNP. Firstly, 
normal values were determined in 20 healthy horses and a median BNP concentration of 
77.79 (37.20-513.36 pg/mL) was found. In comparison to humans and small animals, the 
BNP concentration was unexpectedly high and had a broad range. However, the results 
of the present study should be interpreted with caution as the porcine BNP assay was 
not validated for use in horses. Different BNP cut-off values have been described 
depending on the disease which has to be detected. In humans, a cut-off value of 17.9 
pg/mL for the detection of left ventricular systolic dysfunction has been described [32]. 
In dogs, a cut-off value of 23 pg/mL [33], 24.6 [34] and 6.21 pg/mL [35] has been 
described for the detection of cardiac disease, for the distinction between cardiac and 
non-cardiac dyspnea and for the detection of dilated cardiomyopathy, respectively. 
However, the clinical utility of BNP for the detection of cardiac disease in dogs has been 
questioned, since a lot of healthy dogs also have BNP concentrations above the cut-off 
value [36] and NT-proBNP measurement might be more useful for the detection of 
cardiac disease in clinical practice [22]. The maximal BNP concentration and the BNP 
range of these dogs were still lower than the values in the present study. Although it is 
possible that the BNP concentration is higher in horses than in humans or dogs, also 
cross reactivity with other NPs, such as proBNP, NT-proBNP or other degradation 
products [37] may lead to increased BNP detection values. The presence of cross 
reactivity in BNP and NT-proBNP assays has also been described in human medicine and 
makes clinical interpretation of assay results challenging [38]. In dogs, this cross 
reactivity might be decreased in a second generation ELISAa which uses specific capture 
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and detection antibodies targeted against canine NT-proBNP epitopes [39]. Heterophile 
antibodies can cause false positive reactions and might therefore also explain the high 
BNP result [40]. However, a competitive ELISA was used and normally, heterophile 
antibodies are too weak to compete with the high affinity antigens in these assays and 
cause only false positive results when sandwich ELISAs are used [41]. Another possibility 
is that the monoclonal antibodies did not attach to equine BNP. Although there is only a 
limited difference between the sequence of equine BNP and porcine BNP (Table 6, 
Chapter 1), it remains possible that the monoclonal antibodies of the porcine BNP assay 
were developed against a BNP region where the equine and porcine BNP amino acid 
sequences differ. Since many samples had a BNP concentration above the limit of 
detection and because a significant difference between sample storage temperatures 
was detected, it seems likely that the monoclonal antibodies did detect equine BNP or at 
least an equine BNP-like molecule. Cross reactivity with another equine molecule might 
explain why no difference was found between horses of group 1 and 2 and why no 
correlation with echocardiographic variables was found. Antibodies against porcine BNP 
have been used to detect BNP-like activity in atrial cardiac myocytes [24]. ANP reactivity 
was detected in these same myocytes. Therefore, a cross reaction between ANP and the 
anti-BNP antibodies could possibly explain the BNP immunoreactivity which was found 
with the anti-BNP antibodies. However, the hypothesis was tested and no such cross 
reactivity could be detected [24]. Another explanation for the lack of difference between 
groups and the wide BNP range in healthy horses is the presence of confounding factors. 
Age, sex and breed have been described to affect the BNP concentration: a higher BNP 
concentration has been found in older patients and in women [42]. Similarly, high NT-
proBNP values have been found in Labrador retrievers and Newfoundland dogs [43]. A 
negative correlation between BNP and obesity has also been reported [44]. In the 
present study, no correlation was found between the BNP concentration and the sex, 
age or weight in the group of healthy horses (unpublished data), however, the group of 
healthy horses was very small. All healthy horses were also Warmblood horses, thus the 
influence of breed could not been examined. Since 14/18 horses with cardiac disease 
were also Warmblood horses, the influence of breed on the results seems limited.  
The difference in sample storage time might also influence results. The samples of group 
1 were stored for a significantly shorter time than samples of groups 2a and 2b. If the 
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BNP concentration in samples of group 2a or 2b had been reduced due to longer 
storage, the BNP difference between healthy horses and horses with cardiac disease 
would have become smaller. However, according to manufacturer’s instructions, 
samples can be stored for 2 months at -80°C, and the BNP concentration in the present 
study seemed surprisingly high in comparison to other species. Therefore, the influence 
of sample storage seemed limited. The presence of a large inter-assay variability could 
also explain the results. The inter-assay CV was determined by the manufacturer for the 
porcine BNP molecule. A different inter-assay CV could apply when measuring equine 
BNP. A large inter-assay CV means that repeated measurement of the same samples 
gives different results. Three different ELISA plates were used for analysis of all samples. 
If there had been a large inter-assay variation between the three plates, the difference 
between healthy horses and horses with cardiac disease would have become smaller. 
Samples from healthy horses analysed with plate 1, had a very high BNP concentration 
in comparison to plate 2 and 3. When only samples from plates 2 and 3 were included in 
this study, a significant difference between horses with cardiac dilatation and healthy 
horses and between horses with dilatation and horses with regurgitation without 
dilatation was found. However, a correlation with echocardiographic measurements was 
still not found and only a small number of horses were included (group 1= 11, group 2a= 
7 and group 2b= 9). Therefore, from these results it could not be concluded that BNP 
increases in case of cardiac dilatation. Finally, BNP is especially correlated to ventricular 
dilatation and most of the horses of group 2 had atrial dilatation. Only 2 of the 10 horses 
of group 2b had ventricular dilatation, thus this might explain why no significant 
difference was found between healthy horses and horses of group 2b.The BNP-80 
concentrations of both horses with ventricular dilatation were 88.79 and 243.35 pg/mL. 
Therefore, future studies on BNP or NT-proBNP measurement in horses should include 
more horses with ventricular dilatation or heart failure.   
Sample storage temperature had a strong influence on sample concentration: samples, 
which were stored at -80°C had a significantly (P<0.001) higher concentration than 
samples stored at -20°C. Since both samples from the same horse were analysed on the 
same ELISA plate, the inter-assay CV could not have influenced these results. Previous 
studies in human medicine have also shown that BNP is unstable at -20°C [45]. As it is 
possible that in the present study, a BNP-like molecule was measured instead of BNP, it 
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could not be determined whether the difference was fully attributable to BNP sample 
stability. This pilot study is the first, in which measurement of equine plasma BNP using 
a porcine assay was attempted. The major limitation of the study was the use of a non-
validated BNP assay. BNP-like immunoreactivity in the samples was measured but it was 
not proven whether it concerned BNP or not. The possible existence of peptide cross-
reactivity, sample instability and assay variability further complicated the results. These 
three factors should also be taken into account when measuring ANP and NT-proANP 
measurement in horses. Currently, only one ANP assay validation study has been 
published [18] and shows that there is a high inter-assay variability and that different 
ANP assays are poorly comparable. Therefore, there is a need for a validated, species-
specific equine BNP /NT-proBNP test and a reliable ANP or NT-proANP assay for the use 
in clinical practice.   
Conclusion 
BNP-like activity was found in equine plasma samples using a porcine BNP assay. Despite 
the high homology (>90%) between equine and porcine BNP, the porcine BNP ELISA 
could not differentiate healthy horses from horses with cardiac disease probably due to 
a high inter-assay CV and cross reactivity with other plasma proteins. A major limitation 
of the study was that a non-validated assay was used. Therefore, further studies on 
assay validation, imprecision and accuracy should be performed. Ideally, equine specific 
BNP and NT-proBNP assays should be developed in order to study horses with and 
without cardiac disease. 
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Footnotes 
a Cardiopet, IDEXX Europe, Hoofddorp, the Netherlands 
b GE Vivid 7 Dimension, GE Healthcare, Diegem, Benelux 
c 3S Phased Array Transducer, GE Healthcare, Diegem, Benelux 
d EchoPAC software version 12, GE Healthcare, Diegem, Benelux 
e Vacutainer 1.6 mg K3 EDTA and 50 KIU aprotinin/mL blood, BD Diagnostics, 
Erembodegem, Belgium 
f Venosafe, Terumo Europe, Leuven, Belgium 
g Cryovials, 2 mL, VWR International, Leuven, Belgium 
h ELISA, E90541Po, USCN, Wuhan, China 
i SPSS Statistics 22.0, Chicago, IL 
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Summary 
N-terminal proBNP (NT-proBNP) is routinely used in human and small animal medicine 
to diagnose cardiac disease. Since the NT-proBNP concentration is related to ventricular 
pathologies, measurement of equine NT-proBNP might be useful to detect ventricular 
dilatation in horses. Detection of equine NT-proBNP is currently impossible as no equine 
assay is available. Therefore, the aim of this study was to develop a specific equine NT-
proBNP assay. Polyclonal antibodies against the whole recombinant equine NT-proBNP 
molecule and two smaller parts (sequence peptide 1: LQQDRGPAEASETRGA and peptide 
2: ASEQSGIQELLDRLGD) of this molecule were produced in different rabbits. The 
interaction of these antibodies with the recombinant NT-proBNP was monitored in real 
time using an optical biosensor. The lowest dissociation rate constant (Kd) and thus the 
strongest binding with NT-proBNP was found for antibodies against peptide 1 
(Kd=3.6х10
-3 s-1) followed by antibodies against peptide 2 (Kd=9.3x10
-3 s-1) and against 
the whole recombinant NT-proBNP molecule (Kd=38.0x10
-3 s-1). In addition, part of these 
antibodies were biotinylated to use them as detection molecules in combination with 
unbiotinylated antibodies in a sandwich enzyme-linked immunoassay (ELISA). The 
highest signal-to-noise ratio was demonstrated when antibodies against peptide 1 and 2 
were used as detection and capture antibodies, respectively. A limit of detection of 0.5 
ng/mL was established, whereafter ten samples from healthy horses and ten from 
horses with ventricular dilatation were analysed. Only one horse with ventricular 
dilatation had a detectable NT-proBNP concentration of 41.4 ng/mL. Further assay 
optimization and validation is necessary before this ELISA can be used in clinical practice.
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Introduction 
The natriuretic peptides (NPs) are a family of peptide hormones which are released in 
case of increased intravascular volume and can be used for diagnosis, prognosis or 
monitoring of cardiac disease [1-4]. The atrial and B-type NPs are the most important 
members of this NP family. Atrial NPs are very homologous between species. Therefore, 
human assays have been used to determine the atrial NPs in horses and a significant 
correlation with left atrial dilatation has been demonstrated [5-7]. In contrast, B-type 
NPs are more variable between species and more related to ventricular pathologies [8, 
9]. B-type NPs are routinely determined in the human emergency department to 
differentiate between cardiac and non-cardiac causes of dyspnea [10, 11]. Similarly, they 
are used in small animals to distinguish acute respiratory problems caused by heart 
failure from non-cardiac causes [12-15] and to diagnose hypertrophic or dilated 
cardiomyopathy [16, 17]. B-type NPs are stored as prohormones (proBNP1-108) in 
granules in the cardiac myocytes. In response to stretch, they are cleaved into a 
biologically inactive component (N-terminal proBNP or NT-proBNP1-76) and an active 
component (BNP77-108) [18]. Since NT-proBNP1-76 is more stable and has a longer half-life 
than BNP77-108, it is mostly determined in clinical practice [19]. Studies on B-type NPs in 
horses are missing [20], since a specific equine test remains to be developed. Therefore, 
the aim of this study was to develop an equine NT-proBNP assay.  
Table 1. Equine proBNP sequence determined by IDEXX Laboratoriesa. The sequence of 
the NT-proBNP molecule is given in bold and of the BNP molecule in italic. The 
sequences of the two cleaving products: peptide 1 and 2 are colored in green and red.  
Y P L G G L G P A S E Q S G I Q E L L D 
R L G D S V L E P Q A E R M T L E P L Q 
Q D R G P A E A S E T R G A A P T G V L 
G P R T K V L Q A L R G L R S P K N M R 
N S G C F G R R L D R I G S F S G L G C 
N V L R R Y  
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Materials and methods 
Peptides and antigens  
The sequence of the equine proBNP molecule is demonstrated in Table 1 and was 
determined by IDEXX Laboratoriesa. A purified recombinant NT-proBNP molecule was 
provided by IDEXX Laboratories (2.3 mg/mL NT-proBNP stored in 50 mM Tris, 20 mM 
NaCl, 1 mM EDTA, pH 8.0). Two additional peptides were delivered by Eurogentecb 
(Table 1) as pure lyophilized peptides (24.0 mg lyophilized peptide 1 and 23.2 mg 
lyophilized peptide 2) and as conjugates with keyhole limpet hemocyanin (KLH) 
(conjugation yield: 55%, antigen 1: 0.64 mg/mL; antigen 2: 0.65 mg/mL). Both peptides 
had a purity of more than 70%. The lyophilized peptides were dissolved in 1 mL 
ultrapure water at a final concentration of 24.0 mg/mL (peptide 1) and 23.2 mg/mL 
(peptide 2).  
Polyclonal antibody production 
The study was approved (EC2013/131) by the ethical committee of the Faculty of 
Veterinary Medicine and Bioscience Engineering of Ghent University. Six hybrid white 
rabbits (Oryctulagus cuniculus) were immunized three or four times (with three weeks in 
between) with different concentrations of antigen 1, antigen 2 or the recombinant NT-
proBNP protein (Table 2). For each immunization, half the antigen quantity was injected 
subcutaneously (in the neck and back) and the other half intramuscularly (in the 
quadriceps or gluteus muscles) using a 22 Gauge needle. Blood was collected from each 
rabbit before the first immunization and three weeks after the third immunization. 
Hereto the rabbits were clipped and lidocaine gelc was applied over the region of the 
vena saphena lateralis. After 5 minutes, 2 mL blood was collected and serum was stored 
in cryovialsd at -20°C.  
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Table 2. Rabbit immunization protocol indicating antigen (antigen 1, antigen 2 or the 
recombinant NT-proBNP molecule), serum antibody titers at euthanasia (Te) and after 
biotinylation (Tb). Of each rabbit, the immobilized antibody amount on the Biacore 
sensorchip (RU: resonance units), dissociation rate constant (Kd) and antibody-antigen 
complex half-life (T1/2) are given for comparison of the antibody affinity. Antibodies with 
a lower Kd, have a longer T1/2 and thus a higher affinity for the NT-proBNP molecule.  
 
Rabbit Antigen 
Amount of antigen 
(µg) injected at 
immunization 
number 
Te Tb 
Immobilized 
antibody 
amount 
(RU) 
Kd 
(1/s) 
T1/2 
(s) 
1 2 3 4 
Rabbit 
1 
1 500 500 500  20000 >8000 13964 3.6x10-3 194 
Rabbit 
2 
1 250 250 313  4000 4000 16441 48X10-3 14 
Rabbit 
3 
2 500 500 250  48000 4000 15653 9.3X10-3 75 
Rabbit 
4 
2 250 250 250  56000 10000 17180 28X10-3 25 
Rabbit 
5 
Recombinant 
NT-proBNP 
500 500 500 500 3000 2000 15961 38X10-3 17 
Rabbit 
6 
Recombinant 
NT-proBNP 
250 250 500  5000 4000 20065 46X10-3 15 
Monitoring antibody titers 
An indirect ELISA was used to determine the antibody titer of each serum sample. Serum 
samples before immunization were added as negative controls. Peptide 1, 2 and the 
recombinant NT-proBNP molecule were diluted in coating buffer (0.05 M sodium 
bicarbonate, pH 9.4). Three PolySorp 96-well ELISA platese were coated with 100 µL of a 
10 µg/mL peptide or antigen solution and incubated at 37°C for 2 hours. Next, 250 µL 
blocking buffer (Phosphate buffered saline (PBS, pH 7.4) with 0.2% Tween 80f) was 
added to each well. After overnight incubation at 4°C, the plates were washed three 
times with PBS containing 0.2% Tween 20f. All serum samples were diluted twofold 
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starting at a dilution of 1:10 till 1:10240 in dilution buffer (PBS containing 0.05 % Tween 
20) and 100 µL of each sample was added to each well. After 1 h incubation at 37°C, the 
plates were washed again and 100 µL conjugate (1:1000, polyclonal swine-anti rabbit-
horse radish peroxidaseg) was added to each well. The plates were incubated for 1 h at 
37°C, washed twice with washing buffer and once with PBS. Finally, 50 µL of 2,2'-azino-
bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTSh) was added and the optical density 
(OD) was measured after 45 min at 405 nm. Rabbits were reimmunized if titers were 
below 3000 after three immunizations and euthanized for final serum collection if 
higher. The antibody titer at euthanasia was determined using the same procedure and 
serum samples were stored at -20°C until further use.  
Purification of the antibodies 
The serum antibodies were purified on a 1 mL HiTrap protein A columni using the ÄKTA 
explorer chromatography systemj. All serum samples were centrifuged for 10 min at 
18626 g and a 1:2 dilution in 200 mM sodium phosphate buffer (pH 7.0) was filtered 
over a 0.22 µM Millex GV syringe filter unitk. The protein A column was consecutively 
washed with 10 mL binding buffer (100 mM sodium phosphate buffer, pH 7.0), with the 
filtered samples and with 15 mL washing buffer (10 mM sodium phosphate buffer, pH 
7.0) at a flow rate of 1 mL/min. Bound antibodies were eluted with 10 mL elution buffer 
(100 mM glycine-HCl, pH 2.7) at a flow rate of 0.5 mL/min and 500 µL elution fractions 
were collected of which the pH was immediately neutralized by adding 75 µL of 
neutralization buffer (1 M Tris Base pH 8.0). Next, the buffers were exchanged with PBS 
using Slide-A-Lyzer dialysis cassettesl. After hydration of the cassette membrane, 2 mL of 
sample was added and sample dialysis was performed in 1 L PBS for two times two 
hours and overnight at 4°C. In between steps, the PBS buffer was changed. Finally, the 
samples were recollected with a syringe and stored in cryovials at -20°C. The final 
protein concentration was determined with a bicinchoninic acid (BCA) protein assay kitm 
according to manufacturer’s instructions and the OD was measured at a wavelength of 
562 nm.  
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Antibody biotinylation 
From each rabbit, 2 mL of the serum samples was biotinylated with the EZ-Link-Sulfo-
NHS-LC-LC-Biotinn kit using the Slide-A-Lyzer dialysis cassettes. The antibody titer of the 
biotinylated antibodies was determined with the indirect ELISA assay procedure 
described above using a 1:10000 streptavidine peroxidase solutiono as conjugate. 
Western blotting 
Western blotting was performed to determine the molecular weight of the equine NT-
proBNP molecule. Of a 2.3 mg/mL recombinant NT-proBNP solution, 1.83 µL was mixed 
with PBS and 20 µL of loading buffer (a mixture of 475 µL sample buffer and 25 µL-B-
mercaptoethanol). Five different vials of the same NT-proBNP solution were included. 
Electrophoretic separation of these samples was performed on a 12% sodiumdodecyl 
sulfate polyacrylamide gel using a Mini-Protean Tetra Cellp for 10 min at 90 V, for 45 min 
at 120 V and for 30 min at 130 V. After electrophoresis, the proteins were blotted onto a 
nitrocellulose membrane in transfer buffer (192 mM glycine with 25 mM Tris Base and 
20% MeOh) for 2 h at 50 V. In subsequent steps, the non-specific binding sites were 
blocked overnight at 4°C (with PBS supplemented with 5% non-fat dry milk powder and 
0.3% Tween 80), with 20 mL of a 1:200 serum dilution in PBS with 0.5% non-fat dry milk 
for 1 h at room temperature and with polyclonal swine-anti rabbit horse radish 
peroxidase 1:1000 diluted in ultrapure water 1 h at room temperature. In between each 
step the membrane was washed 3 times with 35 mL washing buffer (PBS with 0.3% 
Tween 20). Next, the membrane was dried and 0.5 mL peroxide solution and 0.5 mL 
luminol enhancer solutionq was added, where after the membrane was dried again and 
imaging was performed on the ChemiDoc MP systemr. Each run included mass markers 
(Magic Mark XP Western Protein Standardr and All Blue Precision Plus Proteinr) to 
identify the molecular weight of the recombinant protein.  
Biacore 2000 
The interaction of the polyclonal antibodies with the recombinant NT-proBNP was 
investigated in real time by using an optical biosensors, which is based on the surface 
plasmon resonance (SPR) phenomenon. SPR detection is based on the changes of 
refractive index of the medium close to a thin metal layer. Binding or dissociation at the 
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close vicinity of the sensor surface causes changes in refractive index and thus a shift in 
the resonance angle, which is measured by the detection system of the biosensor. The 
response is expressed in resonance units (RU) and 1 RU corresponds to a shift in angle of 
0.0001°, or a change in mass concentration of 1 pg/mm2 on the sensor surface [21]. By 
plotting the measured angular shift against time, a sensorgram is obtained illustrating 
the progress of the interaction at the sensor surface in real time. Briefly, a molecule 
(here the polyclonal antibody) is immobilized on a sensor chip. Next, a constant sample 
flow of an interaction partner (NT-proBNP) is passed over this surface. Binding of this 
partner to the ligand causes a shift in the refractive index and is recorded in a 
sensorgram in which the response is proportional to the mass of bound analyte. In this 
way, the antigen-antibody interaction can be monitored without using labeled 
molecules [22]. First, the optimal pH for immobilization of the polyclonal antibodies 
(ligand) on the microchip was determined by performing a pH immobilization scouting 
experiment using 10 mM sodium acetate with pH 4.5, 5.0 and 5.5 as immobilization 
buffer. Next, the different antibodies were immobilized by amine coupling. The dextran 
layer was activated by injection of 70 µL of a 1:1 mixture of 75 mg/mL N-
hydroxisuccinimide (NHS) and 75 mg/mL N-ethyl-N’-(3-diethylaminopropyl)carbodiimide 
(EDC). Antibodies against peptide 1 from rabbit 1 were immobilized in flow cell 2 (FC2), 
against peptide 2 from rabbit 3 in FC3 and against the recombinant NT-proBNP molecule 
from rabbit 5 in FC4 by injection of 70 µL of a 50 µg/mL dilution of each antibody in the 
optimal immobilization buffer. Antibodies from rabbit 2, 4 and 6 were immobilized at 
the same manner on a second microchip. The remaining reactive carboxylgroups of the 
dextran layer were blocked by injection of 10 µL of 1.0 M ethanolamine-HCl (pH 8.5) and 
the immobilized amount of antibodies was determined. The optimal regeneration 
conditions were determined by performing a regeneration scouting experiment using 
either 10 mM glycine HCl (pH 3.0, 2.5, 2.0 and 1.5) or 50 mM sodium hydroxide (pH 
10.5) as described by the manufacturer. Next, the recombinant NT-proBNP molecule 
(analyte) was diluted in running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 
0.005% v/v Surfactant P20) to a 12.5 µg/mL solution and 30 µL of this dilution was 
injected at a flow rate of 20 µL/min to each flow cell. Between each injection, the 
surface was regenerated by injection of 10 µL of regeneration buffer at a flow rate of 10 
µL/min.  
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Sandwich ELISA procedure 
The purified antibodies were used in all possible combinations to develop a sandwich 
ELISA for detection of equine NT-proBNP. MaxiSorp 96-well ELISA platesf were coated 
with 100 µL of each antibody solution (10 µg/mL). The plates were incubated for 2 h at 
37°C and blocking buffer was added as described above. After overnight incubation at 
4°C, the plates were washed five times with washing buffer and 100 µL of a 1:10 NT-
proBNP dilution (range 0.1-10.0 µg/mL) was added, except for eight wells, in which only 
dilution buffer was added (negative controls). After 1 h incubation at 37°C, the plates 
were washed again and 100 µL of the biotinylated antibodies (5 µg/mL) was added to 
each well. The plates were incubated for 1 h at 37°C and washed five times. Next, 100 µL 
of a 1:20000 dilution of streptavidine conjugated to horse radish peroxidaset was added 
for 1 h at 37°C. Finally, 50 µL of ABTS was added and the OD was measured after 15 min. 
The antibody combination with the highest signal-to-noise ratio was selected and the 
sandwich ELISA protocol was repeated to define the limit of detection of NT-proBNP 
(dilution range 0.04– 100.00 ng/mL) in the assay.  
Detection of circulating NT-proBNP 
Samples from ten healthy Warmblood horses (age: 9±5 years, weight: 568±55 kg; 3 
geldings, 7 mares) and ten horses with ventricular dilatation (left ventricular internal 
diameter during diastole: >13.30 cm; age: 10±8 years, weight: 462±119 kg; 7 geldings, 2 
mares, 1 stallion; 7 Warmblood horses, 1 Spanish horse, 2 pony’s) were used. Five of 
these horses had heart failure and were euthanized due to the severity of their signs. 
From each horse, an ethylenediaminetetraacetic acid (EDTA) tube was collected by 
puncture of the jugular vein with a venojectu. The blood samples were immediately 
stored on ice and centrifuged (1000 g, 15 min, 2-8°C) within 30 minutes. Next, the 
plasma was harvested, transferred into cryovials and stored at -80°C until analysis with 
the developed NT-proBNP sandwich ELISA (range: 0.04-100.00 ng/mL).  
Statistical analysis  
Antibody titer  
Each sample was tested in duplicate and the mean of both measurements was used in 
further calculations. The antibody titer was defined as the inverse of the dilution with an 
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OD slightly higher than a cut-off value defined as the mean OD of the serum samples 
before vaccination plus three times the standard deviation.  
Biacore 2000  
The immobilized amount of antibodies on each flow channel of the sensor chips and the 
dissociation rate constants (Kd) for each ligand-analyte binding were calculated using 
manufacturer’s softwarev. The antibody-antigen complex half-life time was defined as 
the time needed for half of the complexes to dissociate and was calculated as:  
 

 ≈ 
.

 [23].   
 
Sandwich ELISA  
The signal-to-noise ratios [24] of the different detection and capture antibody 
combinations were calculated as the absorbance value of the lowest standard divided by 
the absorbance of the blank reading. The calibration curve of the optimal antibody 
combination was calculated with statistical softwarew and based on a four-parameter 
logistic model. The limit of detection was calculated as the mean OD plus three times 
the standard deviation of the blank reading.   
Figure 1. Western blotting of 
different samples of the equine 
recombinant NT-proBNP protein 
(S1-S5) with antibodies of rabbit 3, 
immunized with antigen 2. 
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Figure 2. Sensorgram demonstrating an immobilization pH scouting experiment with the 
Biacore 2000. The positively charged antibodies of rabbit 3 (against antigen 2), diluted at 
50 µg/mL in 10 mM sodium acetate buffers with pH 4.5, 5.0 or 5.5, were injected at a 
flow rate of 10 µL/min and coupled electrostatically to the negatively charged 
carboxymethylated dextran matrix surface of the sensor chip. After each injection, 30 µL 
wash solution (1.0 M ethanolamine HCl, pH 8.5) was injected to remove any trace of 
polyclonal antibodies. The highest binding occured if a sodium acetate buffer with pH 
5.0 was used (RU=resonance units).  
 
Figure 3. Sensorgram demonstrating the immobilization of antibodies of rabbit 3 
(against antigen 2) using 10 mM sodium acetaat pH 5.0 as immobilization buffer. After 
activation of the surface with EDC/NHS, the bound amount of antibodies was 21088 
resonance units (RU), deactivation of the surface with 1.0 M ethanolamine HCl (pH 8.5) 
gave a total immobilized amount of 15653 RU.  
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Results 
Antibody titer after immunization and biotinylation 
The serum antibody titers against the immunogens in each rabbit at euthanasia are 
provided in Table 2. For antigen 1, the higher antigen dose (500 µg) resulted in a higher 
antibody titer compared to the lower dose (250 µg). This was less clear for antigen 2 or 
recombinant NT-proBNP.  
Western blotting  
The molecular weight of the equine recombinant NT-proBNP molecule was between 10-
15 kDa. All antibodies recognized the recombinant NT-proBNP molecule. Figure 1 
demonstrates a representative Western blotting result using antibodies of rabbit 3, 
immunized with antigen 2.  
 
Biacore 2000 
The highest immobilization rate was obtained using 10 mM sodium acetate pH 5.0 as 
immobilization buffer (Figure 2). Using this buffer, the immobilized amount (Figure 3) of 
antibodies of rabbit 1-6 was between 13964 resonance units (RU) and 200065 RU (Table 
2). For most proteins, 1000 RU corresponds to a surface concentration of approximately 
1 ng/mm2 [25]. Regeneration with 10 mM glycine HCl (pH 1.5-3.0) was either too mild 
(with ineffective loosening of the binding between the antibodies and NT-proBNP and 
thus baseline increase) or too harsh (with antibodies loosening of the surface and thus 
with a baseline decrease). A good regeneration with consistent analyte response and 
stable baseline was found after addition of 50 mM sodium hydroxide (pH 10.5), which 
was used in further experiments as regeneration buffer (Figure 4).   
The Kd and correlated half-lives of each rabbit are given in Table 2. Figure 5 
demonstrates the sensorgram of the binding interaction between the immobilized 
antibodies from rabbit 1, 3 and 5 on the first microchip (ligand) and the recombinant NT-
proBNP molecule (analyte).  
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Figure 4. Sensorgram of the regeneration scouting experiment after immobilization of 
antibodies of rabbit 3 (against antigen 2). Regeneration with glycine HCl (pH 2.5) after 
injection of the analyte (50 µg/mL NT-proBNP) gave a baseline decrease (regeneration 
conditions are too harsh). After regeneration with 50 mM NaOH (pH 10.5) the baseline 
and analyte reaction remained stable.  
 
Figure 5. Sensorgram 
demonstrating the 
association and 
dissociation between 
NT-proBNP and the 
antibodies against 
peptide 1 from rabbit 1 
(green), peptide 2 from 
rabbit 3 (red) and the 
recombinant NT-proBNP 
molecule from rabbit 5 
(blue). The slowest 
dissociation and thus 
the strongest biological 
interaction was found 
between NT-proBNP 
and antibodies against 
peptide 1 (green).  
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Sandwich ELISA 
Figure 6 demonstrates the results of the first sandwich ELISA (NT-proBNP range: 0.1 – 
10.0 µg/mL). The highest signal-to-noise ratio was seen if antibodies from rabbit 1 were 
combined with antibodies from rabbit 3. Therefore, this combination (combination 1: 
capture antibody rabbit 3; detection antibody rabbit 1) was selected to determine the 
detection limit of recombinant NT-proBNP in a range between 0.04 and 100.00 ng/mL. 
To study the influence of the affinity of the capture antibodies, the same sandwich ELISA 
was performed, but capture antibodies of rabbit 5 against the recombinant NT-proBNP 
molecule were used (combination 2). The calibration curves of these two combinations 
are given in Figure 7. The limit of detection of combination 1 (capture antibody against 
antigen 2, detection antibody against antigen 1) and combination 2 (capture antibody 
against the recombinant molecule, detection antibody against antigen 1) were 0.5 
ng/mL and 1.5 ng/mL, respectively.  
Detection of circulating NT-proBNP 
None of the healthy horses had a detectable NT-proBNP concentration. Of the horses 
with ventricular dilatation, a high NT-proBNP concentration was found for one horse in 
both sandwich ELISAs: 41.4 ng/mL with antibody combination 1 and 40.4 ng/mL with 
combination 2.  
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Figure 6. Comparison between the signal-to-noise ratios of different detection and 
capture antibody combinations. The highest signal-to-noise ratio was found if antibodies 
against peptide 1 (rabbit 1) were used in combination with antibodies against peptide 2 
(rabbit 3) (R1-R6: rabbit 1-6). 
 
Figure 7. Standard curve demonstrating the relationship between the optical density and 
the recombinant NT-proBNP concentration when combination 1 (red, capture antibody 
against peptide 2, detection antibody against peptide 1) or combination 2 (blue, capture 
antibody against the recombinant molecule, detection antibody against peptide 1) are 
used. 
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Discussion 
At the beginning of this study, no information was available on equine NT-proBNP. 
Polyclonal antibodies against peptides of this molecule (peptide 1 or 2) or against the 
whole equine recombinant NT-proBNP molecule were successfully produced in rabbits 
and used in Western blotting to determine the molecular weight of the recombinant 
equine NT-proBNP molecule. A molecular weight between 10-15 kDa was found, slightly 
higher than the molecular weight of human NT-proBNP (±8.5 kDa) [26]. However, the 
molecular mass of circulating proBNP products might differ from this result as the post-
translational maturation is more complex than simple fragmentation of the proBNP 
molecule into a NT-proBNP and BNP part [26, 27]. In human medicine immunoreactive 
NT-proBNP forms with a high and low molecular weight have been detected in the 
circulation (Chapter 1, Figure 6). The nature of these circulating peptides is still not fully 
elucidated, but can partly be explained by glycosylation or oligomerization of the 
proBNP-derived peptides [26, 28]. Since a similar mechanism might also exist in horses, 
a better characterization of the circulating equine NT-proBNP peptides is needed.    
In a second part of this study, the affinity between the rabbit polyclonal antibodies and 
the recombinant NT-proBNP protein was monitored in real time. Sensorgrams (Figure 5) 
were obtained demonstrating the association and dissociation of the different polyclonal 
antibody preparations. The affinity of an antibody-antigen interaction can be defined by 
the equilibrium constant (Keq) which is equal to the ratio of the association (Ka) and 
dissociation rate constant (kd) [29]. The polyclonal rabbit sera are actually a mixture of 
antibodies with different affinities and unknown concentrations [30]. Since the Ka is a 
concentration dependent factor [31], it cannot be calculated for polyclonal antibodies. 
Instead, the Kd, a concentration independent factor [31], was calculated to compare the 
affinity of the different antibodies. The slowest dissociation and thus the strongest 
binding to NT-proBNP was found for antibodies from rabbit 1 followed by antibodies 
from rabbit 3. Since a positive correlation exists between the antibody affinity and the 
ELISA performance [32], the antibody affinity differences might partly explain why the 
highest signal-to-noise ratio was found if antibodies with the highest affinity for the NT-
proBNP protein were combined. In agreement with the signal-to-noise ratios, the limit of 
detection increased from 0.5 ng/mL to 1.5 ng/mL when capture antibodies with a lower 
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affinity (rabbit 5 instead of rabbit 3) were used in combination with the same detection 
antibody (rabbit 1). Interestingly, although different rabbits (e.g. rabbit 1 and 2) were 
immunized with the same antigen, their Kd value differed (Table 2). This difference might 
be explained in part by the fact that rabbits were initially immunized with a different 
amount of antigen, but it could also be caused by differences in polyclonal antibody 
response as rabbits targeted with the same antigen, can produce different polyclonal 
antibodies [33].   
The sandwich ELISA did successfully detect equine recombinant NT-proBNP. However, as 
described above, the circulating NT-proBNP forms might differ from this original 
recombinant molecule which might negatively affect the antibody recognition. If 
antibodies are for example directed against an epitope which is glycosylated during 
processing, these antibodies might not recognize glycosylated NT-proBNP forms [34]. 
Ten plasma samples from healthy horses and horses with ventricular dilatation were 
tested and one horse with ventricular dilatation had a high NT-proBNP concentration. 
This horse had a very large left ventricular diameter (15.7 cm during diastole, reference 
range: 11.33±1.19 cm [35]) and severe signs of acute heart failure caused by rupture of 
the chordae tendineae of the mitral valve, which very likely resulted in a high NT-proBNP 
concentration. Although more samples should be examined, it looks like the produced 
antibodies could indeed detect circulating NT-proBNP, which can be explained by the 
fact that polyclonal antibodies were used, which are more tolerant to minor changes in 
the antigen recognition sites [33]. The NT-proBNP concentration in all other horses was 
undetectable, probably because the sensitivity of the assay is too low. The NT-proBNP 
concentration in healthy humans might be as low as 20 pg/mL and even in humans with 
heart failure (270 pg/mL or 0.270 ng/mL), the NT-proBNP concentration [36] lies still 
under the limit of detection of our assay (500 pg/mL or 0.5 ng/mL). Further assay 
optimization of our equine sandwich ELISA seems necessary and can consist of 
adjustment of the reagent concentration, the incubation time, the incubation 
temperature or the blocking buffers [37]. In addition, further assay validation is needed 
to determine result variability and possible cross reactivity with other molecules. 
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Conclusion 
Polyclonal antibodies against the recombinant equine NT-proBNP molecule were 
successfully produced and used as detection and capture antibodies in a sandwich ELISA. 
The limit of detection of the test was 0.5 ng/mL. Future assay optimization and 
validation is needed before the assay can be used in clinical practice. 
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Footnotes 
aIDEXX Laboratories, Hoofddorp, The Netherlands 
b Eurogentec, Seraing, Belgium  
c Xylocaine 5%, Astrazeneka, Ukkel, Belgium 
d Cryovials, 2 mL,VWR International, Leuven, Belgium 
e Sigma-Aldrich, Diegem, Belgium 
f Thermo Fisher Scientific, Erembodegem, Belgium 
g P0217, Dako, Heverlee, Belgium 
h 11112422001, Roche Diagnostics, Vilvoorde, Belgium 
i GE Healthcare, Diegem, Belgium 
j ÄKTA explorer, GE Healthcare, Diegem, Belgium 
k SLGV033 RV, Merck Millipore, Overijse, Belgium 
l 66380, Thermo Fisher Scientific, Erembodegem, Belgium 
m BCA-1, Sigma Aldrich, Diegem, Belgium 
n 21338, Thermo Fisher Scientific, Erembodegem, Belgium 
o 11089153001, Roche Diagnostics, Vilvoorde, Belgium 
p Bio Rad, Temse, Belgium 
q Pierce ECL Western Blotting Substrate, Thermo Fisher Scientific, Erembodegem, 
Belgium 
r Invitrogen, Life Technologies, Ghent, Belgium 
s BIAcore 2000, GE Healthcare, Diegem, Benelux 
t Streptavine-POD, 11089153001, Roche Diagnostics, Vilvoorde, Belgium 
u Venosafe, Terumo Europe, Leuven, Belgium 
v BIA evaluation 4.1 software, GE Healthcare, Diegem, Benelux 
w SigmaPlot version 13.0, Systat software GmbH; Erkrath, Germany
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Summary 
In human medicine, atrial natriuretic peptides and cardiac troponins are significantly 
correlated and a multi-marker approach for detection of heart failure has been 
proposed. However, the correlation between different cardiac biomarkers has never 
been examined in horses. Therefore, the aim of this study was to investigate their 
relationship and to determine the most accurate biomarker for detection of atrial 
dilatation.  
Concentrations of atrial natriuretic peptide (ANP), proANP, cardiac troponin I (cTnI) and 
T (cTnT) were compared in 23 healthy horses, 12 horses with valvular regurgitation 
without atrial dilatation and 42 horses with valvular regurgitation and atrial dilatation. A 
significant (P<0.05) correlation was found between all cardiac biomarkers. A significant 
cut-off value for atrial dilatation was demonstrated for ANP (52 pg/mL, Chapter 5.1), 
proANP (573.8 pmol/L, Chapter 5.2) and cTnI (0.055 ng/mL; P=0.034). However, for cTnI, 
a low sensitivity (46.9%, specificity: 91.7%) was found. The highest number of correctly 
classified horses (80.3%) was achieved when a proANP cut-off of 573.8 pmol/L value was 
used, followed by the ANP (52 pg/mL; 74.5%) and cTnI (0.055 ng/mL; 70.6%) cut-off 
value. Combining the proANP cut-off value with the cTnI cut-off value only resulted in a 
minimal improvement in correct classification of the horses (81.4%). Therefore, 
measurement of the proANP concentration seems to be most accurate for detection of 
atrial dilatation in horses.  
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 Introduction 
 
Cardiac biomarkers can be diverted into two groups: the cardiac troponins (troponin I 
and troponin T) and the natriuretic peptides (atrial and B-type natriuretic peptides). 
Cardiac troponin I (cTnI) and T (cTnT) are part of the contractile apparatus of cardiac 
muscle tissue and are used as indicators for myocardial damage in the human 
emergency department [1, 2]. In contrast, atrial and B-type natriuretic peptides (NPs) 
are regulatory hormones which are synthesized in the cardiac myocytes and stored as 
prohormones (proANP and proBNP) in secretory granules [3-5]. These prohormones are 
released into the bloodstream in case of cardiac overload and cleaved into an amino-
terminal fragment (NT-proANP and NT-proBNP) and a biologically active hormone (ANP 
and BNP). Atrial NPs are mainly related to atrial pathologies, while B-type NP expression 
is up-regulated in case of ventricular dysfunction [6]. In human medicine, a significant 
correlation between atrial NPs and cardiac troponins has been demonstrated [7] and a 
multi-marker approach has been suggested [8]. Combining different biomarkers, each 
reflecting a different pathophysiological pathway, may help to understand the 
pathophysiology of cardiovascular disease [9] and may increase the diagnostic power of 
a test [8]. In human medicine NPs and cardiac troponins have been combined to better 
predict the prognosis in patients with acute or chronic heart failure [10, 11]. Previous 
studies [12-18] demonstrated the diagnostic utility of cardiac troponins and atrial NPs in 
horses. However, the relationship between the different cardiac biomarkers has never 
been examined.   
The first aim of this study was to investigate the correlation between atrial NPs and 
cardiac troponins in healthy horses and horses with cardiac disease. The second aim was 
to compare the accuracy of the different biomarkers and to determine the most optimal 
biomarker or biomarkers combinations for detection of atrial dilatation.  
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Materials and methods 
Study population 
The study population consisted of 23 healthy horses (group 1: 8±4 years; 567±54 kg; 
168±5 cm) and 54 horses with cardiac disease (group 2). Based on the left atrial-to-aortic 
diameter ratio (LAD/AoD) [19] measurements of the 23 healthy horses, a cut-off value for 
atrial dilatation was defined. Horses which had a LAD/AoD which was higher than this 
value, were classified as having atrial dilatation. Horses were divided into subgroups: 
group 2a consisted of horses with valvular regurgitation without atrial dilatation and 
group 2b of horses with valvular regurgitation and atrial dilatation.  
Cardiac biomarker analysis 
The proANP concentration was determined in all horses. ANP, cTnI and cTnT was only 
determined in part of these horses (Table 1) as described in the previous chapters 
(Chapter 4.3 and 5.1). Briefly, the proANP concentration was measured on 
ethylenediaminetetraacetic acid (EDTA) plasma samples stored at -80°C using processing 
independent analysis (Chapter 5.2). ANP was measured with a commercially available 
enzyme-linked immunosorbent assaya on EDTA-plasma samples with aprotinin, stored at 
-80°C. CTnI and cTnT were determined with the Access Accu cTnI assayb and the high 
sensitive troponin T assayc on serum samples stored at -20°C.  
Statistical analysis 
Data were analyzed using commercially available softwared. The cut-off value for atrial 
dilatation was defined as the mean LAD/AoD + 1.96 x standard deviation from group 1.    
Since results were not normally distributed, all data are expressed as median and range. 
Individual groups were compared by the Kruskal Wallis test. The Spearman correlation 
coefficient was used to compare the concentration of the different cardiac biomarkers. 
The optimal cut-off value (cut-off value with the highest sensitivity and specificity) for 
detection of atrial dilatation was determined for all cardiac biomarkers by a Receiver 
Operator Characteristic (ROC) curve (for ANP and proANP, see Chapter 5.1 and 5.2). 
Binary logistical regression was used to examine the ability of each biomarker or 
biomarker combination to predict atrial dilatation and to determine their performance 
characteristics.  
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Table 1. The median (range) proANP, ANP, cTnI and cTnT concentrations of the horses of 
group 1, 2a and 2b. Different letters indicate significant differences. The concentrations 
of all four cardiac markers were determined in a total of 42 horses: 20 horses of group 1, 
8 horses of group 2a and 15 horses of group 2b.  
 
 
 
Table 2. Spearman correlation coefficient between ANP, proANP, cTnI and cTnT (**: 
P<0.05; *: P<0.01) 
 proANP ANP cTnI cTnT 
proANP 1.000    
ANP 0.321* 1.000   
cTnI 0.381** 0.448** 1.000  
cTnT 0.407** 0.300* 0.468** 1.000 
 
 proANP 
(pmol/L) 
n 
ANP 
pg/mL 
n 
cTnI 
(ng/mL) 
n 
cTnT 
(pg/mL) 
n 
Group 1 491.6
a 
(429.5-765.9) 
23 
31.2a 
(31.2-380.2) 
20 
0.03a 
(0.03-0.04) 
22 
 
10.0a 
(10.0-10.0) 
 
22 
Group 2a 544.4
a,b 
(457.0-677.6) 
16 
31.2a 
(31.2-1151.8) 
14 
0.04b 
0.03-3.14 
15 
10.0a 
(10.0-10.0) 
11 
Group 2b 761.4
b 
(442.1-1859.1) 
38 
136.1b 
(31.2-2000.0) 
21 
0.04b 
(0.03-2.93) 
31 
10.0b 
(10.0-3230.0) 
31 
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Table 3. The ability of individual cardiac biomarker cut-off values (based on the Receiver 
Operator Characteristic curves) or combinations of these cut-off values to predict atrial 
dilatation. The given P-values are based on the results of binary logistic regression (ANP: 
atrial natriuretic peptide, cTnI: cardiac troponin I, cTnT: cardiac troponin T, correct% = 
percentage of correctly classified animals compared to echocardiography; PPV: positive 
predictive value, NPV: negative predictive value).   
 
 
Cut-off 
value 
P Correct % Specificity Sensitivity PPV NPV 
proANP 
573.8 
pmol/L 
<0.001 80.3% 81.8% 78.7% 81.3% 79.4% 
ANP 
52 
pg/mL 
0.001 74.5% 76.5% 71.4% 65.2% 81.3% 
cTnI 
0.055 
ng/mL 
0.026 70.6% 91.7% 46.9% 83.3% 66.0% 
cTnT 
11.0 
pg/mL 
0.999 64.1% 100.0% 28.1% 100.0% 58.1% 
proANP 
573.8 
pmol/L 
0.007 
78.7% 86.7% 64.7% 73.3% 81.3% 
ANP 
52 
pg/mL 
0.027 
proANP 
573.8 
pmol/L 
0.002 
81.4% 81.3% 81.5% 78.6% 83.9% 
cTnI 
0.055 
ng/mL 
0.026 
ANP 
52 
pg/mL 
0.001 
     
cTnI 
0.055 
ng/mL 
0.796 
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Results 
The LAD/AoD cut-off value for atrial dilatation was 1.50 (1.32±0.09). Horses which had a 
LAD/AoD > 1.50 were categorized in group 2b. Sixteen horses had valvular regurgitation 
without atrial dilatation (14±7 years; 517±98kg; 165±10 cm) and 38 horses had valvular 
regurgitation and atrial dilatation (11±7 years; 522±121 kg; 162±14 cm). Details about 
this study population can be found in Chapter 5.2.   
The median cardiac biomarker concentrations are compared in Table 1. The proANP 
(P<0.001), ANP (P=0.003), cTnI (P=0.001) and cTnT (P=0.018) concentrations were 
significantly higher in horses of group 2b compared to horses of group 1. All cardiac 
biomarkers showed a significant correlation (Table 2), but the highest associations 
(P<0.01) were found between cTnI-cTnT and between cTnI-ANP.  
The performance characteristics of all biomarkers and their combinations are compared 
in Table 3 and the correctly predicted percentage of animals (using echocardiography as 
gold standard) with or without atrial dilatation is given. Of all animals, 80.3% was 
correctly classified if the proANP cut-off value of 573.8 pmol/L was used. The odds of 
having atrial dilatation was 16.71 times (95% confidence interval (CI): 4.95-56.40) higher 
if horses had a proANP concentration higher than 573.8 pmol/L. The odds of having 
atrial dilatation was only 8.13 (95% CI: 2.36-27.93) times higher if horses had an ANP 
concentration higher than 52 pg/mL. If horses had a cTnI concentration higher than 
0.055 ng/mL, the odds of having atrial dilatation was 9.71 times higher (95% CI: 2.46-
38.23-63.2). No significant cut-off value could be established for cTnT.   
If the proANP and cTnI cut-off values were combined, the correctly predicted percentage 
of animals was only slightly higher (81.4%) than when using proANP only. Combinations 
of other biomarkers did not lead to an increased number of correctly predicted animals 
(Table 3).  
Chapter 7: Discussion  
230 
 
Discussion 
 
Both proANP and ANP can be used for detection of atrial dilatation in horses (Chapter 
5.1 and 5.2). CTnI and cTnT are primarily detectors of primary myocardial damage. 
However, as Chapter 4.1 and 4.3 demonstrate, cardiac troponins can also increase in 
case of secondary myocardial damage due to severe structural heart disease. In human 
medicine, the combination of NPs and cardiac troponins is used to assess prognosis of 
patients with heart failure [10, 20]. However, the relationship between NPs and cardiac 
troponins has never been examined in horses.  
Table 2 demonstrates the significant correlation between cardiac troponins and atrial 
NPs. Surprisingly, a stronger correlation was found between cTnI and ANP than between 
proANP and ANP. Nine horses had an ANP concentration above and a proANP 
concentration under the cut-off value. Three of these horses were healthy, four horses 
had atrial dilatation caused by severe mitral (n=3) or aortic valve regurgitation (n=1) and 
two horses had aortic regurgitation without atrial dilatation. Similarly, five horses had a 
proANP concentration above and an ANP concentration below the cut-off value. Two of 
these horses were healthy. The three other horses had atrial dilatation caused by severe 
mitral valve regurgitation, severe tricuspid regurgitation and an aortopulmonary fistula. 
Although measured with a different technique, measurement of both ANP and proANP 
demonstrates a quantification of the atrial NP release and should therefore give similar 
results. An exact reason for the disagreement between the two techniques could not be 
determined. One possible explanation is a ventricular contribution to the ANP, but not 
the proANP levels. A partial cross reactivity between ANP and BNP molecules, produced 
by the equine ventricle, cannot be excluded as both molecules (Chapter 1, Table 6) have 
similar amino acid sequences (e.g. amino acids: CFG-DRIG-SGLGCN). This might explain 
the high ANP levels in the three horses with aortic regurgitation. This could also explain 
the stronger correlation between ANP and cardiac troponins: cardiac troponins are a 
structural component of the cardiac myocytes and not specifically related to the atrium, 
thus a ventricular contribution to the measured cTnI concentrations is most likely 
present.   
Besides proANP and ANP, a significant cut-off value for atrial dilatation was also 
established for cTnI. In human medicine, high cTnI concentrations have also been 
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described in patients with congestive heart failure [21]. Similarly, dogs with mitral valve 
regurgitation or dilated cardiomyopathy had significantly higher cTnI concentrations 
[22]. These high cTnI concentrations are probably caused by myocardial cell death due 
to cardiac remodelling. Since cardiac remodelling is a continuous process, this might 
explain why the cTnI values remain elevated despite their short half-life [21, 22].   
Combining different cardiac biomarkers did hardly increase the number of correctly 
classified animals (Table 3). Thus, using a multi-marker approach seems to be less 
interesting in horses. ProANP was the best detector of atrial dilatation in our study. 
However, pre-analytical sample processing (Chapter 5.2) is quite complicated. 
Therefore, proANP measurement using processing independent analysis is probably the 
best technique for clinical research, but is less applicable for everyday clinical 
measurement [23, 24]. Similarly, ANP measurement is difficult to use in equine clinical 
practice as samples for ANP should be stored at -80°C and an automated assay is not 
available. Since cTnI is more stable and automated assays exist, measurement of cTnI is 
the only cardiac biomarker which can be currently used by equine practitioners for 
detection of atrial dilatation. CTnI seems to be an excellent detector for primary 
myocardial damage (Chapter 4.3), but its sensitivity for atrial dilatation is far too low 
(Table 3), thus horses with a normal cTnI value still could have atrial dilatation. In 
contrast, a high specificity was found. Therefore, if a horse from our population had a 
clinically significant cardiac murmur and a high cTnI concentration, the presence of atrial 
dilatation was very likely. A significant cut-off value could not be established for cTnT, 
which was caused by the fact that half of the samples were analyzed at a laboratory 
which used a limit of detection (LOD) of 10.0 pg/mL instead of the LOD of 4.0 pg/mL, 
which is indicated by the manufacturer (see Chapter 4.3). Subtle increases in the cTnT 
concentration might therefore be missed. If a LOD of 4.0 pg/mL is used (as performed by 
other laboratories, Chapter 4.3), cTnT might be as useful as cTnI for the detection of 
atrial dilatation in horses.   
One of the limitations of our study, is that not all samples were analyzed at the same 
moment. However, sample storage has been described in detail in the previous chapters 
(Chapter 4.1, 4.3, 5.1 and 5.2) and its influence on cardiac biomarker concentrations 
seems to be limited as the manufacturer’s instructions were followed. The increased 
sample size for proANP could have led to higher statistical power for this biomarker. 
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However, also when only horses were selected in which ANP was measured, proANP still 
performed better than ANP for detection of atrial dilatation.  
Conclusion 
Atrial NPs and cardiac troponins are significantly correlated in horses with valvular 
regurgitation, which suggests the presence of minor myocardial damage in these cases. 
A significant cut-off value for atrial dilatation could be established for ANP, proANP and 
cTnI. However, comparison of these different cardiac biomarkers demonstrated that 
measurement of the proANP concentration is the best technique for detection of atrial 
dilatation in horses.   
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Footnotes 
a E90225EQ, USCN, Wuhan, China 
b Beckman Coulter Inc, Fullerton, CA 
c Roche Diagnostics GmbH, Indianapolis, IN 
d SPSS Statistics 21.0, Chicago, IL
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Chapter 8: General discussion 
In human medicine, cardiac troponins are routinely measured to diagnose acute 
myocardial infarction. Similarly, natriuretic peptide (NP) measurement is used in the 
emergency department to distinguish cardiac from respiratory dyspnoea. The literature 
regarding cardiac biomarkers in human medicine is very detailed regarding sample 
stability, assay differences and molecular differences and reference values and 
consensus statements are regularly updated (Chapter 1). However, at the start of this 
thesis, little information was available on the diagnostic utility of cardiac biomarkers in 
horses whereby the question arose whether blood biochemistry would also be a useful 
method for diagnosis and follow-up of cardiac disease in horses. Cardiovascular disease 
is the third main cause of poor performance in the horse [1] and the final diagnosis is 
nowadays often limited to auscultation, electrocardiography and echocardiography. In 
first line clinical practice, echocardiography and electrocardiography are not always 
available and the detection of cardiac disease is usually performed by cardiac 
auscultation. However, not all murmurs are pathological and auscultation alone also 
does not allow to assess the severity of cardiac disease [2]. Biochemical blood 
examination could become a relatively easy aid to diagnose cardiac disease in horses 
and might be useful for follow-up of cardiac disease. Before cardiac biomarkers can be 
used, more specific information is needed as extrapolation of data from human 
medicine or small animal veterinary medicine is not always correct (Chapter 2).   
In this thesis, the utility of cardiac biomarkers in horses was evaluated by determining 
reference and cut-off values, by comparing different assays and by investigating the 
relationship between cardiac troponins and NPs.  
8.1 Cardiac troponin I and T can detect myocardial damage  
8.1.1 Assay validation and assay differences  
In Chapter 4, cardiac troponin I (cTnI) and T (cTnT) were compared and it was 
demonstrated that both molecules are excellent detectors of primary myocardial 
damage and should replace the less sensitive lactate dehydrogenase and creatine 
kinase-myocardial band isoenzymes. However, analytical validation of an assay is 
necessary before it can be used in clinical practice. Chapter 4.2 demonstrated that the 
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high-sensitivity troponin T assay (hs-cTnT)a has an excellent accuracy for use in the 
horse. Unfortunately, the inter-assay and intra-assay coefficient of variation (CV) could 
not be determined for samples with a very low cTnT concentration as all samples from 
healthy horses had a cTnT concentration below the limit of detection (4.0 pg/mL). In a 
previous cTnI validation study it was demonstrated that the CV decreases with higher 
troponin concentration [3]. In our study on cTnT, an excellent inter-assay CV was found 
for samples with a cTnT concentration of 18.0 pg/mL. Therefore, the closer the cTnT 
concentration lies to this value, the more precise it can be interpreted.  
As different cTnI assays exist and assay differences can be important (Chapter 4.1), 
analytical validation should be performed for each cTnI assay individually. Most 
laboratories have automated cardiac troponin assays with a high turn-over, results are 
usually obtained within one or two days. Nowadays, bedside analysers such as the i-
STAT assayb, (which should not be confused with the STAT-Ib assay (Chapter 4.1)) are 
available. With the use of these point of care analysers, results can be obtained within 
ten minutes, but these analysers probably have an inferior sensitivity compared to other 
troponin assays [4]. The i-STAT point of care analyser has been studied in equine 
medicine. Normal values (0.00-0.06 ng/mL) were obtained and a good correlation with a 
bench top analyser was found [5]. However, assay comparison was performed on a small 
population of monensin-treated horses and detailed information regarding the 
specificity and sensitivity of the assay in a large population of horses is still missing. At 
our own laboratory, a similar study was initiated to compare the i-STAT assay with the 
Access Accuc assay in horses with cardiac disease (Van Der Vekens et al., unpublished 
data), but the study was terminated due to analytical problems. In brief, the cTnI 
concentration was compared in samples from 19 horses with primary myocardial 
disease and 7 horses with severe valvular regurgitation. The cTnI concentration 
measured with the i-STAT assay was generally lower compared to the concentration 
measured with the Access Accu assay. Of the 19 horses with myocardial disease, 18 had 
increased (>0.095 ng/mL) cTnI concentrations on the Access Accu assay, while only 12 
had increased (>0.06 ng/mL) levels on the i-STAT assay. Most horses with valvular 
regurgitation had a cTnI concentration below the limit of detection of both assays, but 
one horse with heart failure caused by valvular regurgitation only had an increased cTnI 
concentration with the Access Accu assay, not with the i-STAT assay. An advantage of 
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the i-STAT assay is that it can give cTnI results within a few minutes, which allows quick 
decision making. One must be aware that false negative results might be found and in 
those cases, an additional analysis using an automated laboratory assay might still be 
indicated.   
Sample collection for cardiac troponin measurement is easy. Serum blood samples are 
excellent for cardiac troponin measurements, but heparin can also be used according to 
most manufacturers. The effect of sample storage can depend on the used assay, thus 
the manufacturer’s instructions should always be followed (Chapter 1). Sample storage 
for several hours at room temperature probably has only a negligible effect on the 
troponin concentration [6]. Therefore, samples can easily be obtained in the field and 
transported to a nearby laboratory.   
8.1.2 Interpretation of cardiac troponin I and T results  
Similar as in human patients, both cTnI and cTnT increase in case of myocardial damage 
in horses (Chapter 4.1 and 4.3). In contrast to human medicine, acute myocardial 
infarction is rare in horses and primary myocardial damage is mostly caused by toxins or 
inflammation of the cardiac muscle (Chapter 1) [5, 7-11] such as in horses with 
myocarditis or atypical myopathy. This myocardial damage often produces very high 
cardiac troponin concentrations. During the study period of this thesis, we measured a 
maximal cTnT of 2010.0 pg/mL in a horse with myocarditis and a maximal cTnI 
concentration of 816.00 ng/mL in a horse with lasalocid intoxication. Most of the other 
horses with primary myocardial damage had cTnI or cTnT concentrations well above the 
established cut-off values. Regarding cTnI, it is very likely that such high values are being 
detected by different cTnI assays. Thus, cTnI assay differences, which have been 
described in Chapter 4.1, are probably less important in these cases where massive 
increases in troponins occur. However, to monitor the evolution of cTnI in a horse, the 
same cTnI assay has to be used. During our study, several horses with myocarditis or 
atypical myopathy were followed up and the cTnI or cTnT concentration was measured 
on a regular basis. Horses with the highest cardiac troponin concentrations did not 
necessarily have the worst outcome. Therefore, monitoring the evolution of the cardiac 
troponin concentration might be better than determining the absolute concentration to 
assess prognosis. In most horses, cTnI or cTnT dropped quickly (up to a tenfold decrease) 
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within one or two days, which can be explained by the short half-life (0.47h) [12]. After 
this initial troponin drop, the troponin concentration often remained raised for more 
than one week. Although there might be ongoing myocardial damage, these sustained 
cardiac troponin values can also be explained by the continued leaking of cardiac 
troponins out of the necrotic cells [13] which can be found in cases of atypical myopathy 
[14] or myocarditis [9]. Similarly, the half-life of troponin release from necrotic cells in 
humans is more than 20 hours, while the half-life of the cTnI molecule is about 2 hours 
[13].   
Theoretically, mild primary myocardial damage might also be found after transvenous 
electrical cardioversion of atrial fibrillation (AF). The impact on the myocardial tissue, 
however, is probably limited as the post-cardioversion troponin concentration usually 
remains below the limit of detection [15]. In our study, a mildly increased troponin 
concentration (e.g. cTnI: 0.13 ng/mL and cTnT: 6.2 pg/mL) was only found in a horse 
which had undergone an exceptionally high number of shocks (e.g. 15 shocks of up to 
360 J).   
In contrast to the high cardiac troponin levels in case of primary myocardial damage, a 
mild cTnI increase was found in horses with severe structural heart disease (Chapter 4.1 
and 4.3). Most of these horses had dilatation of one or more chambers or congestive 
heart failure. A cut-off value for atrial dilatation could be established (Chapter 7) but a 
lot of false negative results were found, thus cTnI probably only increases in the worst 
cases. A significant cut-off could not be established for cTnT, but this was probably 
related to the fact that half of the samples were analysed at a laboratory in which the 
limit of detection was set at 10.0 pg/mL (Chapter 7). Using a limit of detection of 4.0 
pg/mL will increase the sensitivity and specificity of the test. Increased cTnI or cTnT 
concentrations have also been described in men [16-18] and dogs with acute or chronic 
heart failure and demonstrate the presence of cellular apoptosis, which is caused by the 
increased oxygen demand during cardiac remodelling [19]. In horses with primary 
myocardial damage, an acute event causes the troponin release (see above). In contrast, 
cardiac dilatation or heart failure is an ongoing process in which troponins are probably 
continuously released. This probably explains why the serum cTnI values were elevated 
in horses with cardiac dilatation or congestive heart failure despite the short cTnI half-
life [18].  
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As mentioned in Chapter 1, cardiac troponins might also be increased by non-cardiac 
factors. A very mild [20, 21] cTnI increase was found in healthy horses after racing. An 
influence of musculoskeletal disease has also been described (Chapter 1) and might be 
important in horses as musculoskeletal and cardiovascular disease are both causes of 
poor performance (Chapter 2). During our study, a normal cTnI concentration (<0.03 
ng/mL) was found in one horse with myopathy without any underlying cardiac disease. 
However, the cTnT concentration was not tested. Renal disease can also cause increased 
cTnI or cTnT concentrations [22, 23]. Interestingly, a mild cTnT increase (9.8 pg/mL), but 
normal cTnI concentration (0.04 ng/mL) was seen in one horse with renal insufficiency 
with normal echocardiographic examination. In human medicine, renal disease is 
associated with more elevated cTnT than cTnI concentrations, which has been explained 
by the absorption of the cTnI molecule to the membrane of the dialysis equipment 
(Chapter 1.3.1.4). As this cannot be the case in horses, the presence of minor myocardial 
damage is more likely. Minor myocardial damage in human patients with renal failure 
might also be caused by a decreased myocardial blood flow due to water overload, 
myocardial fibrosis and cellular hypertrophy [24]. In this case, the difference between 
cTnI and cTnT can be explained by differences in assay imprecision at the lower 
measuring range [24]. In human medicine, cTnT assays are more precise compared to 
cTnI assays at low troponin concentrations. This might also be the case in horses 
(Chapter 4.2).   
Musculoskeletal and renal influence on cardiac troponin concentrations may especially 
be important in horses with atypical myopathy as both can be present [25]. Since the 
cardiac troponin increase is much higher than expected in case of musculoskeletal or 
renal disease [23] (Chapter 4), the high troponin values are mainly caused by the 
presence of myocardial damage, which has been demonstrated with 
electrocardiography, echocardiography and on post-mortem examination [11, 14].  
In conclusion, both cTnI and cTnT can be used in equine clinical practice for the 
detection of myocardial damage. A high cTnI or cTnT increase is most likely caused by 
primary myocardial damage. A small cTnI or cTnT increase in horses with severe valvular 
regurgitation suggests ongoing cardiac remodeling. Especially for mild cTnI or cTnT 
elevations, the presence of renal or musculoskeletal disease should be taken into 
account. Finally, for follow-up of patients, the same troponin assay should be used. 
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8.2 Atrial natriuretic peptides can detect atrial dilatation  
8.2.1 ANP study differences  
In most equine studies, a human atrial natriuretic peptide (ANP) radioimmunoassay is 
used to measure equine ANP based on the 100% homology between equine and human 
ANP [26-29]. In one of these studies [28] no relationship was found between atrial NPs 
and atrial dilatation while in two other studies, a correlation was found between the left 
atrial dimensions and the measured ANP concentrations [26, 29]. Although the same 
assayd was used in several of these studies, results differed substantially: the normal 
plasma ANP concentration ranged from 10-45 pg/mL in one study [28], from 22-230 
pg/mL in a second study [30] and from 17-512 pg/mL in a third study [29]. This might be 
explained by a large inter-assay imprecision, by differences in the study population, in 
the sample collection protocol, in the sample storage or in the classification system and 
demonstrates that a very detailed description of each of these elements is essential 
before results can be interpreted correctly.   
The most probable explanation for the absolute concentration differences between the 
three studies [27-29] is the high inter-assay CV of the used test. According to Trachsel et 
al. (2014) [27], the inter-assay CV of the test lies between 21-25% (recommended inter-
assay CV: <15% [31]) for samples between 29 and 139 pg/mL. Although Leroux et al. 
(2014) [29] mention assay validation, results were not included in the manuscript. This 
poor assay repeatability does not only make comparison between different studies 
difficult, it can also be important within one study if different plates are used: if most of 
the samples from horses with atrial dilatation were measured in one batch and most of 
the samples from healthy horses in another batch, the differences between both groups 
could be entirely explained by the high inter-assay CV instead of the difference in ANP 
release. Unfortunately, none of the studies provided information about the exact 
analysis scheme.   
Differences in the study population might also explain the variable results. The largest 
number of horses (n=91) was studied by Leroux et al. (2014) [29]. However, most 
animals were healthy (n=61) and only 16 horses with dilatation were examined, thus the 
number of horses with an increased ANP concentration still remained limited.  
Thirdly, differences in sample collection and storage might explain the different results. 
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In two of the studies [28, 30], aprotinin was used as a proteinase inhibitor, while in the 
other study [29] another proteinase inhibitor (benzamidine) was chosen as it is also 
frequently used in human medicine. As two studies with the same protein inhibitor had 
a large difference in ANP concentration, the influence of the proteinase inhibitor seems 
to be limited. In all three studies, a similar storage temperature (-70°C) was used. 
Sample storage time was not mentioned in one study [28] and comparable (maximal 26 
months) in the other two studies. Normally, the recommended storage time of the 
manufacturer should be followed (Chapter 1). However, as the maximal storage time 
was not defined by the manufacturer, it remains questionable if samples were stable for 
26 months at -70°C. Sample stability is especially important if the sample storage time is 
different between groups: if samples from healthy horses are stored longer than 
samples from horses with atrial dilatation and ANP degradation is present, the ANP 
concentration might be higher in horses with atrial dilatation even without a higher ANP 
release. Unfortunately, none of the studies compared the sample storage time between 
groups. The laboratory analysis itself was performed according to the manufacturer’s 
instructions and should therefore be similar in the three studies. However, small 
differences can still be present, since analysis was performed at different laboratories.   
Echocardiographic measurements were used to classify horses into groups and differed 
between studies as there is no consensus on how to measure the left atrium. Two 
different measurements were used in this thesis based upon comments from different 
reviewers. In Chapter 5.1, the left atrial-to-aortic diameter ratio (LAD/AoD) from a right-
sided short axis view was measured as described by De Clercq et al. (2008) [32], while in 
Chapter 5.2 and Chapter 7 the method of Schwarzwald et al. (2007) [33] was used to 
classify the horses. Based on the population of 23 healthy horses used in our study, two 
different cut-off values (mean + 1.96 x standard deviation) for atrial dilatation were 
found. If horses had a LAD/AoD>1.25 (1.15+1.96x0.05) by the method from De Clercq et 
al. [32] or >1.50 (1.32+1.96x0.09) by the method of Schwarzwald et al. [33], they were 
classified as having atrial dilatation. Interestingly, the outcome of these two methods 
were very similar: 70/77 horses in our study were classified similarly when using these 
two different cut-off values and the proANP and ANP cut-off values which were 
obtained using both classification systems were exactly the same (Van Der Vekens et al., 
unpublished data). By inclusion of the aortic diameter, which is correlated to the size of 
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the horse, measurements were corrected for differences in body weight. Similarly, 
echocardiographic measurements were normalized to a body weight of 500 kg in two 
other studies [26, 29]. However, only Leroux et al. (2014) classified the horses according 
to the stage of congestive heart failure [29] and demonstrated that horses with a higher 
stage also had a significant higher ANP concentration. Horses were divided into 4 stages: 
horses with no or mild regurgitation on echocardiography (stage A, n=61), horses with 
moderate/severe regurgitation without echocardiographic evidence of cardiac 
remodelling (stage B1, n=14), horses with moderate/severe regurgitation and with 
echocardiographic evidence of cardiac remodelling (stage B2, n=8) and horses with 
clinical signs of congestive heart failure and echocardiographic evidence of cardiac 
remodelling (stage C, n=8). Using the same criteria on our data did not provide similar 
results: ANP concentrations in horses with atrial dilatation and clinical signs of heart 
failure (stage C) were not significantly higher than those of horses with atrial dilatation 
without clinical signs (stage B2) and the LAD/AoD was not higher in horses of stage C 
compared to stage B2 (Van Der Vekens et al., unpublished data). However, the number 
of horses with clinical signs (n=3) in our study was smaller than in the study of Leroux et 
al. (2014) (n=8). If the same classification scheme was used on proANP data (Chapter 
5.2), the proANP concentration was significantly different between horses of stage C and 
horses of stage A (P<0.001), B1 (P=0.024) and B2 (P=0.005), but not between the other 
groups (Van Der Vekens et al., unpublished data). Since horses of stage C also had a 
significantly higher (P=0.024) LAD/AoD ratio than horses of stage A (P<0.001), B1 
(P<0.001) or C (P=0.024), this possibly explains the higher proANP concentration. Leroux 
et al. (2014) also demonstrated a good linear relationship between the plasma ANP 
concentration and the percentage of left atrial dilatation (R²=0.637) [29]. The left atrial 
internal diameter was measured from the 2D left parasternal long-axis view of the left 
ventricle, normalized to a body weight of 500 kg and the percentage of dilatation was 
compared to the upper limit of the 95% confidence interval of healthy horses. No such 
correlation was found in our study (Chapter 5.1), when the left internal diameter 
measured from the 2D left parasternal 2 chamber-view was used. However, if the 
LAD/AoD [32] was used to calculate the percentage of dilatation, a significant (R²=0.335; 
P=0.002) linear relationship was found between the percentage of left atrial dilatation 
and the ANP plasma concentration (Van Der Vekens et al., unpublished data). Left atrial 
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diameter measurements from left parasternal long-axis images are thought to be more 
subject to variation compared to those taken form a right parasternal approach [34] 
which might explain the obtained differences.   
A disadvantage of using the LAD/AoD and thus the aortic diameter to correct for the size 
of the horse, is that horses with severe aortic regurgitation might have a larger end-
systolic aortic diameter due to the presence of left ventricular dilatation. This means 
that the LAD/AoD might be <1.25 [32] in horses with aortic regurgitation and atrial 
dilatation. Seven horses in Chapter 5.1 had moderate or severe aortic regurgitation and 
three of these horses had left atrial dilatation (LAD/AoD >1.25). However, if the short axis 
left atrial diameter corrected to a body weight of 500 kg was used to identify horses 
with left atrial dilatation, only one additional horse (with a LAD/AoD of 1.22 and ANP 
concentration of 31.20 pg/mL) was classified as having left atrial dilatation. Therefore, 
the use of the aortic diameter (as compared to allometric scaling) probably only has a 
limited influence on the results. One study [35] also describes a positive relationship 
(P=0.003) between the aortic diameter (measured at end-diastole from the 2D-mode 
right parasternal long-axis five chamber view at level of the sinus of Valsava) and the age 
of the horse. This was also confirmed in our study: older healthy warmblood horses 
(n=23) had a significantly larger (R²=0.451; P=0.001) end-diastolic aortic diameter 
(measured at end diastole at the sino-tubular junction). As no significant age difference 
was found between groups with and without atrial dilatation, the influence of the age 
on our results is probably limited.   
The best classification scheme or the best echocardiographic measurement for 
detection of left atrial dilatation remains to be determined. In addition, only a subjective 
assessment of the right atrial size can be performed at the moment, since accurate 
echocardiographic measurements of the right atrium are still missing. Besides the 
influence of atrial dilatation, ventricular dilatation might also have an effect on the atrial 
NP levels in horses (Chapter 5.1). Unfortunately, the number of horses with ventricular 
dilatation without atrial dilatation was too small to draw conclusions from our results.   
In conclusion, the absolute ANP concentration differs between studies, which is 
probably caused by differences in assay, study population, sample collection, sample 
storage or classification system. However, the correlation between atrial NPs and atrial 
dilatation was demonstrated repeatedly in literature [26, 29] and was confirmed in this 
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thesis independent of the used classification system using two different methods (ANP 
and proANP) for atrial NP measurement. Thus, we can conclude that atrial NP release is 
indeed caused by atrial stretch.  
8.2.2 Need for an automated assay against a stable ANP fragment 
Atrial NPs can indeed be used as detectors of atrial dilatation. However, their use in 
clinical practice remains challenging as no equine automated assay is available (Chapter 
7) and sample collection is difficult: EDTA-plasma samples obtained by centrifugation at 
4°C are recommended, which is not always easy to obtain in first line clinical practice.   
In clinical research, equine ANP is mostly measured using ANP assays validated for use in 
human patients (Chapter 1). However, the proANP products, such as NT-proANP and 
ANP, can undergo further modifications. This post-translational phase might differ 
between species [36, 37] and can change the antibody recognition sites. Therefore, 
human assays can give variable results in other species and species specific assays are 
preferred. An ANP cut-off value was established with an equine enzyme-linked 
immunoassay (ELISA) in Chapter 5.1. The ANP concentrations measured with the equine 
ELISA were generally higher than previously reported in studies using human assays, 
which might partially be explained by post-translational differences (Chapter 5.1). 
However, ANP was unstable and samples should be stored at -80°C. Since proANP is 
more stable and can be stored at -20°C, total proANP measurement by processing 
independent analysis might be a good alternative (Chapters 5.2). Chapter 7 
demonstrates that proANP even has a better accuracy than ANP for detection of atrial 
dilatation. However, sample extraction and enzymatic treatment is necessary before 
sample analysis and makes total proANP measurement more complicated for everyday 
diagnostics. As NT-proANP1-98 has a longer half-life and is more stable than ANP, an 
automated equine NT-proANP1-98 assay might be a good alternative for use in clinical 
practice. However, human studies have showed that molecular fragmentation of NT-
proANP1-98 might exist [38] and that measurement of the stable mid-regional part of the 
proANP molecule might be a better alternative. Therefore, a new automated sandwich 
immunoassay for detection of human mid-regional proANP53-90 has been developed in 
2004 [39]. Sample storage at -20°C or repeated freeze-thaw cycles did not influence the 
proANP53-90 concentration [39], thus proANP53-90 is also a stable molecule. A comparison 
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between proANP53-90 and BNP measurement demonstrated that proANP53-90 was as 
useful as BNP for diagnosis of acute heart failure. Similarly, a proANP31-67 fragment was 
measured in dogs and seemed to be a good diagnostic tool for detection of heart failure, 
thus an automated assay of a mid-regional proANP fragment might also be the best 
option for measurement of atrial NPs in equine clinical practice.  
In conclusion, atrial NP measurement with human assays is probably inaccurate due to 
equine and human post-translational differences. Measurement with an equine ANP 
ELISA seems to be a better alternative, but as ANP is unstable, sample collection and 
storage is challenging in equine clinical practice. Measurement of the stable total 
proANP molecule is probably the most accurate option, but currently remains limited to 
clinical research due to complex sample processing. Therefore, future studies should 
focus on the search for a stable proANP fragment which can be measured quickly in 
equine clinical practice.  
8.2.3 Eliminating the grey zone 
A considerable grey zone or inconclusive zone of intermediate values, corresponding to 
a prediction not precise enough for diagnostic decision [40], still exists and should be 
eliminated in further studies. Although an absolute proANP and ANP cut-off value for 
atrial dilatation was established (Chapter 5.1 and 5.2), false negative and false positive 
results were still present (Chapter 7) and suggest that the definition of an absolute cut-
off point is difficult. Many horses have an intermediate proANP or ANP concentration 
around the cut-off value. As mentioned above, this might be partially explained by the 
used classification scheme: it cannot be ruled out that some horses with a LAD/AoD <1.25 
(De Clercq et al., 2008) or <1.50 (Schwarzwald et al., 2007 [33]) already had mild atrial 
dilatation and thus a higher proANP or ANP concentration. However, NPs are hormones 
and part of a complex water and salt regulating scheme (Chapter 2). They can be 
influenced by many factors which should be taken into account when interpreting NP 
levels and which might explain the limited diagnostic accuracy of these hormones for 
atrial dilatation. Since atrial NPs can increase after exercise [41, 42] and a larger ANP 
difference between healthy horses and horses with mitral regurgitation was 
demonstrated after exercise in one study [30], sample collection immediately post-
exercise might improve the diagnostic accuracy of the atrial NPs. The splenic contraction 
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which is seen in horses at the beginning of exercise (Chapter 2), increases the blood 
volume and the atrial pressure and might thus partially explain the more pronounced 
ANP increase after exercise in horses with mitral valve regurgitation than in healthy 
horses. However, as only seven horses with mitral valve regurgitation were included in 
this study [30], more research is needed to confirm these results.   
The grey zone can also be reduced by obtaining adapted cut-off values which take 
physiological or pathological factors into account such as sex, age, breed, renal failure, 
myocardial damage or AF. Higher NP levels have been described in women than in men 
[43]. The influence of sex on atrial NP levels in horses has only been examined in one 
small study: in 36 horses, 6 stallions had a lower ANP and NT-proANP concentration 
compared to geldings or mares [44]. No significant difference between geldings, stallions 
or mares could be demonstrated in our study, since most of the healthy horses had a 
ANP concentration below the limit of detection (Chapter 5.1). However, two mares had 
a high ANP concentration and mares had also higher proANP concentrations compared 
to geldings (Chapter 5.2). In contrast to women, horses have a seasonal oestrus cycle 
[45]. As the oestrogen release might be more prominent during the breeding period, the 
atrial NP release might also fluctuate, thus the influence of oestrogens might be more 
complicated in horses than in women. An effect of breed on NP levels has recently been 
described in small animals [46], but has not yet been confirmed in horses. In our study, 
the control group consisted of Warmbloods in order to establish reference values for 
atrial NP concentration in this breed, while the other groups included different breeds. 
The influence of breed could therefore not be examined. In human medicine, age 
specific reference values have been described [47]. No specific age influence was found 
in our study (Chapter 5) but only one healthy horse was older than 14 years. Sixty-one 
healthy horses (9±6 years) were examined in a study of Leroux et al. (2014) [29], but no 
influence of age was found. Since most of the healthy horses were again relatively young 
and confounding factors such as breed or sex were present, it remains to be determined 
whether or not NPs increase with age.  
Pathological factors such as renal failure, myocardial damage and AF might also 
influence NP concentrations. Increased NT-proBNP levels have been described in human 
patients and dogs with renal disease [48, 49]. During our study, one horse with renal 
failure had indeed a high ANP (1251 pg/mL) and NT-proANP (135 pg/mL) concentration. 
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The proANP concentration of this horse was 520 pmol/L and therefore still under the 
cut-off value for atrial dilatation. In one other horse with renal failure, a very high 
proANP concentration (944.7 pmol/L) was found. Since echocardiographic examination 
was normal in both horses, the decreased renal function probable explains the high 
atrial NP levels. A high proANP concentration (727 pmol/L) was also seen in a horse with 
myocarditis and normal heart dimensions. After two weeks, the proANP concentration 
decreased to 473 pmol/L. Increased ANP concentrations have also been reported in 
human patients with myocarditis [50]. Endomyocardial biopsy samples were examined 
with immunohistochemistry and the highest ANP expression was seen at the edges of 
myocardial lesions. Therefore, regional stress might be the cause of this atrial NP 
increase: myocyte necrosis and fibrosis might disturb the movement of the surrounding 
myocytes and thus cause local stress and stimulation of atrial NP expression. This 
mechanism can also explain the mild correlation between atrial NPs and cardiac 
troponins which was demonstrated in Chapter 7. A high ANP (1252 pg/mL), NT-proANP 
(135 pg/mL) and proANP (978 pmol/L) concentration was also found in a horse with 
atypical myopathy and probably demonstrates again the presence of myocardial 
damage in these cases [11, 14]. However, the presence of renal failure caused by 
myoglobinuria might also contribute to the high atrial NPs concentration and makes the 
interpretation of results more difficult.   
A close correlation between atrial size and the susceptibility to AF exists [51]. Of all 39 
horses with atrial dilatation (Chapter 5.2), 20 horses also had AF. Within the group of 
horses with left or right atrial dilatation, the median proANP concentration was 
significantly (P=0.008) higher in horses with AF (906 (574-1859) pmol/L) than in horses 
without AF (650 (442-1113) pmol/L). Since horses with atrial dilatation and AF did not 
have a higher (P=0.08) LAD/AoD (1.91(1.56-3.09) [33]) than horses with atrial dilatation 
without AF (1.71 (1.38-2.40) and as an increased proANP concentration (784 pmol/L and 
660 pmol/L) was also seen in two horses with AF in the absence of atrial dilatation, AF 
probably causes atrial NP release even without atrial dilatation. Similarly, it has been 
described in human medicine that atrial NP secretion is increased in patients with acute 
AF and that it decreases after successful cardioversion which suggests that AF is indeed 
the cause of the atrial NP release [52]. In human patients with longstanding AF this 
plasma atrial NP increase is reduced, probably due to AF-induced structural remodelling 
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(fibrosis) [52, 53]. Interestingly, the ANP response after exercise might be useful to 
assess prognosis in patients with longstanding AF. A high ANP increase after exercise 
(110±41.2 pg/mL) has been correlated to a low AF recurrence rate after cardioversion, 
while a reduced ANP response after exercise (43.8±36.1 pg/mL) is linked to unsuccessful 
cardioversion or a high AF recurrence rate [54]. Since AF is also very common in horses 
[55] (Chapter 2), the atrial NPs increase after exercise might also be useful to predict the 
outcome of cardioversion in patients with AF.   
Finally, one should not forget that specific disorders in the secretion of this cardiac 
hormones might also exists. Cellular malfunctions might cause decreased atrial NP 
secretion. In contrast, normal or elevated NP concentrations without any biological 
effects might also exist [56]. Since NPs have a cardio-protective function, disorders in 
the NP system might even partially explain the differences in the evolution of the same 
cardiac disease.  
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8.3 The challenge of equine B-type natriuretic peptide determination  
At the start of this thesis, no information was available about B-type NPs in horses. Due 
to their longer half-life compared to atrial NPs, B-type NPs are an interesting target for 
use in equine medicine, especially in case of ventricular dilatation. As no equine B-type 
NP assay is available in horses, an attempt was made to measure equine B-type 
natriuretic peptide (BNP) using assays developed for other species.   
First, we measured equine NT-proBNP with a human NT-proBNP assaye in 20 healthy 
horses and 30 horses with cardiac disease (Van Der Vekens, unpublished data). All values 
were under the limit of detection of the assay (20 pg/mL), except for one healthy horse 
which had a concentration of 69 pg/mL. As less than 50% of the human and equine NT-
proBNP amino acids are the same, cross reactivity between the equine and human NT-
proBNP molecule was unlikely and the result was interpreted as false positive.  
Secondly, we measured equine NT-proBNP using a commercially available feline NT-
proBNP assayf (Van Der Vekens, unpublished data). A feline assay was chosen above a 
canine NT-proBNP assay since a slight cross reactivity between feline NT-proBNP 
antibodies and equine NT-proBNP was found in previous studies (personal 
communication prof. dr. W. Woloszczuk, Vienna, Austria). The NT-proBNP concentration 
was measured in 4 healthy horses and 6 horses with cardiac disease and laid again under 
the limit of detection in all these horses. Finally, we used a porcine BNP ELISAg to 
measure equine BNP (Chapter 6.1). Equine and porcine BNP are more homologous 
(±91%) than equine and porcine NT-proBNP (±67%). Thus, a porcine BNP ELISA was 
chosen above a porcine NT-proBNP ELISA, despite the longer half-life of NT-proBNP [57-
60]. As described in Chapter 6.1, the assay did detect an unstable BNP-like molecule, but 
there was no significant difference between horses with and without chamber 
dilatation.   
Realizing the need for an equine specific NT-proBNP assay, we tried to develop an 
equine specific NT-proBNP ELISA test (Chapter 6.2). Polyclonal antibodies were 
produced in rabbits against the whole recombinant NT-proBNP molecule and against 
two smaller peptides of this molecule. Part of these antibodies were biotinylated in 
order to use them as detection molecule in combination with unbiotinylated antibodies 
in a sandwich ELISA. After selection of the antibody combination with the highest 
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sensitivity, a sandwich ELISA was developed which could successfully detect an equine 
recombinant NT-proBNP concentration between 0.5 and 100.0 ng/mL. Although the 
antibodies recognized recombinant NT-proBNP, it was uncertain if circulating NT-proBNP 
would also be recognized. Circulating proBNP products can be modified during post-
translational maturation, which can alter their antibody recognition site [61-63]. 
However, a high NT-proBNP concentration was measured in one horse with ventricular 
dilatation, thus the antibodies probably did recognize endogenous NT-proBNP. This 
might be explained by the fact that polyclonal antibodies were used, which are, 
compared to monoclonal antibodies, less affected by changes in their recognition sites. 
A false positive result caused by cross reaction with other equine molecules or by the 
presence of heterophile antibodies could not be excluded with full certainty. 
Heterophile antibodies are non-specific antibodies which can cause false positive results 
by binding between the capture and detection antibodies of an assay [64] (Chapter 1, 
Figure 7). The heterophile antibody concentration is usually low, thus the problem of 
heterophile antibody interference is mostly encountered in assays which attempt to 
measure a very low plasma or serum concentration such as the sensitive troponin assays 
[64, 65]. False positive results caused by heterophile antibodies have also been 
described in a canine BNP sandwich ELISA and were successfully eliminated by addition 
of antibody blocking solution [65]. Heterophile antibodies have also been demonstrated 
in equine plasma [66]. A relatively low prevalence (4.7%) was found [66], which makes 
the presence of a false positive result in our sandwich ELISA less likely. The influence of 
heterophile antibody interference on the equine specific NT-proBNP ELISA needs to be 
investigated further [67].  
Since only one horse with ventricular dilatation had a measurable NT-proBNP 
concentration, the assay sensitivity should be increased by further assay optimization. In 
addition, pre-analytical (sample stability, influence of anticoagulants,…), analytical (inter- 
and intra-assay variability, cross reactivity with other NPs,…) and clinical characteristics 
(influence of age, sex,…) should be further investigated before it can be used in equine 
clinical practice [67]. If the equine test is marketed, batch-to-batch variability might 
become an issue as polyclonal antibodies are used and polyclonal antibodies from other 
rabbits against the same antigens might show slight differences [68] (Chapter 6.2). As a 
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consequence, Roche Diagnosticsa has modified their automated human NT-proBNP 
assay in 2009 and replaced the polyclonal by monoclonal antibodies to get more 
reproducible results [68]. The monoclonal immunoassay produced slightly lower values 
(-2.5%), but had comparable analytical characteristics to the former polyclonal 
immunoassay. Using monoclonal antibodies against unmodified epitopes is crucial, thus 
before an equine test with monoclonal antibodies can be developed, a full 
understanding of the equine proBNP protein and its processing is needed. 
Chapter 8.4: Future prospects  
 
256 
 
8.4 Future prospects  
Both cTnI and cTnT should definitely be used in clinical practice as sensitive detectors of 
myocardial injury in horses. However, the question remains if these markers can provide 
a good indication of the prognosis of cardiac or even non-cardiac disease. In addition, 
although the effect is expected to be small, the influence of musculoskeletal damage on 
the troponin concentration should be examined further by measurement of the 
troponin concentration in horses with myopathy without cardiac dysfunction or by 
performing Western blot analysis of equine cardiac and skeletal muscle homogenate as 
described previously [69]. Currently, atrial or B-type NPs cannot be used routinely in 
equine clinical practice as a reliable, validated automated assay is not available. Future 
studies on atrial and B-type NPs should focus on the cellular synthesis, circulation and 
elimination of both equine proANP and proBNP products to define a stable proANP or 
proBNP fragment. If an automated equine atrial or B-type NP assay against such a 
fragment becomes available, it might allow the detection of atrial or ventricular 
dilatation in clinical practice. However, for correct data interpretation, the atrial and B-
type NP secretion patterns should also be clarified further by immunohistochemistry of 
atrial and ventricular myocardium from healthy horses and horses with cardiac disease. 
The correlation between cardiac biomarkers and new imaging techniques such as Tissue 
Doppler (TDI) or two dimensional Speckle Tracking (2DST) should be examined and could 
enhance our understanding of the NP pathophysiology. For example, atrial NP 
determination in combination with atrial function follow-up by TDI [70] might be useful 
to study the presence of structural remodeling in case of AF. In addition, the 
combination of NPs and left ventricular dysfunction detected by TDI or 2DST [71, 72] 
might be valuable to assess prognosis in horses with valvular disease.   
The search for new cardiac biomarkers in equine medicine has probably only just begun. 
Emerging techniques such as proteomics, which examines the rapid change of proteins 
in response to cellular processes on a large scale, can increase our understanding of the 
pathophysiology of cardiac disease rapidly and lead to the discovery of a whole new 
panel of diagnostic and prognostic markers [73, 74].   
 Chapter 8: General discussion 
 
257 
 
In conclusion, cardiac biomarker determination forms an important part of the complete 
equine cardiac work-up. Since an ideal biomarker or a perfect diagnostic test does not 
exists, results should always be interpreted in combination with clinical, 
echocardiographic and electrocardiographic findings.  
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Footnotes 
a Roche Diagnostics GmbH, Indianapolis, IN 
b Abbott Diagnostics, Wavre, Belgium 
c Beckman Coulter Corporations, Fullerton, California 
d RIA kit S-2011, Peninsula Laboratories, member of the Bachem Group, San Carlos, USA 
e Vidas NT-proBNP assay, Biomérieux Benelux, Schaarbeek, Belgium 
f Cardiopet, proBNP test, IDEXX, Laboratories Inc, Hoofddorp, the Netherlands 
g ELISA, E90541Po, USCN, Wuhan, China
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In human medicine, cardiac biomarkers are routinely used for diagnosis, prognosis and 
monitoring of cardiac dysfunction. First studies have also appeared in small animal 
veterinary medicine where cardiac biomarkers are mostly used to differentiate cardiac 
and non-cardiac diseases. At the start of this thesis, little information was available on 
the diagnostic utility of cardiac biomarkers in horses, but our research has demonstrated 
that different cardiac biomarkers can also be successfully used in horses to detect 
myocardial damage and cardiac dilatation. 
In Chapter 1, a detailed literature overview of the physiology, structure and diagnostic 
utility of cardiac biomarkers is given. Chapter 1 demonstrates that cardiac troponins are 
excellent detectors of myocardial damage, while the natriuretic peptides are mostly 
used in human and small animal veterinary medicine to detect heart failure. In addition, 
the influence of other extra-cardiac factors on the cardiac troponin and NP 
concentration is described, which is important for correct interpretation of cardiac 
biomarker results. Finally, Chapter 1 summarizes the current use of cardiac biomarkers 
in equine veterinary medicine and demonstrates that cardiac troponins have already 
been successfully used for detection of myocardial damage in horses, but that studies on 
NPs are limited with sometimes conflicting results.   
Chapter 2 demonstrates that it cannot be assumed that human and equine cardiac 
biomarker behavior is comparable. Species differences in physiology and 
pathophysiology exist and corroborate that extrapolation from human medicine to 
veterinary medicine and vice versa should be avoided and that species specific studies 
are needed.   
The specific aims of this thesis are described in Chapter 3. The first objective of this 
thesis was to assess the use of cardiac troponin I (cTnI) and T (cTnT) for detection of 
myocardial damage in horses (Chapter 4.1-4.3). The second objective was to evaluate 
atrial NPs as detectors for atrial dilatation in horses (Chapter 5.1-5.2). No equine studies 
on B-type NPs have been published, thus a third objective of this thesis was to measure 
equine B-type NPs (Chapter 6.1-6.2). Finally, by comparing the obtained results, the 
most accurate biomarker or combination of biomarkers for detection of atrial dilatation 
was defined in Chapter 7.  
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In Chapter 4, different troponin assays are evaluated for detection of myocardial 
damage in horses. Human studies demonstrate that a wide variety of cTnI assays with 
different target peptides and antibodies exists and that results may differ. Therefore, in 
the first part of this chapter (Chapter 4.1), two different cTnI assays (Access Accu assay 
(Beckman Coulter Corporations, Fullerton, California) and STAT-I assay (Abbott 
Diagnostics, Wavre, Belgium)) were compared in 23 healthy horses and 72 horses with 
cardiac disease. A significantly higher cTnI concentration was demonstrated in horses 
with cardiac disease for both the Access Accu and STAT-I assay, but a significant cut-off 
for cardiac disease was only demonstrated for the Access Accu assay. In addition, large 
mean differences between the cTnI concentrations of both assays were found. Chapter 
4.1 demonstrates that results of cTnI assays in horses are not interchangeable and that 
the same assay should always be used to monitor myocardial damage. Results of cTnT 
assays are better standardized, since only one manufacturer has produced cTnT assays. 
Before the cTnT assay can be used in clinical practice, analytical validation is necessary. 
Therefore, in Chapter 4.2, the analytical performance of a high-sensitive cTnT assay was 
evaluated in horses. In addition, the influence of hemolysis on cTnT results was 
determined as this might occur in clinical practice. Serum samples from horses were 
mixed into three pools with a low, medium and high cTnT concentration and the within-
day and between-day coefficients of variation were determined. Two pools were diluted 
to estimate dilution linearity. The influence of hemolysis was estimated by two methods. 
First, hemolysis was mechanically induced in serum samples from four horses. Secondly, 
hemolysate was prepared and added at different concentrations to EDTA plasma from 
three other horses. The within- and between-day coefficients of variation were <10% for 
all pools and a good linearity dilution was found. These results demonstrate that the 
high-sensitive cTnT assay has a good precision for diagnostic use in the horses. As a 
lower cTnT concentration was found in samples with increased hemolysis index, 
appropriate cTnT sample handling and collection are needed. In Chapter 4.3, the high-
sensitive cTnT assay is compared to the Access Accu cTnI assay to evaluate its clinical 
utility. CTnI and cTnT were determined in 35 healthy horses, 23 horses with primary 
myocardial damage and 41 horses with secondary myocardial damage. Although large 
quantitative differences existed, both cTnI and cTnT were significantly higher in horses 
with primary myocardial damage than in healthy horses and a significant cTnI (0.095 
 Summary 
 
271 
 
ng/mL) and cTnT (6.6 pg/mL) cut-off value for detection of primary myocardial damage 
could be established. The area under the Receiver Operator Characteristic curves of cTnI 
and cTnT did not differ. Chapter 4.3 demonstrates that the diagnostic value of cTnI is 
comparable to cTnT for the detection of myocardial damage in horses. 
In Chapter 5, atrial NPs are evaluated for the detection of atrial dilatation in horses using 
two different techniques. In Chapter 5.1, ANP and N-terminal proANP (NT-proANP) were 
measured using an equine ANP and a human NT-proANP enzyme-linked immunosorbent 
assay (ELISA) in 20 healthy horses, 11 horses with mitral valve regurgitation without left 
atrial dilatation and 16 horses with mitral valve regurgitation and left atrial dilatation. 
Sample storage at -20°C and -80°C was also compared to study ANP and NT-proANP 
stability. Horses with atrial dilatation had a significantly higher ANP but not NT-proANP 
concentration than horses without atrial dilatation and an ANP cut-off value for 
detection of left atrial dilatation (52 pg/mL) could be established. A larger decrease in 
ANP as compared to NT-proANP was found when samples were stored at -20°C 
compared to -80°C. Thus, we can conclude that ANP, not NT-proANP, is suitable for 
detection of left atrial dilatation in horses, but that samples should be stored at -80°C to 
prevent ANP degradation. In Chapter 5.2, a new technique called processing 
independent analysis was used for the first time in horses to measure the total proANP 
product by detecting a stable proANP fragment. The total proANP product was 
measured in 23 healthy horses, in 12 horses with cardiac disease without atrial dilatation 
and in 42 horses with cardiac disease with atrial dilataton. The proANP concentration 
was significantly higher in horses with atrial dilatation compared to healthy horses and 
an optimal cut-off value for atrial dilatation (573.8 pmol/L) was established. Sample 
storage at -20°C was as good as sample storage at -80°C. These results demonstrate that 
the stability of the total proANP product and especially the reliability of the technique 
make it an excellent technique for future use in horses. 
Since B-type NPs are species specific molecules and no equine B-type NPs assays are 
available, we decided to develop a technique for B-type NP measurement (Chapter 6). 
As more than 90% homology exists between equine and porcine BNP, in Chapter 6.1, we 
attempted to measure equine BNP using a porcine BNP ELISA in 20 healthy horses, 8 
horses with cardiac disease without cardiac dilatation and 10 horses with cardiac disease 
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with cardiac dilatation. Although a BNP-like molecule was measured and a significant 
difference between sample storage at -20°C and -80°C was demonstrated, no difference 
was found between healthy horses and horses with or without cardiac dilatation. As 
such, development of an equine specific B-type NP assay seemed required in order to 
measure equine B-type NPs. Since NT-proBNP is probably more stable and has a longer 
half-life than BNP, we chose to develop an equine NT-proBNP assay (Chapter 6.2). In 6 
rabbits, polyclonal antibodies were produced against the whole equine recombinant NT-
proBNP molecule and against two smaller parts (peptide 1 and 2). Next, the interactions 
of these antibodies with the recombinant molecule were evaluated in real time using an 
optical biosensor. Part of the antibodies were biotinylated and used as detection 
antibodies in combination with unbiotinylated capture antibodies in a sandwich ELISA. 
The antibody combination with the highest signal-to-noise ratio was selected and a limit 
of detection of 0.5 ng/mL was established. Finally, the equine NT-proBNP concentration 
was measured in 10 healthy horses and 10 horses with ventricular dilatation. Only one 
horse with ventricular dilatation had an elevated NT-proBNP concentration. In the other 
horses no NT-proBNP was detected, probably because the sensitivity of the assay was 
still too low. Future assay optimization is therefore needed before the equine NT-
proBNP assay can be used in clinical practice. 
Combining different cardiac biomarkers may help to unravel the pathophysiology of 
cardiovascular disease and to improve the diagnostic power of a test. In Chapter 7, the 
relationship between the cardiac troponins and NPs was investigated and the optimal 
cardiac biomarker or biomarker combination for detection of atrial dilatation was 
determined. Concentrations of ANP, proANP, cTnI and cTnT were compared in 23 
healthy horses, 12 horses with valvular regurgitation without atrial dilatation and 42 
horses with valvular regurgitation and atrial dilatation. A significant cut-off for atrial 
dilatation was found for ANP, proANP and cTnI and a correlation was demonstrated 
between atrial NPs and cardiac troponins, which suggests that minor myocardial damage 
is also present in horses with atrial dilatation. Since the highest number of correctly 
classified horses was found for proANP and because combining different cardiac 
biomarkers only resulted in a minimal improvement in correctly classified horses, 
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proANP measurement seems to be the most accurate test for detection of atrial 
dilatation.  
Finally, the general discussion and conclusions follow in Chapter 8. High cTnI and cTnT 
concentrations are generally caused by primary myocardial damage while mild 
elevations in cTnI or cTnT are found in horses with severe valvular regurgitation, 
suggesting ongoing myocardial remodeling. A correlation between atrial NPs and atrial 
dilatation probably exists, but sample collection for atrial NP measurement remains 
challenging in equine clinical practice and there is a need for an automated assay against 
a stable ANP fragment. Currently, proANP measurement seems most promising. First 
results demonstrate that equine NT-proBNP can probably be detected using our equine 
NT-proBNP ELISA, but that futher assay optimization is required in order to lower the 
detection threshold.   
Cardiac troponins are already used in clinical practice but future studies should evaluate 
their clinical use for evaluation of prognosis and follow-up in horses with cardiac 
disease. Further understanding of the atrial and B-type NP synthesis, secretion, 
circulation and elimination patterns is needed to explore the applicability of equine 
specific atrial or B-type NP assays for detection of atrial or ventricular dilatation in 
clinical practice.    
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Cardiale biomerkers worden routinematig gebruikt in de humane geneeskunde voor 
diagnose, prognose en monitoring van hartaandoeningen. Bij kleine huisdieren worden 
biomerkers vooral gebruikt om cardiale en niet-cardiale aandoeningen van elkaar te 
onderscheiden. Bij het begin van dit doctoraatsonderzoek was er weinig informatie 
beschikbaar omtrent het gebruik van cardiale biomerkers voor de diagnose van 
hartaandoeningen bij paarden. Ons onderzoek toonde aan dat verschillende van deze 
cardiale biomerkers echter succesvol kunnen gebruikt worden voor de detectie van 
myocardschade en hartdilatatie bij paarden. 
Hoofdstuk 1 geeft een gedetailleerd overzicht van de fysiologie, structuur en het gebruik 
van de cardiale biomerkers voor de diagnose van hartaandoeningen. Cardiale 
troponinen zijn excellente detectoren van myocardschade, terwijl natriuretische 
peptiden (NP’s) in de humane geneeskunde en bij kleine huisdieren vooral gebruikt 
worden om hartfalen te detecteren. De invloed van extra-cardiale factoren op de 
cardiale troponinen en NP concentratie wordt in detail omschreven omdat deze factoren 
belangrijk kunnen zijn voor correcte interpretatie van resultaten. Hoofdstuk 1 eindigt 
met een overzicht van het huidige gebruik van cardiale biomerkers bij paarden en toont 
aan dat cardiale troponinen al wel succesvol gebruikt werden voor detectie van 
myocardschade maar dat studies omtrent NP’s beperkt zijn en zelfs tegenstrijdige 
resultaten opleveren.  
Hoofdstuk 2 toont aan dat er niet van uitgegaan mag worden dat humane en equine 
cardiale biomerkers zich gelijkaardig gedragen. Fysiologische en pathofysiologische 
diersoortverschillen bestaan en geven aan dat extrapolatie van gegevens van humane 
geneeskunde naar diergeneeskunde (en vice versa) moet vermeden worden. Specifieke 
studies voor elke diersoort zijn nodig.   
De specifieke onderzoeksdoelen van dit doctoraat worden beschreven in Hoofdstuk 3. 
Het eerste doel was het beoordelen van cardiaal troponine I (cTnI) en T (cTnT) voor de 
detectie van myocardschade bij paarden (Hoofdstuk 4.1-4.3). Het tweede doel van dit 
doctoraat was het evalueren van atriale NP’s voor het vaststellen van atriale dilatatie 
(Hoofdstuk 5.1-5.2). In een derde deel werden equine B-type NP’s gemeten voor de 
detectie van hartdilatatie, moleculen waar nog nauwelijks iets over geweten is bij het 
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paard (Hoofdstuk 6.1-6.2). Tot slot werd de meeste accurate biomerker of combinatie 
van biomerkers bepaald voor detectie van atriale dilatatie bij het paard (Hoofdstuk 7).  
In Hoofdstuk 4 worden verschillende troponine testen geëvalueerd voor detectie van 
myocardaandoeningen bij het paard. Humane studies hebben aangetoond dat een grote 
variatie bestaat in cTnI testen die verschillende targetpeptiden en antistoffen gebruiken, 
waardoor resultaten kunnen verschillen. In het eerste deel van dit hoofdstuk (Hoofdstuk 
4.1) werden twee verschillende cTnI testen (Access Accu test (Beckman Coulter 
Corporations, Fullerton, California) en STAT-I test (Abbott Diagnostics, Wavre, Belgium)) 
vergeleken bij 23 gezonde en 72 paarden met hartaandoeningen. Bij paarden met 
hartaandoeningen werd met beiden testen een significant hogere cTnI concentratie 
aangetoond, maar enkel voor de Access Accu test kon een significante cut-off waarde 
bepaald worden. Bovendien werden grote verschillen in de absolute cTnI concentraties 
gevonden tussen beide testen. Hieruit besluiten we dat de resultaten van cTnI testen 
onderling niet direct uitwisselbaar zijn en dat dezelfde test steeds moet gebruikt worden 
om myocardschade op te volgen. Aangezien maar één producent cTnT testen op de 
markt gebracht heeft, zijn de resultaten van cTnT testen beter gestandaardiseerd. 
Alvorens de (hoog-sensitieve) cTnT test kan gebruikt worden in de klinische praktijk, is 
analytische validatie van de test noodzakelijk, wat wordt uitgevoerd in Hoofdstuk 4.2. 
Ook het effect van hemolyse op de cTnT concentratie werd in deze studie bepaald 
gezien men onder praktijkomstandigheden soms met hemolyse geconfronteerd wordt. 
Serum stalen van paarden werden gemengd in drie pools met respectievelijk lage, 
medium en hoge cTnT concentratie. Daarvan werden de “within-day” en “between-day” 
variatiecoëfficiënten bepaald. Twee pools werden ook verdund om de lineariteit van de 
verdunningsreeks te controleren. De invloed van hemolyse werd op twee verschillende 
manieren vastgesteld: enerzijds door mechanische hemolyse op serum stalen van 4 
paarden en anderzijds door toevoegen van hemolysaat in verschillende concentraties 
aan EDTA plasma van drie andere paarden. De “within-day” en “between-day” 
variatiecoëfficiënten waren minder dan 10% voor alle pools en de verdunningsreeks was 
lineair. Dit betekent dat de hoog-sensitieve cTnT test een goede precisie voor 
diagnostisch gebruik heeft bij paarden. Bij stalen met een erge hemolyse werd een 
lagere cTnT concentratie gemeten. Om dit te vermijden moet de afname en verwerking 
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van de stalen op een correcte wijze gebeuren.   
In Hoofdstuk 4.3 wordt deze hoog-sensitieve cTnT test vergeleken met de Access Accu 
cTnI test om zijn klinische bruikbaarheid te evalueren. CTnI en cTnT werden bepaald bij 
35 gezonde paarden, 23 paarden met primaire myocardschade en 41 paarden met 
secundaire myocardschade. Hoewel grote kwantitatieve verschillen werden opgemerkt 
tussen beide testen, waren zowel de cTnI als cTnT concentraties hoger bij paarden met 
primaire myocardschade ten opzichte van de gezonde paarden. Een significante cTnI 
(0.095 ng/mL) en cTnT (6.6 pg/mL) cut-off waarde met vergelijkbare sensitiviteit en 
specificiteit voor de detectie van primaire myocardschade kon bepaald worden. Zo 
wordt in dit hoofdstuk aangetoond dat cTnI en cTnT een vergelijkbare diagnostische 
waarde hebben voor detectie van myocardschade bij paarden. 
In Hoofdstuk 5 worden atriale NP’s getest als detectors van atriale dilatatie bij paarden 
door middel van twee verschillende technieken. In Hoofdstuk 5.1 werden ANP en N-
terminal proANP (NT-proANP) gemeten met een equine enzyme-linked immunosorbent 
assay (ELISA) voor ANP en een humane ELISA voor NT-proANP. Dit werd gedaan bij 20 
gezonde paarden, 11 paarden met mitralis regurgitatie zonder atriale dilatatie en 16 
paarden met mitralis regurgitatie en atriale dilatatie. Stalen werden opgeslagen bij -20°C 
en -80°C om de stabiliteit van ANP en NT-proANP na te gaan. Paarden met atriale 
dilatatie hadden een significant hogere ANP concentratie dan paarden zonder atriale 
dilatatie. Dit kon niet bevestigd worden voor NT-proANP. Een ANP cut-off waarde van 52 
pg/mL kon bepaald worden voor de detectie van linker atriale dilatatie. De ANP 
concentraties waren lager voor stalen opgeslagen bij -20°C dan bij -80°C. Dit was minder 
het geval voor NT-proANP. We kunnen daaruit concluderen dat ANP en niet NT-proANP 
geschikt is voor de detectie van linker atriale dilatatie bij paarden en dat stalen 
opgeslagen moeten worden bij -80°C. In Hoofdstuk 5.2 wordt voor het eerst een nieuwe 
techniek gebruikt voor totale proANP bepaling bij paarden, namelijk “processing 
independent analysis”, waarmee een stabiel proANP fragment gedetecteerd wordt. Het 
totale proANP product werd bepaald bij 23 gezonde paarden, 12 paarden met een 
hartaandoening zonder atriale dilatatie en 42 paarden met een hartaandoening met 
atriale dilatatie. De proANP concentratie was significant hoger bij paarden met atriale 
dilatatie in vergelijking met gezonde paarden. De optimale cut-off waarde voor atriale 
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dilatatie was 573.8 pmol/L. Opslag van de stalen bij -20°C was vergelijkbaar met opslag 
bij -80°C. De stabiliteit van het totale proANP product en meer in het bijzonder de 
betrouwbaarheid van de techniek, maken processing independent analysis erg goed 
geschikt voor toekomstig gebruik bij paarden.  
Aangezien B-type NP’s soortspecifieke moleculen zijn en er op dit moment geen equine 
B-type NP test beschikbaar is, besloten we een techniek voor detectie van B-type NP’s te 
ontwikkelen (Hoofdstuk 6). Er is meer dan 90% homologie tussen equine en porciene 
BNP. In Hoofdstuk 6.1 probeerden we eerst een porciene BNP ELISA te gebruiken voor 
bepaling van equine BNP. Dit gebeurde bij 20 gezonde paarden, 8 paarden met een 
hartaandoening zonder cardiale dilatatie en 10 paarden met een hartaandoening met 
cardiale dilatatie. Hoewel een ‘BNP-achtige’ molecule werd gemeten en een significante 
invloed van de opslagtemperatuur werd vastgesteld, werd geen verschil gevonden in de 
BNP concentratie tussen gezonde paarden en paarden met of zonder hartdilatatie. 
Daardoor leek het noodzakelijk om een specifieke B-type NP test voor het paard te 
ontwikkelen. Gezien NT-proBNP wellicht stabieler is en een langere half-waardetijd 
heeft dan BNP, kozen we ervoor om een equine NT-proBNP test te ontwikkelen 
(Hoofdstuk 6.2). Bij 6 konijnen werden polyclonale antistoffen geproduceerd tegen de 
gehele equine recombinante NT-proBNP molecule en tegen twee kleinere fragmenten 
van de molecule (peptide 1 en 2). Vervolgens werden de interacties van deze antistoffen 
met de recombinante molecule in real-time onderzocht met behulp van een optische 
biosensor. Een deel van de antistoffen werd gebiotinyleerd en gebruikt als detectie 
antistof in combinatie met ongebiotinyleerde “capture” antistoffen in een sandwich 
ELISA. De antistof combinatie met het hoogste signaal (ten opzichte van de achtergrond) 
werd geselecteerd waarmee een detectielimiet van 0.5 ng/mL bekomen werd. Tenslotte 
werd de equine NT-proBNP concentratie gemeten bij 10 gezonde paarden en 10 
paarden met ventriculaire dilatatie. Bij één paard met ventriculaire dilatatie werd een 
verhoogde NT-proBNP concentratie gemeten. Bij de andere paarden werd geen NT-
proBNP gedecteerd, waarschijnlijk omdat de sensitiviteit van de test nog te laag was. In 
de toekomst is het dus nodig om deze equine NT-proBNP test verder te optimaliseren 
vooraleer hij kan gebruikt worden in de praktijk.  
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Het combineren van verschillende cardiale biomerkers kan helpen om de 
pathofysiologie van cardiovasculaire aandoeningen te ontrafelen en om het diagnostisch 
vermogen van een test te verbeteren. In Hoofdstuk 7 werd het verband onderzocht 
tussen cardiale troponinen en NP’s en werden de optimale cardiale biomerkers of 
biomerker combinaties voor detectie van atriale dilatatie bepaald. De concentraties van 
ANP, proANP, cTnI en cTnT werden vergeleken bij 23 gezonde paarden, 12 paarden met 
klep regurgitatie zonder atriale dilatatie en 42 paarden met klep regurgitatie en atriale 
dilatatie. Een significante cut-off waarde voor atriale dilatatie werd gevonden voor ANP, 
proANP en cTnI. Er werd een correlatie aangetoond tussen atriale NP’s en cardiale 
troponinen wat suggereert dat minimale myocardschade aanwezig is bij paarden met 
atriale dilatatie. Wanneer de proANP cut-off waarde gebruikt werd, was het percentage 
correct geclassificeerde paarden het hoogste. Combinatie van verschillende biomerkers 
met proANP resulteerde slechts in een minimale verbetering van dit percentage. 
Bijgevolg lijkt proANP bepaling de beste optie voor detectie van atriale dilatatie bij 
paarden.  
De algemene discussie en conclusies worden weergegeven in Hoofdstuk 8. Er wordt 
besloten dat hoge cTnI en cTnT concentraties meestal wijzen op primaire 
myocardschade. Milde cTnI en cTnT stijgingen worden eerder gevonden bij paarden met 
zeer ernstige klepregurgitaties wat myocardiale remodellering doet vermoeden. Er 
bestaat een verband tussen atriale NP’s en atriale dilatatie. Deze atriale NP’s kunnen 
momenteel echter nog niet routinematig bepaald worden en er is nood aan een 
automatische test die een stabiel ANP fragment detecteert. Op dit moment lijkt proANP 
bepaling het meest belovend. De eerste resultaten van onze zelfontwikkelde equine NT-
proBNP ELISA test tonen aan dat deze molecule kan gedetecteerd worden, maar dat 
verdere optimalisatie nodig is om de detectielimiet te verlagen.   
Cardiale troponinen kunnen reeds succesvol gebruikt worden in de klinische praktijk, 
maar toekomstige studies zouden verdere inzichten moeten verschaffen in verband met 
de troponine concentratie en de prognose en follow-up van hartaandoeningen bij het 
paard. Betere inzichten in de atriale en B-type NP synthese, secretie, circulatie en 
eliminatie zijn nodig om equine atriale en B-type NP testen verder te ontwikkelen voor 
detectie van atriale en ventriculaire dilatatie bij het paard.  
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Dankwoord 
Ik ben er… Het einde van een lange reis, die ongeveer 25 jaar geduurd heeft. Want dat 
betekent een doctoraat toch deels voor mij; het einde van een lange schoolcarrière, het 
laatste diploma en het begin van het “echte” werkleven (of hopelijk toch ☺). Degenen 
die mij al lang kennen, van toen ik nog een kleine verlegen “Nicky-Nick” was, weten dat 
er gedurende die 25 jaar een hele evolutie heeft plaatsgevonden. Het mooiste 
voorbeeld is misschien de “presentation skills”; op mijn 12 jaar stond ik nog triest voor 
de klas bij mevrouw “Perdu”, omdat ik een gedichtje moest voorlezen. Nu 13 jaar later, 
heb ik al gepresenteerd op internationale congressen en ga ik jullie maar eventjes 45 
minuten entertainen met mijn eigen onderzoek. Als je in jezelf gelooft, lukt het wel. 
Zelfvertrouwen, een cliché, maar ook een waarheid als een koe. En dat zelfvertrouwen 
heb ik alleen gekregen dankzij jullie allemaal. Jullie daarvoor hier even bedanken is dus 
wel het minste wat ik kan doen… 
Zoals vele dierenartsen onder ons, heb ik altijd gezworen nooit een doctoraat te willen 
doen. Dagen achter de computer kunnen nooit opwegen ten opzichte van de 
afwisselende praktijk. En toch…  
Het was Prof. Deprez die mij voor het eerst in contact bracht met onderzoek tijdens mijn 
masterproef. Zelfstandig werken (met de nodige hulp achter de schermen), nieuwe 
wegen ontdekken in de literatuur, praktische en intellectuele uitdagingen. Dat is 
onderzoek. Bedankt, Professor Deprez. Niet alleen om mij deze richting uit te sturen, 
maar ook voor de goede begeleiding van onze hele vakgroep.    
Het was ook Prof. Deprez die mij richting Prof. van Loon stuurde om toch eens te horen 
of een doctoraat iets voor mij was. Ik had nog nooit van een biomarker gehoord en 
cardio? Mede thesis-studenten hadden mij vooral verteld dat dat zeer ingewikkeld was. 
Maar Gunther, jij maakt(e) de cardio zo ongelooflijk logisch dat het vooral onmogelijk 
was/is om het niet te begrijpen. Bedankt om mij een kans te geven, om altijd klaar te 
staan, voor je positieve feedback, om mij zovéél bij te leren. En vooral bedankt om mij 
mijn eigen pad te laten kiezen, zodat ik ook de labowereld kon leren kennen. 
Die labowereld brengt mij bij een nieuwe begeleider: Prof. Cox was degene die mij 
aanspoorde om zoveel mogelijk zelf te doen (onder de fantastische begeleiding van 
Gosia) om zo nieuwe technieken aan te leren. Bedankt, u had gelijk, ik heb zoveel 
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bijgeleerd! Ook bedankt voor al uw inzichten in de moleculaire wereld. Het verwondert 
mij nog steeds hoe ik dagen over iets kon nadenken en het ineens allemaal duidelijk 
werd op een korte vergadering. 
Ook bedankt aan de andere leden van mijn lees- en examencommissie om tijd vrij te 
maken om dit werk door te lezen en te verbeteren: Dr. Decloedt, Prof. Dr. Amory: Merci 
pour votre suggestions. Prof. Dr. Schwarzwald, special thanks for your Bland-Altman 
advise! Prof. Dr. Goetze: it was a great cooperation. Thanks to your emails and 
interesting articles, I gained a whole new insight in the world of the natriuretic peptides. 
Please also thank Ingrid and Annette from me. 
Verder bedankt aan Prof. Stanislas Sys, niet alleen voor de statistische analyses, maar 
ook voor de entertainende gesprekken, over koude-bestrijding en koormuziek ☺.   
Tijdens mijn doctoraat had ik het geluk opgenomen te worden in ons “cardio-dream-
team”. En dat was het echt. Bedankt iedereen voor alle steun, op werk en privé-vlak! 
Annelies, een beter voorbeeld hadden ze mij niet kunnen geven. Ik had het geluk om bij 
jou op het bureau terechtkomen in onze eigen beschermde ‘doctoraatsomgeving’. Als ik 
een kwartslag draaide, had ik meteen een dozijn nieuwe inzichten. Je mag jezelf dus 
zeker medepromotor noemen. Ik hoop dat na mij nog veel doctoraatsstudenten zullen 
volgen. Ook merci voor de privé-momenten tussendoor: jij was voor mij de ideale 
combinatie van lachen én werken.   
Dominique, jij bent degene achter de schermen van mijn doctoraat. Bedankt voor zoveel 
praktische hulp tijdens mijn cardio-weken. Ik heb mij al heel veel afgevraagd hoe je het 
allemaal doet. Een carrière en kinderen, het is een uitdagende combinatie. Even 
tussendoor: Chapeau! Ik hoop dat ik later ook een goed evenwicht tussen beide kan 
vinden.   
Sofie, ons recentste team lid. Op jou kun je huizen bouwen. Onvermoeibaar en alles-
kunnend. Het is misschien niet altijd makkelijk om het evenwicht tussen praktijk-theorie 
te vinden, maar ik ben er van overtuigd dat jouw doctoraat een voltreffer wordt. Jouw 
inzichten zijn er in overvloed, dat merk ik in al onze gesprekken. Nu nog gauw even op 
papier zetten en jij hebt nog een afkorting om voor je naam te zetten Drs. Ir. Ven ;-).   
En dan kom ik bij jou, Tinne. Je bent misschien geen huidig lid meer van ons team, maar 
voor mij blijf je ons ECG-wonder. Ik kan oprecht zeggen dat ik jou al veel gemist heb en 
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mij al veel afgevraagd heb hoe het met jou zou gaan. We zien elkaar veel te weinig, maar 
de band die we opgebouwd hebben tijdens onze jaren hier, is voor mij onverwoestbaar. 
Straks gewoon even een datum afspreken ? We geven niet op. Één datum hebben we 
gelukkig al… 
Tijdens mijn doctoraat zijn er stalen verzameld. Héél, héél véél rode, groene, gele, 
blauwe tot zelfs paarse en roze stalen. Gelukkig werd ik bijgestaan door een fantastisch 
labo-team, die op elk moment (helaas meestal net om 12u ‘s middags) deze stalen wou 
verwerken. Dank u Sabrina en Sylvie! Sylvie, ook bedankt voor de administratieve hulp 
tussendoor! Sabrina, jij verdient daarbovenop nog een volledige eigen paragraaf in dit 
dankwoord. Ik heb zoveel van jou geleerd tijdens het labo-werk, te beginnen bij het 
begin: pipetteren ☺. Jouw ervaring en praktisch inzicht hebben mijn leven veel 
gemakkelijker gemaakt. Ik reken op jou om goed voor onze cardio-diepvries te zorgen. 
Ook een dikke merci voor de leuke gesprekken over onze beestenboel. Ik wens je het 
allerbeste toe met jullie nieuwe gezin en als de kinderen graag eens op een paard zitten, 
altijd welkom... 
Naast het cardio- en labo-team, bestaat de vakgroep uit een aantal zeer enthousiaste 
dierenartsen die dag en nacht klaar staan voor de vele patiënten. Dank je wel aan alle 
interns (Thomas, Krisje, Véro, Alex, Steven, Anne, Caroline, Ann, Alexander, Pia, Hana). Ik 
hoop dat jullie nog eens aan mij terugdenken wanneer jullie een bijgeruis of 
onregelmatig ritme horen. Bedankt Caroline, Laurence, Barbara, Joke, Ellen, Kirsten, Sara 
voor de leuke gesprekken onder de middag en voor het melden van mogelijke 
hartpatiënten op stal. Ook ons boviene team mag niet vergeten worden: de kalfjes 
tussendoor waren best leuk, die dikbilrunderen toch een beetje minder ;-)! Bonnie, jouw 
inzet voor de studenten mag ook niet vergeten worden. Veel geluk met jouw doctoraat! 
Bart, bedankt voor de statistische hulp, de goede raad tussendoor en de humor onder 
de middag. Spijtig dat ieder van het groepje Bart-Peter-Stijn-Jeroen zijn eigen weg is 
gegaan. Jullie vier waren hilarisch. Stijn, kom je mij nog eens halen voor een 
afscheidslunch? Linde en Laura, jullie zijn de toekomst. Ik wens jullie het allerbeste met 
jullie doctoraat!  
Daarnaast zijn er nog een aantal mensen die achter de schermen zoveel werk uit voeren 
en zonder wie onze vakgroep nooit zou kunnen draaien. Elvin, bedankt voor de vele 
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bestellingen en de eeuwige sterilisatie van het materiaal. Tony, Carlos, Balder, Julien, 
bedankt om de stallen klaar te maken als ik weer eens een cardio-dag organiseerde. 
Hans, thanks voor het opsturen van de stalen (je weet wel naar Blegdamsvej), voor het 
oplossen van pc problemen en voor de leuke sfeer op het werk (en op feestjes ☺). Tot 
slot nog een dikke, dikke merci aan onze happy-Saar. Thanks voor het helpen bij de 
proeven, voor het toestaan van de vele prikacties op Umbo, voor de goede zorg aan alle 
patiënten, voor het vasthouden van onze niet-altijd-even-meewerkende bunnies,… 
Zonder het te weten, heb jij eigenlijk grotendeels mijn leven bepaald de laatste jaren: 
niet alleen heb je mij geïntroduceerd op de manege (waar ik toch ongeveer 70% van 
mijn vrije tijd doorbreng), jij hebt mij voorgesteld aan Crescendo en Blessy, die beiden 
niet meer weg te denken zijn uit mijn dagelijks leven. Jij bent in eerste plaats een goede 
vriendin geworden; van mij ben je nog niet af, er staan ons nog heel wat lange 
wandelingen te wachten met Umb en Cris! 
Doctoreren kan je alleen mits goede samenwerking met mensen uit andere vakgroepen, 
universiteiten, bedrijven en laboratoria. Het laatste jaar heb ik veel tijd doorgebracht op 
de Vakgroep Immunologie, waar Gosia altijd paraat stond voor al mijn (slimme en 
minder slimme) vragen. Gosia, zonder jou wist ik nog steeds het verschil niet tussen 
Tw20 en Tw80 of tussen een Maxisorp en Polysorp plaat. Jij hebt mij begeleid alsof het 
je eigen werk was (ondanks zoveel ander werk), met aandacht voor alle details. 
Dziękuję! Geniet nog van je prachtige gezin! Ook dank je wel aan Simon, die ik steeds 
kon lastig vallen met alle praktische vragen: hoelang, waarmee en waar staat het? 
Merci! Dank je wel ook aan alle andere leden van jullie vakgroep. De sfeer zit zeker goed 
bij jullie!  
Bedankt aan Petra en Isabelle van Verloskunde, meer specifiek voor de -80°C diepvries, 
die altijd maar voller en voller kwam te zitten.  
Dank je wel aan de mensen van Heelkunde en Anesthesie, zonder wie geen enkel AF-er 
kon geconverteerd worden.  
Een extra bedanking is ook op zijn plaats voor Johan Vandeweghe van GE Healthcare; 
bedankt voor de excellente service en fantastische samenwerking.    
Voor de analyse van de stalen kon ik terugvallen op een vlotte samenwerking met 
verschillende humane en diergeneeskundige laboratoria: Bedankt aan Arlette 
Vandenberghe (Algemeen Medisch Laboratorium), Filip Barbé en Tom Nagels (Zoolyx), 
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Bruno Heyndrickx (AZ Jan Palfijn, Gent), Hendrik De Puydt en Marie-Astrid van Dievoet 
(AZ Sint-Lucas, Gent) voor de vlotte analyse van de stalen en deskundige begeleiding. 
Special thanks to IDEXX laboratories for the delivery of the recombinant NT-proBNP 
molecule and to Prof. W. Woloszczuk for the NT-proBNP ELISA information.  
Voor de financiële kant van mijn doctoraat wil ik graag het Bijzonder Onderzoeksfonds 
van de Universiteit Gent bedanken. Bedankt voor 4 jaar steun.  
Tenslotte wil ik ook alle paardeneigenaren bedanken die hun gezonde paarden speciaal 
naar Merelbeke hebben vervoerd voor mijn studie. Referentiewaarden zijn onmisbaar, 
bedankt voor alle moeite. 
En dan kom ik bij de mensen die mij vooral kennen als -gewoon- Nicky…  
De studie diergeneeskunde was zwaar, maar ik heb er wel fantastische mensen 
ontmoet. Gerty, wij hebben grotendeels samen de weg naar een doctoraat afgelegd en 
dat heeft ons dichter bij elkaar gebracht. Spijtig dat de mailtjes in de toekomst niet meer 
zullen eindigen met: “groetjes van de overkant” nu we ieder onze eigen weg gaan. 
Jorien, jouw vakgroep boft met zoveel inzet, hou nog even vol, jouw doctoraat wordt 
meer dan super! Nele, jij bent misschien geen dieren-arts, maar toch was jij via Jorien 
overal nauw bij betrokken. Superblij dat ik jou zo heb leren kennen! Karolien, Kimberley, 
merci voor de gesprekken tussendoor! Altijd leuk om jullie in de resto tegen te komen.  
Tijdens het middelbaar heb ik het geluk gehad om in een klas terecht te komen, waar ik 
gewoon mezelf kon zijn. Vele wijntjes, pintjes en martini’s later, zijn we onze wilde 
haren een beetje verloren, maar plezier maken kunnen we nog altijd. Effie -niet-zoals-
de-boter- Senepar(t), onze stevige kern, in eerste plaats bedankt om mij in jullie groep te 
introduceren zoveel jaar geleden. Ilse, onze sterke madam. Veel geluk met Sam in jullie 
prachthuis! Ik kijk al uit naar jullie trouw ☺! Sarah/Saar, op jou kan ik altijd rekenen. Een 
extra thanks voor de steun in de Gilles-periode. En yes, nog een trouw! Lieve Liesbet, de 
afstand tussen jou en Dendermonde is misschien toegenomen, maar blijkt toch 
eenvoudig te overbruggen. Op naar ons volgende hond/kat gesprek! Catherine, onze 
momenten samen zal ik nooit vergeten, blij dat je het geluk bij je gezinnetje gevonden 
hebt. Lotte, ik ben jou stiekeme bewonderaar ☺ (ook al deel je mijn dierenliefde niet): 
een echte levensgenieter en het beste middel tegen opkomende depressies: van jou 
word ik altijd goedgezind. Ellen, als jij vraagt “hoe is het?”, weet ik zeker dat je gemeend 
luistert, bedankt voor alle goede gesprekken. Tom, je droge humor is onvervangbaar, 
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ook bedankt voor de tussentijdse biotechnologie-hulp. Celine, Anne, Daphne en Elien, 
extra merci voor een fantastische tijd in Cadzand!!   
Tijdens onze vriendschap is er een hele bende mannen bijgekomen, sommige zijn weer 
vertrokken, maar ik moet zeggen dat de beste gebleven zijn: Kristof, Kris, Lieven, Sam, 
Thomas, Geert, Jens en Filip; jullie zijn gewoon toppers.  
Dat brengt mij bij de manege-people, de mensen waardoor ik altijd net iets langer op de 
manege blijf hangen dan nodig en waarmee gesprekken nooit vervelen. Melissa, 
Mireille, Nick en Virginie,… zullen we nog een zeetje doen?  
Van vrienden naar familie…  die helaas sterk geslonken is de laatste jaren.   
Een speciale dank je wel aan mijn tante Marie-Jeanne en mijn pépé Pieter. Tante, jij bent 
de sterke kern van de Van Der Vekens, bedankt om altijd voor mij klaar te staan. Pépé 
Pieter, jij bent ongetwijfeld het brein van de familie. Bedankt voor alle steun!  
Mel(issa), bedankt om mij mee te nemen op paardijles… nooit gedacht dat dit het 
resultaat ging zijn van onze ritjes met Tinky, Pistache, Asterix, Nostrum en Quinto.    
Zus, je toewijding voor de klas en Hebbeding verdienen meer dan een pluim. Geniet 
samen met Ward van jullie fotogenieke krullenbol.   
Mama en papa, het is pas de laatste jaren dat ik echt stil gestaan ben, wat jullie allemaal 
voor mij gedaan hebben. Jullie hebben mij mijn eigen weg laten kiezen. Een weg, die 
misschien voor jullie niet altijd vanzelfsprekend was, maar jullie stonden altijd op de 
achtergrond klaar om mij op te vangen. Papa, je gelooft het vast niet, maar je bent het 
toonbeeld van een onderzoeker: leergierig en kritisch. Mama, Hebbeding is jouw 
pronkstuk, ongelooflijk hoe je ons winkeltje combineert met een job, daar mag je trots 
op zijn. 
Cedric, mijn stiekeme voorbeeld, tegenover jouw harde werk is dit doctoraat bijna een 
kinderboekje. Het is niet altijd makkelijk om in onze chaos orde te scheppen, maar 
vandaag bewijzen we maar weer dat het ons lukt, als team. Bedankt, schattie, om 
ondanks jouw zware dagen toch voor mij klaar te staan. Bedankt om alles te begrijpen, 
ook mijn dierenpassie. Jij maakt alles beter. π !!!  
  
  
 
  
  
 
 
 
 
